













This thesis has been submitted in fulfilment of the requirements for a postgraduate degree 
(e.g. PhD, MPhil, DClinPsychol) at the University of Edinburgh. Please note the following 
terms and conditions of use: 
 
This work is protected by copyright and other intellectual property rights, which are 
retained by the thesis author, unless otherwise stated. 
A copy can be downloaded for personal non-commercial research or study, without 
prior permission or charge. 
This thesis cannot be reproduced or quoted extensively from without first obtaining 
permission in writing from the author. 
The content must not be changed in any way or sold commercially in any format or 
medium without the formal permission of the author. 
When referring to this work, full bibliographic details including the author, title, 
awarding institution and date of the thesis must be given. 
 
A Semi-automated Framework for the










Motivation Translational bioinformatics(TBI) has been defined as ‘the development
and application of informatics methods that connect molecular entities to clinical enti-
ties’ [1], which has emerged as a systems theory approach to bridge the huge wealth of
biomedical data into clinical actions using a combination of innovations and resources
across the entire spectrum of biomedical informatics approaches [2]. The challenge
for TBI is the availability of both comprehensive knowledge based on genes and the
corresponding tools that allow their analysis and exploitation.
Traditionally, biological researchers usually study one or only a few genes at a
time, but in recent years high throughput technologies such as gene expression mi-
croarrays, protein mass-spectrometry and next-generation DNA and RNA sequencing
have emerged that allow the simultaneous measurement of changes on a genome-wide
scale. These technologies usually result in large lists of interesting genes, but meaning-
ful biological interpretation remains a major challenge. Over the last decade, enrich-
ment analysis has become standard practice in the analysis of such gene lists, enabling
systematic assessment of the likelihood of differential representation of defined groups
of genes compared to suitably annotated background knowledge. The success of such
analyses are highly dependent on the availability and quality of the gene annotation
data.
For many years, genes were annotated by different experts using inconsistent, non-
standard terminologies. Large amounts of variation and duplication in these unstruc-
tured annotation sets, made them unsuitable for principled quantitative analysis. More
recently, a lot of effort has been put into the development and use of structured, domain
specific vocabularies to annotate genes. The Gene Ontology is one of the most suc-
cessful examples of this where genes are annotated with terms from three main clades;
biological process, molecular function and cellular component. However, there are
many other established and emerging ontologies to aid biological data interpretation,
but are rarely used. For the same reason, many bioinformatic tools only support anal-
ysis analysis using the Gene Ontology.
The lack of annotation coverage and the support for them in existing analytical
tools to aid biological interpretation of data has become a major limitation to their util-
ity and uptake. Thus, automatic approaches are needed to facilitate the transformation
of unstructured data to unlock the potential of all ontologies, with corresponding bioin-
formatics tools to support their interpretation.
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Approaches In this thesis, firstly, similar to the approach in [3,4], I propose a series
of computational approaches implemented in a new tool OntoSuite-Miner to address
the ontology based gene association data integration challenge. This approach uses
NLP based text mining methods for ontology based biomedical text mining. What
differentiates my approach from other approaches is that I integrate two of the most
wildly used NLP modules into the framework, not only increasing the confidence of
the text mining results, but also providing an annotation score for each mapping, based
on the number of pieces of evidence in the literature and the number of NLP mod-
ules that agreed with the mapping. Since heterogeneous data is important in under-
standing human disease, the approach was designed to be generic, thus the ontology
based annotation generation can be applied to different sources and can be repeated
with different ontologies. Secondly, in respect of the second challenge proposed by
TBI, to increase the statistical power of the annotation enrichment analysis, I propose
OntoSuite-Analytics, which integrates a collection of enrichment analysis methods into
a unified open-source software package named topOnto, in the statistical programming
language R. The package supports enrichment analysis across multiple ontologies with
a set of implemented statistical/topological algorithms, allowing the comparison of en-
richment results across multiple ontologies and between different algorithms.
Results The methodologies described above were implemented and a Human Dis-
ease Ontology (HDO) based gene annotation database was generated by mining three
publicly available database, OMIM, GeneRIF and Ensembl variation. With the avail-
ability of the HDO annotation and the corresponding ontology enrichment analysis
tools in topOnto, I profiled 277 gene classes with human diseases and generated ‘dis-
ease environments’ for 1310 human diseases. The exploration of the disease profiles
and disease environment provides an overview of known disease knowledge and pro-
vides new insights into disease mechanisms. The integration of multiple ontologies
into a disease context demonstrates how ‘orthogonal’ ontologies can lead to biological
insight that would have been missed by more traditional single ontology analysis.
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The study of complex diseases requires the effective integration and analysis of dis-
parate features that originate from genotypic, phenotypic, and environmental sources.
Instead of a microscopic approach which focus on detailed analyses of a single data
type, a macroscopic approach offers a holistic view for exploring complex diseases
as systems by coalescing many heterogeneous data types. Translational bioinformat-
ics(TBI), defined as “the development and application of informatics methods that con-
nect molecular entities to clinical entities” [1], has thus emerged as a systems theory
approach to bridge the huge wealth of biomedical data into clinical actions using a
combination of innovations and resources across the entire spectrum of biomedical
informatics approaches [2]. By the integrative exploitation of information, TBI will
enable a deeper understanding of disease mechanisms and provide a new paradigm for
the study and treatment of disease. The challenge is the availability of both comprehen-
sive sources of gene annotation data and tools that allow their analysis and exploitation.
Traditionally, biological researchers usually study one gene or only a few genes at
a time. Nowadays, new high-throughput scanning approaches such as DNA-Seq [5],
RNA-Seq [6] and RNA microarrays [7] allow researchers to simultaneously measure
the properties of genome-wide genes and proteins across entire genomes. These high-
throughput technologies usually generate large gene lists, however, to understand the
biological interpretation of these potentially interesting genes to gain disease insight is
still a major challenge.
1
2 Chapter 1. Introduction
1.1 Existing gene annotation data
The first challenge is the lack of structured gene annotation data. Biomedical sci-
ences are facing an enormous increase of data available from public sources. However,
most of this data is unstructured and not suitable for modern bioinformatics methods
(fig. 1.1). An example would be one of the most commonly used disease annotation
databases, the Online Mendelian Inheritance in Man (OMIM), where genes are anno-
tated with largely unstructured text which is of a historical narrative design, making
it difficult to compare or integrate with annotations from other sources. Such unstruc-
tured annotation is informative to human user, but it is not computationally friendly,
and of limited use in its raw form for model bioinformatics analysis.
Efforts have been made to establish controlled vocabularies for use in gene annota-
tion such as the International Classification of Diseases (ICD) [8], the National Library
of Medicine Medical Subject Headings (MeSH) [9] and Thesaurus like the Unified
Medical Language System (UMLS) Metathesaurus [10] which were developed to fa-
cilitate gene annotation and the building of electronic information systems that create,
process, retrieve, integrate, and/or aggregate biomedical and health data and informa-
tion, as well as in informatics research. The MEDLINE/PubMed database, one of
the most heavily used medical databases, is indexed by MeSH controlled vocabularies
which greatly improves searches of millions of publication entities.
On the other hand, ontology, sometimes used as terminology, is a formal, explicit
representation of a body of knowledge, within a given domain. An ontology provides
explicit definition of concepts and their relations as well as cross references to other
ontology, features that makes it to be one of the great enabling technologies of modern
bioinformatics, especially suitable for annotating genes.
One of the most widely used ontologies in the biomedical domain is the Gene On-
tology(GO) [11]. The successful development of the Gene Ontology provided a set
of standard, consistent, unambiguous and structured terms to annotate genes or gene
products. After more than a decade’s effort by the GO consortium and numerous re-
search communities, the GO has became one of the most used and well developed
ontologies in the biomedical field. This is partly because GO has a good gene anno-
tation coverage [12]. Originally annotation was performed by human experts/curators
who read a research paper and assigned the most relevant GO terms to the genes or
gene products studied in the paper. This approach requires extensive domain knowl-
edge from the curators and is time consuming and error prone. A wide range of tools
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Figure 1.1: An example of unstructured text based annotation and the corresponding
ontology based annotation. The five sentences in the top box use five different words
(synonyms, abbreviation, etc.) for the disease ‘Alzheimer’s disease’ which make it hard
to be annotated accurately, especially when trying to automate the process computa-
tionally across large data corpora. Ontologies can provide unique, consistent, formal
representations of disease relevant information, allowing reasoning base on their rela-
tions, which is neededythe foundation of most of the modern data integration/analysis
techniques.
have since been developed to support the annotation process [13]. For example, the
Textpresso software tool was one of the first tools developed to support literature cu-
ration for GO, and is still used in model organism databases [14]. The Phylogenetic
Annotation and Inference Tool [15] is also used by the GO consortium, which assists
curators to infer annotations among members of a protein family. Such a ‘hybrid’ an-
notation style that combines manual assignment and electronic inference, is helpful
to speed up the annotation process, which as a result, produces a better annotation
coverage.. What’s more, since GO has become a standard in many analysis pipelines,
many model organism databases and genome annotation groups use the GO and con-
tribute their annotation sets to the GO resource [11]. The successful development of
the Gene Ontology also facilitated a wide range of downstream analytic tools which
are reviewed by Huang et.al in [16].
1.1.1 Definition of an ontology
An ontology is a formal, explicit representation of a body of knowledge, within a given
domain. Ontologies usually consist of a set of classes or terms with relations between
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them. Many definitions of ontology have been proposed in the literature [17–19] based
on criteria such as their intended use or degree of formalization. One of the most
widely used ontologies in biological sciences, started in around 1998, is the Gene
Ontology [20]. By 2007, following the success of the Gene Ontology, interests and
demand for ontologies grew and resulted in national and international coordination
efforts such as the Open Biomedical Ontologies (OBO) Foundry [21] and the National
Center for Biomedical Ontologies (NCBO) [22]. By September 2016, there were more
than 500 ontologies stored in NCBO and accessible through the NCBO bioportal web
interface. Despite the different definitions, ontologies provide several unique features
which are used in almost all of their applications [23]:
1.1.1.1 Classes and relations
Classes and relations between classes are referred to by an identifier. The identifier is
consistent across different versions of the ontology, enabling consistent and unambigu-
ous knowledge sharing and data integration. A standard class identifier in an ontology
usually consists of a prefix string followed by a colon and a series of digits. In the
Gene Ontology, for example, ‘GO:0000016’ is an identifier for a class while ‘part of’
and ‘regulates’ are relations (fig. 1.2).
1.1.1.2 Controlled domain vocabularies
A set of controlled domain vocabularies, i.e. a list of string labels associated with the
ontology’s classes and relations used to refer to the kind of things a class or relation
represents. They may be provided in multiple languages and multiple labels can be
assigned to a single class. A primary label is often used to refer to class while other
secondary labels or synonyms are used as complementary labels to capture the usage
of a class or a relation in different contexts. The distinction between label and class
identifier is that the label may change during the development of the ontology while the
class identifier and the intended meaning of the class remains the same. The vocabular-
ies in an ontology aim to cover a domain completely, this usually provides a large set
of relevant terms within that domain as well as a set of terms used to describe the ways
these terms may interact. For example, GO not only contains classes and relations to
represent gene and gene product attributes, but also provides a large set of terms used
to refer to these attributes and their relations. An example would be ‘maltose biosyn-
thetic process’ (the chemical reactions and pathways resulting in the formation of the
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disaccharide maltose) has an ‘is a‘ relation to ‘maltose metabolic process’ and ‘dis-
accharide biosynthetic process’ while having a set of synonyms including ‘malt sugar
biosynthesis’ and ‘maltose anabolism’.
1.1.1.3 Textual definitions and descriptions
These provide additional metadata for classes and relations which provide a precise
description of the class. There has been discussion about how to create a ‘good’ tex-
tual definition [24]. The majority of ontologies contain two main kinds of additional
information, 1) textual definitions and descriptions that provide examples, background
information and conditions that make the intended meaning of a class in ontology as
precise as possible and 2) additional information that cross link one class to other en-
tries in literature, other databases or other ontologies and vocabularies. For example,
‘A cell cycle process that controls cell cycle progression by monitoring the integrity
of specific cell cycle events. A cell cycle checkpoint begins with detection of defi-
ciencies or defects and ends with signal transduction.’ is the textual definition of the
GO term ‘GO:0000075 cell cycle checkpoint’ which is cross linked to the Reactome
pathway database entities in different species including ‘REACT 100401 Cell Cycle
Checkpoints, Gallus gallus’, ‘REACT 1538 Cell Cycle Checkpoints, Homo sapiens’
and ‘REACT 90285 Cell Cycle Checkpoints, Mus musculus’. Another example would
be ‘GO:0043076 megasporocyte nucleus’ is a ‘GO:0005634 nucleus’ that is part of a
‘CL:0000320 megasporocyte’ which is a term defined in the Cell Ontology [25].
1.1.1.4 Formal definitions and axioms
‘Machine-readable’ formal definitions and axioms. These are some of the most valu-
able features of ontologies that enable computational analyses and graph/network based
analyses with ontology data. Most commonly, ontologies in biological and biomedi-
cal domain are expressed directly in a formal language. The Web Ontology Language
(OWL) [26], a formal language based on description logic, has become increasingly
popular in representing ontologies. The graph-based OBO flat file format, which was
initially used to represent ontologies, has become a sub-language of OWL but tools are
available [27] for parsing between the two formats. Currently, in September 2016, 351
ontologies are represented natively in OWL in the NCBO bioportal ontology repository
while 106 ontologies are represented natively in OBO.
Graph representation of ontologies can be directly derived from an ontology’s for-
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mal definitions and axioms. A typical ontology graph contains nodes and edges where
nodes commonly represent classes (terms) and edges represent types of axiom (rela-
tions) between classes. An ontology graph is structured hierarchically as a directed
acyclic graph (DAG) with a root node. In such as DAG structure, the concept ‘level’
(depth) was also often used to refer to the location of a node in the ontology structure,
for example, the ontology root has a level of 1. It is also appropriate to talk about a
parent-child relationship between nodes where parent refers to a connected node closer
to the root of the graph, and child to that closer to leaf nodes. The parent (high-level
term located near the top of the ontology root) would be a conceptually broader term
(class) in the defined domain of the ontology, and the child (low-level term) would
represent a more specific term. Nodes can have any number and type of relationship to
other nodes as long as there are no directed cycles in the graph. That is to say, a node
may have connections to more than one child (more specific) node, or it can also have
more than one parent (broader) node, and different relations to its different parents, but
it cannot have any connection between its sibling nodes (nodes with the same parent
nodes) since it will create directed cycles.
In terms of the type of relationship between nodes, some ontologies including the
Human disease ontology and Human phenotype ontology are simpler than others, only
using one type of relationship (in most cases, the ‘is a’ relationship which can be in-
terpreted as ‘is a subtype of’). Other relationships are defined in the OBO Relations
Ontology (RO) and used to represent different types of relationship between nodes
such as ‘part of’ or ‘ negatively regulates’ such as in the Gene Ontology. An impor-
tant property of the relations between ontology terms is that some of the relations such
as ‘is a’ and ‘part of’ are transitive in nature, which means that new relations can be
inferred based on existing ones (dash lines in fig. 1.2a). For example, in the Gene
Ontology, the term ‘mitochondrion’ is an ‘intracellular organelle’ and ‘intracellular
organelle’ is an ‘organelle’, therefore mitochondrion is an organelle. This leads to an-
other important feature of ontology hierarchy called the ‘True Path Rule’(TPR) which
defines each term’s meaning by (multiple) inheritance. In other words, the path from
a node up to the root node (‘True Path’) must always be true. Since a node can have
more than one parent, there can be more than one true path, thus a True Path Graph of
a node is defined to be the sub graph comprising all of the True Paths of the term [28].
Additionally, annotation from a child term also hold for all of the ancestors in its
TPs. This feature is especially useful in the context of ontology based gene annotation:
“an annotation for a term in the ontology hierarchy is automatically transferred to its
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ancestors based on the TPR, while genes not annotated to a term cannot be annotated
for its descendants”. Such aggregation of gene annotation inspired the development of
new algorithms for a variety of analytic methodologies such as gene function predic-
tion [29–32] and over-presentation analysis [33] which takes advantage of the topology
structure of the ontology. The OntoSuite framework developed in this project explicitly
considers the TPR and will be discussed in later sections of this thesis.
1.1.1.5 Slim/clip ontologies
One common use of the Gene Ontology is functional annotation of results of high
throughput experiments, such as transcription profiling arrays [35,36] where GO terms
are linked to a particular treatment based on affected genes or gene products. In such
cases, the changes in gene expression in response to different treatments can be char-
acterized by a list of associated GO terms rather than a list of genes, which gives
additional insights. However, GO includes a very large number of terms, covering
most biological knowledge related to gene function from the three main components:
cellular component, biological process, and molecular function. For any given sys-
tem, many terms may be completely unrelated yet are still considered during analysis
which usually complicates the analysis and leads to undesired results. In the case of
term enrichment analyses, including unrelated GO terms dilutes the proportion of ac-
tual hits, increasing the likelihood of falsely reporting enrichment and complicating the
interpretation of the resulting list of terms. Consider, for example, the use of the term
GO:0007321 sperm displacement, when studying systems such as brain development.
Including this term in the enrichment analysis, which in most likelihood has very lim-
ited contribution to the interpretation of the result, will increase the number of terms
considered in the analysis, in turn reducing the statistical power of the enrichment
analysis by requiring more rigorous multiple testing correction.
The most obvious way to overcome this problem is to construct a better defined
domain-specific ontology, for example, a brain development ontology and link its terms
to all those genes that can be defined by these terms. However, this approach is labour
intensive, time-consuming and requires extensive domain knowledge. Moreover, this
largely overlaps with the massive efforts of the GO consortium. An alternative ap-
proach is to prune existing ontologies such as GO, leaving out the irrelevant terms and
only keeping terms that are pertinent to the specific task. This approach has already
been used extensively in generating GO ‘slims’, which is constructed by choosing
high-level terms from GO that give a broad overview of the ontology content, such as
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(a)
(b)
Figure 1.2: (a) Part of the Gene Ontology structure taken from [34]. The domains that
GO represents are biological processes, molecular functions and cellular components
which are three separate ontologies with no overlapping terms. The nodes in the graph
represent ontology terms while the edges represent relation between terms. The edge
label indicates the type of relations including ‘I’(is a), ‘P’(part of) and ‘R’(regulates). The
dashed lines represent inferred relations based on the ‘True Path Rule’. (b) A GO term
definition in the OBO format.
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‘metabolism’ or ‘signaling’, without the detail of the specific fine grained terms. Cur-
rently (September 2016), the GO consortium maintains 10 GO slims including a ‘Yeast
slim’, a ‘Metagenomics slim’ and a ‘Chembl Drug Target slim’. These slims contain
a small number of terms that separate gene products into very broad categories within
the domain. However, while useful for achieving a bird’s eye view, the massive loss
of resolution greatly reduces the ability of GO-slims to pinpoint relevant processes,
limiting their usage.
Alternatively, instead of using a ‘top-down’ approach, Geifman et. al. [37] pre-
sented an innovative way that prunes the ontology from the ‘bottom-up’ to produce a
domain-specific ontology named ‘NIGO’ (The Neural/Immune Gene Ontology) that is
a subset of the Gene Ontology. “Clipping” selects only the most relevant terms (bottom
most term in the ontology DAG) to a specific system and clips irrelevant terms from
the ontology. The fundamental difference between a clipped ontology and a slimmed
ontology is that, in terms of enrichment analysis, a slimmed ontology will achieve
an improvement of statistical scores assigned to the enriched terms which are usually
general top-level terms that will reveal a lot about the nature of the biological differ-
ences between two sets of samples, but little regarding the specific responses. On the
other hand, the clip ontology not only improves the statistical scores but also provides
enriched terms from all hierarchical levels which reveals more about the biology un-
derlying the study. In short, better and more comprehensible/interpretable results for
functional analysis of microarray data can be achieved, with minimal loss of resolution
using a clip ontology. As an example, Geifman et. al. [37] used nine neural and/or im-
mune related microarray data sets together with three non neural/immune data sets(as
control) to perform functional analysis with GSEA algorithm [38] on ‘NIGO’, full GO
and a generic GO slim. The results show that functional analysis of neural/immune
related microarray experiments with ‘NIGO’ improved the false discovery rate (FDR)
values of relevant GO terms in comparison to the full GO and the generic GO slim with
minor loss of relevant terms for the related experiments, but not for neural/immune un-
related experiments. Note that using a clip in analysis such as enrichment analysis is
not going to help to generate more significantly enriched terms, on the contrary, some
of the significant terms may not pass the threshold when using a clip ontology, oth-
ers may received reduced significant values due to the reduce of number of irrelevant
terms compare to using the full ontology. Thus, the use of a clip can be considered as
an extra step to filter out false positives (conservative) from the enrichment result.
Despite the fact that an ontology slim or a clip ontology require less effort than cre-
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ating domain specific ontology from scratch, it is still challenging to automate a such
process. Even through a 5-step filtration process was proposed to automate most of
the work in creating the NIGO in [37], domain knowledge is still extensively needed,
thus the process cannot be easily adapted to create clip ontologies in other domains.
An alternative method of creating a clip for a domain would be to analyze the enrich-
ment results of a well studied gene list that are relevant to the domain and pick those
enriched terms to ‘seed’ of the clip and walk up/down the ontology DAG from the
seeds to manually pick appropriate terms. However, such a process requires human
involvement, and is therefore hard to scale and standardize.
1.1.1.6 Essential elements of an ontology
Ontologies provide rich features associated with their controlled vocabularies to rep-
resent concepts and their relation to a domain. The minimum requirements of an on-
tology are a unique identifier and term name, and the definition of terms and their re-
lations. Beside these essential elements of the ontology, some other optional elements
that provide extra information are often used, including:
• Secondary IDs or alternate IDs, that refer to a term. These IDs are created when
two or more terms are identical in meaning, and are merged into a single term.
All terms IDs are preserved so that no information (for example, annotations to
the merged IDs) is lost.
• Synonyms. Alternative words or phrases closely related in meaning to the term
name, with indication of the relationship between the name and synonym given
by the synonym scope. This can be very useful when using an ontology as a
dictionary for NLP task(see below section).
• Database cross-references, or dbxref, refer to identical or very similar objects in
other databases or other ontologies. For instance, the molecular function term
“retinal isomerase activity” is cross-referenced with the Enzyme Commission
entry EC:5.2.1.3; the biological process term sulfate assimilation has the cross-
reference MetaCyc:PWY-781.
• Comment, including any extra information about the term and its usage.
• Subset, indicates that the term belongs to a designated subset of terms, e.g. a
slim or a clip.
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• Obsolete tag, indicates that the term has been deprecated and should not be used.
1.1.1.7 Ontology annotation
Gene annotation refers to the process of assigning relevant information to gene or gene
products. Such information can be the gene’s functions, relevant diseases/phenotypes
or pathways that generated from different research groups, databases etc. The lack of
a standard and of guidance for preparing sources and using this information results in
a huge variation in the format, granularity and quality of the annotations. For example,
disease annotation for ‘Alzheimer’s disease’, in the OMIM database for ‘Alzheimer
disease’ refer to the disorder and contains more than 20 disorder entities with differ-
ent subtypes (‘Alzheimer disease 1, familial’ or ‘Alzheimer disease 6’) and conditions
(‘Alzheimer disease, type 3’,‘Alzheimer disease, type 3, with spastic paraparesis and
apraxia’ or ‘Alzheimer disease, type 3, with spastic paraparesis and unusual plaques’).
In the Ensembl variant database, both ‘Alzheimer disease’ and ‘Alzheimer’s disease’
are used to refer to the same disease with more than 30 different text entities repre-
senting subtypes or conditions including ‘Alzheimer disease type 1’,‘ALZHEIMER
DISEASE FAMILIAL 3’, ‘ALZHEIMER DISEASE FAMILIAL 3 WITH UNUSUAL
PLAQUES’ and ‘Alzheimer’s disease (late onset)’. The two databases use different
terminologies for the same disease, and even the same subtypes are represented differ-
ently (‘Alzheimer disease type 1’ vs ‘Alzheimer disease 1, familial’). Such inconsis-
tency and unstructured text based annotation is far from comprehensive, not computa-
tion friendly and hard to be integrated or used in any modern analysis technique.
1.1.2 The challenges of ontology based annotation
The Gene Ontology (GO) (fig. 1.3) based annotation is currently the only annotation
data source used the most, due to the fact that the GO has been developed for over a
decade to get a good annotation coverage. GO is designed to represent knowledge for
biological process, molecular functions and cellular components. However, annotation
with single ontologies is often not sufficient to explain experimental results. There are
many other established and emerging ontologies that would be beneficial for the bio-
logical interpretation of data in a different range of areas but they are rarely used. For
example, there were more than 500 unique ontologies (September 2016) in the NCBO
repository [22], including the Human Disease Ontology (DOID) [39], Human Pheno-
type Ontology (HP) [40] and Alzheimer’s disease ontology (ADO) [41], each of which
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focuses on a specific domain. Together, these ontologies can be used to formalize large,
unstructured and often diverse data types such as those from clinical records. Multiple
ontologies can be used together to capture information and knowledge from different
perspectives including drug, phenotypes, disease, environmental factors, behavior and
diagnostic procedures, which will potentially lead to novel therapies, methods for pa-
tient classification and clinical decision making, which is one of the key objectives
of TBI. However the lack of annotation coverage in these ontologies greatly limits
their usefulness and places a huge barrier to their usage with existing data analysis
techniques [42]. As an example, the gene HMOX2 was shown to be involved in the
process of pigment biosynthesis by McCoubrey et al. in 1992 [43] but it is still not
annotated as such today. More commonly, because of the time lag necessary for the
manual curation process, some of the recent discoveries are not yet available.
Figure 1.3: Part of the Gene Ontology structure. Nodes represent Gene Ontology terms
while edges between nodes indicate their relationship. The most common relation is
the ‘is a’ relation, indicated by a capital ‘I’ on the edge, which connects a GO term with
its sub concepts(children terms). Other relation including ‘R’ for regulates and P for
‘part of’ are also defined in GO.
Since manual curation is not sufficient [44], it is impractical to manually annotate
all ontologies. In recent years, Natural language processing (NLP) has been proven to
be a reliable and accurate method to identify and extract relevant data from biomedi-
cal text corpora, showing promise for the automation of the ontology annotation pro-
cess [45]. Attempts have been made to use text mining to learn more about human
diseases. Rappaport et. al. [46] proposed a disease annotation system called ‘MalaC-
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ard’, which integrated 44 disease sources and used an in house automatic disease name
unification algorithm to generate disease entities. Text mining algorithms have also
been to improve chemical-gene-disease curation in The Comparative Toxicogenomics
Database (CTD) [47] and the ‘Genetic Association Database’(GAD) [48] which aims
to collect, standardize and archive genetic association study data with data mining
tools. ‘DisGeNET’ provides gene disease association data by combining manually
curated data together with an NLP-based approach [49]. These works all use text min-
ing approaches to discover gene disease associations from biomedical text, however,
instead of using ontologies to represent diseases, they use different terminologies for
representation/classification. This lack of consistency on the use of formal data struc-
tures makes it hard to determine the number and types of diseases each database con-
tains. It also makes it impossible to compare/integrate gene disease annotations across
these databases. For example, in the GAD database, a search for ‘Crohn’s disease’
returns 25 results but searching for ‘regional enteritis’ returns no results.
Osborne et. al. [3] proposed an NLP based approach with the MetaMap [50] and
mined the NCBI GeneRIF database for human gene disease associations. Instead of
using unstructured terminologies, Human Disease Ontology (HDO) [39] was used to
represent human diseases. The resulting HDO based gene annotation was assessed
against the Homayouni gene collection [51] and suggested a 91% recall rate and 97%
precision rate. In a similar approach, LePendu et. al. [4] applied a different NLP ap-
proach with the NCBO annotator [52] and mined HDO terms from titles and abstracts
of PubMed entries. The resulting HDO based gene disease annotation can be easily
reasoned, aggregated, filtered, and cross-referenced. Such ontology based annotation
facilitates a range of downstream analysis, for example, ontology term enrichment
analysis and network analysis, which are likely to bring new insights into human dis-
eases.
1.2 Existing Tools for Functional Annotation Analysis
The second part of the TBI challenge is the availability of the appropriate bioinformat-
ics tools for the analysis and exploitation of gene annotation data. Functional analysis
of gene lists, derived in most cases from high-throughput genomic, proteomic and
bioinformatics scanning approaches, is still a challenging and daunting task. Over the
last decade, gene-annotation enrichment analysis has become standard practice in the
analysis of such lists, making it possible to systematically assess enriched and pertinent
14 Chapter 1. Introduction
biological features and processes. The assumption underlying enrichment analysis is
that biological processes are the result of the cohorts of genes rather than a single
individual gene. Under this assumption, for a particular biological process in a given
study, the co-functioning genes should have a higher (enriched) potential to be selected
as a relevant group by the high-throughput screening technologies. Instead of focusing
on an individual gene, such analysis consider a group of relevant genes at the same
time, increasing the likelihood for researchers to identify the most pertinent biological
processes under study.
Many Bioinformatics enrichment tools have been developed over the last decade.
These tools play an important and successful role in gene functional analysis and are
often applied to gene lists for various high-throughput biological studies [49, 53–59].
In a survey, Huang et al. [16] identified and reviewed at least 68 different enrichment
methods. The 68 methods were classified into three categories: singular enrichment
analysis (SEA); gene set enrichment analysis (GSEA); and modular enrichment anal-
ysis (MEA).
Singular Enrichment Analysis (SEA)
SEA is the most traditional way to identify predefined annotated gene sets (ontology
terms such as GO terms in ontology based annotation), that appear significant more
frequently than random in a candidate gene list. Such enrichment analysis often takes
a list of preselected ‘interesting’ genes (e.g. differentially expressed genes with a p-
value ≤0.05 and fold-change ≥1.5) and then iteratively tests the enrichment of each
ontology term one-by-one in a linear mode. The resulting enriched ontology terms
are then ranked by significance and presented as a flat list. A toy example of the SEA
approach is shown in fig. 1.4.
The SEA approach is a simple but efficient way to gain a first biological insight
into the important functions associated with a set of genes. A family of enrichment
tools was developed, implementing the SEA approach, such as GoMiner [55], Onto-
Express [54], DAVID [60], GIEASE [61] and GFinder [62]. They have been widely
used in enrichment analysis with significant success by many researchers [49, 56–59].
However, since the pre-selection genes for the input list has a great impact on the en-
richment result. For example, the use of differentially expressed genes with a p-value
≤0.05 vs a p-value ≤0.01 from the same experiment may result in totally different
enrichment result. Such arbitrary ‘cut-off’ made to select the genes makes SEA sub-
jective to a certain degree. The SEA is also criticized for its assumption of the indepen-
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dence of genes within the predefined gene sets (genes annotated to an ontology term).
In fact, an extensive correlation between genes is a well-documented phenomenon.
For example, Gatti et. al. [63] investigated the correlation between genes within gene
sets (genes annotated with the sane GO term and genes involved in the same KEGG
pathway) by analyzing 8,656 arrays from Gene Expression Omnibus [23] data. Their
results gave strong evidence of consistent correlations between genes in GO term and
KEGG pathway, suggesting that the gene independence assumption is inappropriate
and the correlations between gene within gene set are non-trivial which, if ignored,
may lead to overly optimistic results (smaller p-value with more false positives) in
SEA analysis [16, 64–67]. In addition, the flat list of enriched terms generated by the
SEA can something be very large and overwhelmed by groups of ‘similar’ terms, for
instance, Gene Ontology terms like cell growth, unidimensional cell growth, multi-
dimensional cell growth, cell tip growth, pollen tube growth, etc., which dilute the
interrelationships of relevant biology concept in the result.
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Figure 1.4: A toy example illustrating the SEA work flow: First, a candidate gene list
of interest is generated. This, for example, could be a list of genes from a microarray
experiment where gene expression values are measured in different conditions. A p-
value is given to each gene based on a null hypothesis and those genes that passed
a specific cut-off will become the candidate genes. Then, for each ontology term, the
frequency of the term in the candidate gene list is compared to the frequency of the term
in a reference background (usually includes all the ontology terms and their annotated
genes). Finally, A two-by-two contingency table is created and used to assess the
significance of such an observation, accounting for the size of the candidate gene list
and the background, for example, using a Fisher exact test. The background set in the
example consists of M=100 genes which is all the gene from the microarray with at least
one ontology annotation. The set of interest has N = 4 genes which are the genes that
pass the user defined threshold (p-value ≤0.05 and fold-change ≥1.5). Term A has
three links to 3 genes within the set of interest (n = 3) and 1 genes to the background
set which is not in the set of interesting (m = 4). A contingency table was created
to calculate the statistical significance with Fisher’s Exact Test, which in this particular
example, p− value = 9.81e−05, indicating a significant enrichment of Term A
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Gene Set Enrichment Analysis (GSEA)
To overcome the arbitrary ‘cut-off’ limitations of the SEA approach, gene set enrich-
ment analysis (GSEA) was introduced in [68]. The GSEA is a ‘cut-off’ free approach
that takes all the genes from a high-throughput experiment, for example at the same
time. The primary advantages of GSEA are that 1) it objectively considers the entire
list of genes so that those genes that would have been removed by the ‘cut-off’ (with
a relatively small fold-change or ranked at the bottom of the gene list) are included
and contribute to the enrichment analysis in certain degrees; 2) it used a permutation
based resampling approach to estimate the enrichment, maintaining the gene-gene de-
pendency that reflects real biology and have been proven reducing the false positives
from the result [63, 69].
In a typical GSEA scenario, genome wide gene expression profiles are generated
from samples belonging to one of two classes, for example, tumors that are sensitive
vs. resistant to a drug. These genes are ranked by their correlation to the classes C with
a ranking metric, for example, signal to noise ratio. The task is to find out whether a
predefined gene set S (genes in the same pathway or sharing the same GO annotation)
is overrepresented towards the top or bottom of the ranked list L. An enrichment score
(ES) is calculated by walking down the ranked list L, increasing a running-sum statistic
when encountering a member gene of set S (Phit) and decreasing it when encountering
a non-member gene of set S (Pmiss) (Equation eq. (1.1) on the following page). The
ES is defined to be the maximum deviation of the running-sum from zero across all
genes (Phit −Pmiss), which corresponds to a weighted Kolmogorov-Smirnov statistic.
The magnitude of the increment during the running-sum process is controlled by an
exponent p. When p = 0, increment steps are equal to those in a standard Kolmogorov-
Smirnov statistic. When p = 1, the increment of hitting a gene in S is weighted by their
correlation to class C normalized by the sum of the correlations over all of the genes
in S. For each gene S, a permutation test is performed to shuffle the gene expression
values a predefined number of times N in order to obtain an ESnull distribution. An
enrichment p-value for S is then computed as the fraction of shuffles which produces
an ES at least as great as the observed.
The Leading-Edge Subset of genes in gene set S, as defined in [38], are those genes
in the gene set S that appear in the ranked list L at, or before, the point where the
running sum reaches its maximum deviation from zero (fig. 1.5). These genes can be
interpreted as the core members of a gene set that account for the enrichment signal
and these often reveling important biological insights as shown in [38].
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where Phit(S, j) is the normalized step length for the j th gene in the ranked List L
which also in the gene set S, Pmiss(S, i, j) is the normalized step length for the j th gene
in the ranked List L but not in the gene set S. i is the position in order list L, r j is the
correlation of gene g j with class C, N is the total number of genes in L and NH is the
number of overlapping gene in S and L.
Figure 1.5: GSEA work flow. Genes are ranked by their correlation to the classes
(e.g. disease vs control) with a ranking metric, for example, signal to noise ratio. An
enrichment score (ES) is calculated by walking down the ranked list L, increasing a
running-sum statistic when encounter a member gene of set S and decreasing it when
encounter a non-member gene of set S. The ES is defined to be the maximum devia-
tion of the running-sum from zero across all genes, which corresponds to a weighted
Kolmogorov-Smirnov statistic [38].
In the original implementation of GSEA [68], the exponent p was set to 0 which
yielded high ES value for gene sets clustered near the middle of the rank list. These
sets were found not to represent biologically relevant correlation with the classes. This
issue has been solved by an improved version of GSEA introduced by Subramanian
et al [38] which weights the steps based on each gene’s correlations with the sample
classes (i.e. condition vs control or A and B in fig. 1.5), which correspond to seting
p = 1. In this project, a conceptually similar GSEA algorithm is proposed and im-
plemented. The exponent p has been set according to a confidence score based on
HDGDB which increases the magnitude of the effect of those confident annotations
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and decreases the magnitude of the effect for less confident ones. This will be dis-
cussed in the detail in section 3.2.7.
Since the publication of the original GSEA method, other GSEA-like gene set
analysis strategies have been developed and implemented such as SAM-GS [70], LR-
path [71] and GAGE [72]. Tools like ErmineJ [73], GO-Mapper [74], ADGO [75] use
slightly different statistical tests but keep the ‘cut-off’ free feature of GSEA. However,
a common feature of GSEA is that the enrichment p-value is mainly driven by genes
towards the extreme of the ranked list (top or bottom, usually those with the highest
fold change). These genes being highly weighted, contribute the most to the ES score.
This is not always true in real biology since some big changes in a gene’s expression
may be caused just by some small but important signal regulation events. Depending
on the research scenario, subtle changes in gene expression can be just as important.
In addition, GSEA is not suitable for experiments that only have small number of sam-
ples. This is because the enrichment p-value is calculated base on a permutation test
that shuffles the sample labels to obtain a ‘null’ distribution. A small sample size heav-
ily affects the quality of the ‘null’ distribution, thus yielding an unreliable enrichment
p-value. For example, if the experiment generates 6 samples belonging to 2 classes,
then the estimated p-value is always greater than 0.05. When only 4 samples are avail-
able, the estimated p-value is always greater than 0.16, which will not generate any
significant results with a commonly used 0.05 threshold. In practice, a minimum of 10
samples is usually required for effective GSEA which is not always possible in real bi-
ology experiments due to the fact that these experiments are often time consuming and
expensive. More evidence on how enrichment results vary depending upon the choice
of ‘null’ distribution can be found in [76]. A workaround to use GSEA on small sam-
ple size data is, shuffle the gene labels in the permutation procedure rather than the
sample labels to obtain the ‘null’ distribution. The rationale of this approach is that
a significant gene set should be distinguishable from an equally sized set composed
of randomly chosen genes. However, gene label shuffling is not strictly appropriate
because it breaks the gene-gene correlations, thus resulting overestimation of signifi-
cance level. This method can however, be useful for hypothesis generation. Sample la-
bel shuffling is generally favoured because it preserves the relationship between genes
and addresses the question of identifying S whose expression changes correlate with
sample class changes. The differing two shuffling approaches generate different ‘null’
distribution which in turn, often leads to different conclusions [77]. Last, but not least,
the KolmogorovSmirnov statistic requires a relatively large number of data points to
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properly calculate the p-value. Thus the GSEA method works better on a predefined
gene set S when S contains a large number of genes. It’s performance and reliability
drop as S becomes smaller in size.
Modular Enrichment Analysis (MEA)
MEA is an extension of SEA/GSEA where network discovery algorithms are consid-
ered base on term-to-term relationships among annotations. Two main kinds of MEA
currently exist. The First kind of MEA uses clustering algorithms to either pre-process
the referenced background or post-process the enrichment result from SEA/GSEA.
For example, tools like ADGO [78] and ProfCom [79] implement algorithms to pre-
process ontology based annotation, using boolean set operations including intersec-
tion, union and subtraction, to generate composite (joint) annotation terms which are
used subsequently as the reference background in the enrichment analysis. These algo-
rithms were motivated by the insufficiency of single ontology in explaining the changes
of specific expression patterns. For example, not all of the genes categorized by a bio-
logical process may alter their expressions as a whole under an experimental condition,
but only those with a particular localization or those involved in a particular pathway
might alter their expressions. Thus, if genes of term A from Gene Ontology Biolog-
ical Process (GOBP) overlaps with term B from Gene Ontology Cellular Component
(GOCC) to a certain degree (can be adjusted accordingly), a set union is performed and
a composite term is created with genes involved in a particular biological process (A)
which takes place in a specific location (B). It is suggested that the use of such joint an-
notations can improve discovery sensitivity and specificity in enrichment analysis [78].
Other tools like COFECO [80]and GENECODIS [81] implement an association rule-
mining algorithm to extract co-occurring annotations and apply clustering algorithms
on the enrichment results to group ‘similar’ terms into the most relevant meta groups.
These approaches take advantage of the relationship between ontology terms and create
joint terms that may contain more meaningful biological information than individual
ones. The results are highly redundant and have interrelationship regarding different
aspects of the underlying biology being studied.
The Second kind of MEA makes use of the ontology hierarchy structure to improve
the design of the enrichment algorithm. Ontology terms are typically structured as a
directed acyclic graph (DAG), with nodes being the terms and edges being the relations
(‘is a’, ‘part of’, etc.). Nodes towards the top (high) of the hierarchy represent general
terms (e.g. a cell) where nodes become more and more specific as you travel down
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the DAG towards the leaves (e.g. synaptic vesicle). TopGO [33] developed a gene
elimination method which utilizes the topology of the ontology structure to find the
most specific term during enrichment analysis. The algorithm starts testing enrichment
from the term located at the bottom of the hierarchy, removing gene annotations from
all of the parent terms if a term is found to be significantly enriched, otherwise, the
gene annotation is rolled up to the parent terms. This effectively stops gene annotations
contributing repeatably to higher level terms (more general) thus favouring reporting
of the most specific terms. A similar approach has also been developed in the pathway
analysis field where the pathway topology structure is used to improve analysis [82].
The key advantage of the MEA approach is that it implements the basic concepts of
SEA/GSEA while incorporating term-to-term relationships shifting enrichment analy-
sis from term-centric to biological module-centric. By taking into account the redun-
dant and graph-structure of ontology annotations, respects the fact that biology often
works in a co-ordinated manner, a bigger and more meaningful biological picture may
be generated from these result. However, MEA implements the core of the SEA/GSEA
and so also inherits their limitations. For example, the quality of the pre-selected gene
list impacts on the results, just as it does in SEA analysis. In addition, orphan terms
or genes are likely to be omitted which could have brought important insights to the
analysis.
Despite the distinct features of the different enrichment tools, the general procedure
for enrichment analysis is similar and can be summarized into three parts: 1) prepara-
tion of the backend annotation database; 2) calculation of the enrichment (algorithm
and statistics) against a reference set; and 3) post-process and presentation of the re-
sult. It is a common misunderstanding to only consider the statistical method alone
in enrichment analysis. In fact, each of the three parts has great influence on the final
enrichment results. Based on these three parts, some common limitations are revealed.
1. Backend Annotation Database
In general, enrichment analysis is designed to detect significantly over-represented
annotations shared by a set of interesting genes when compared to a reference back-
ground gene set. The quality of the annotation is one of the most important components
in the analysis process and has a great effect on the results. In general, two types of
annotation exist in the biological domain, unstructured and structured. The former usu-
ally refers to annotation that uses plain text while the latter usually refers to ontology
based annotation. Huge variation and duplication exist in unstructured annotations due
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to the fact that they are created by different experts using inconsistent, non-standard
terminologies and are not suitable for quantitative analysis such as enrichment anal-
ysis. On the other hand, ontology based annotations provide a formal and consistent
vocabulary for representation of domain knowledge. The structure of the ontology
naturally reflects the interrelationship between the ontology terms, respecting the true
underlying biology, which is very important especially for MEA algorithms that take
into account such structure when calculating the enrichment. In addition, ontology
based annotation is amenable to computer manipulation which makes them ideal for
use in enrichment analysis.
The Gene Ontology (GO) [20] based annotation is currently the only annotation
data source used in most, if not all of the enrichment analysis tools because GO pro-
vides a relatively good gene coverage to be used as a reference background. However,
there are many other established and emerging ontologies that would be beneficial for
biological interpretation in different aspects but are rarely used in enrichment analysis
due to the lack of annotations [16]. In addition to incomplete annotations, some of the
existing annotations are inaccurate. For example, out of 481685 total GO annotations
available for Homo sapiens, 155499 (32%) are inferred exclusively from electronic
annotations (with Evidence Codes IEA, no human expert has been used to check the
annotation’s accuracy). Even though the vast majority of them are reasonably accu-
rate [83], some are incorrect [84, 85].
In terms of disease, a recent survey by Rappaport et al. [46] identified more than 60
disease-related databases, each of which focuses on different aspects of disease annota-
tion and/or contains a specialized list. Moreover, different biological aspects are being
maintained and annotated by different independent resources which have different fo-
cus. For example, OMIM [86] contains gene-disease associations while KEGG [87]
mainly focus on pathways; BIND [88] stores protein-protein interactions while protein
domain information can be found in Pfam [89]. A comprehensive backend annotation
data set should integrate diverse and heterogeneous data sources in a coherent way to
provide a more reliable reference rather than using single data sources such as GO
alone.
Despite the advantages of using ontology based annotations, the usefulness of en-
richment analyses is impacted by the annotation bias present in ontology based anno-
tation databases. Some biological processes or diseases are studied in more detail than
others, thus more data are available for the corresponding ontology terms. If more data
about a specific ontology term is available, more of the genes associated with it will be
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known and hence, the term is more likely to appear as significant than others during
enrichment analysis.
I discussed in chapter 2 on page 33 how we improve the backend annotation
database by implementing a data integration framework and integrated three publicly
available data sources including GeneRIF, OMIM and Ensembl variation using the
Human Disease Ontology. The resulting annotation database, named HDGDB, is po-
tentially more useful than any of the three single databases and is used throughout
subsequent work in this thesis.
2. Creating an appropriate gene reference background
As noted in the previous example, if 20% of the genes under study are found to be
associated with the synapse complexity compared to 8% of genes in the human genome
as a while, a statistical test could be performed against a null-hypothesis passed at
a user-selected α value. In this example, the genes under study are compared to a
reference gene set, the human genome. The choice of the reference gene set has a
great impact on the calculation of p-value, even when using the same statistical test.
Two main approaches exist for selecting reference gene sets. The first approach
selects reference genes background based on the available genes, that is all genes from
a genome [55,90,91] or, for example in a microarray experiment, to select those genes
that exist on a microarray [53, 54], since a gene that is not on the array can never be
found to be differentially expressed , thus including those genes will only increase the
size of the background, which often result in an overly optimistic p−value. A second
approach of selecting reference genes is, on top of the first approach, based on the
annotation availability. For example, when using GO, [90] uses all the genes that have
a GO annotation as the reference gene set. Recently this method has been improved
by selecting genes only with annotations that are relevant to the study. By utilizing the
ontology structure, a sub-set of the ontology terms are first selected to form a pruned
version of the ontology that is specific to a narrowed-down domain, a ‘clip ontology’
(see section 1.1.1.5 on page 7) in [37]. Then the genes with annotations from this
sub-ontology are selected as the reference gene set. This method reduces the number
of genes in the background, thus tend to be conservative but has good performance in
eliminating false positive as reported in [37].
There is no ‘gold’ standard method for selecting a gene reference background.
Sometimes biology experts have domain knowledge that can be used for guiding the
selection of the reference genes. When this information is not available, I believe that
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Null hypothesis is True H0 Alternative hypothesis is True H1 Total
Declared significant V S R
Declared non-significant U T m-R
Total m0 m-m0 m
Table 1.1: Various errors committed when testing multiple null hypotheses. V is the
number of false positives (Type I error) (also called ‘false discoveries’) while ‘T’ is the
number of false negatives (Type II error).
using genes with relevant annotations is the best approach.
3. Multiple Hypothesis Testing
In a typical enrichment analysis, a list of interesting genes are tested against a num-
ber of predefined gene sets (ontology terms) simultaneously against a null-hypothesis
passed at a user-selected α level (commonly set to 5% or 1%). Those terms that have a
p-value less than the pre-selected α level are considered significantly enriched. How-
ever, according to statistical principles, the more gene sets that are tested at the same
time, the greater the chance of an increase in the Family Wise Error Rate (FWER, or
type I error, ‘V’ in table 1.1, the probability of making one or more false discover-
ies among a family of hypothesis tests) [92, 93], thus, any of those significantly en-
riched terms can actually appear with a non-zero probability just by chance. This
issue, refers to the multiple hypothesis testing problem, which is well recognized in
the field [55, 90, 94–97]. The un-adjusted p-value can be misleading and correction
is need. table 1.1 shows possible errors committed when testing m null hypotheses.
It defines some random variables that are related to the m hypothesis tests. m0 is the
number of true null hypotheses. V is the number of false positives (Type I error, also
called ‘false discoveries’), R is the number of rejected null hypotheses (‘discoveries’).
FWER can be formally defined as FWER = Pr(V ≥ 1).
Methods are available to control the FWER in multiple hypothesis testing. Bon-
ferroni correction is one of the simplest methods used to counteract the problem of
multiple comparisons. It controls the FWER by dividing the un-adjusted p-value by
the number of tests performed to ensure that the probability of making even one type
I error in the family stays less than a certain level (such as α ≤ 0.05). This method is
widely used, but is known to be overly conservative in the sense that while it reduces
the number of false positives, it also reduces the number of true discoveries. Thus it is
not suitable for analysis where many gene sets are involved (e.g. more than 50) which
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unfortunately is the case for most enrichment analyses. Improved methods includ-
ing Holm’s step-down procedure [98] and Hochberg’s step-up procedure [99] were
introduced as less conservative adjustments of the p-value. For example, in Holm’s
step-down procedures, p-value are ordered from lowest to highest. For a given level α,
the procedures walk down the list of p-value, accepting the test until the smallest kth
such that Pk > αm+1−k , where m is the number of tests performed and k is the index in
the ordered p-value list.
However, these statistical methods assume independence amount the individual
test, which is known to be false for most of the ontology based enrichment analysis.
For example, the hierarchy of the Gene Ontology indicates that many terms are closely
related, sometimes as parent-child, sometimes as siblings sharing the same parents. In
addition, methods that control the FWER are often criticized as having low power (the
ability of a test to detect an effect). These methods are suitable for studies where any
false positives can lead to a large waste of time to experimentally tested, but are way
too conservative for others such as gene expression data generated by high-throughput
technologies where small sample numbers are tested and large numbers of variables
are measured. Guarding against one or more false positives is typically going to be too
strict and will lead to many missed findings of interesting hypothesis.
A better question to ask, is how many errors are expected, the so called false dis-
covery rate (FDR,the proportion of type I errors among all rejected hypotheses) [93].
FDR is more flexible and has better power than FWER, which is particularly good
for exploratory analysis where it is better to have mostly true findings, rather than
guarding against one or more false positive results. FDR can be formally defined as
FDR = E[ VV+S ] = E[
V
R ] (see table 1.1 for notions). Controlling the FDR is a process
that controls the distribution of the test statistics,f, for example, the distribution of p-
values. f is generally considered as the mixture density of the two populations [100]:




Where f0 and f1 are the distribution of the test statistic under the null-hypothesis (H0)
and the alternative hypothesis (H1) respectively, m0 is the number of true H0, m is the
total number of hypotheses and π0 is the proportion of true H0 among m.
Methods such as those proposed in the original FDR paper by Benjamini et al [93],
compute the FDR directly from the p-value, without estimating π0 (equal to π0 = 1,
assuming complete H0), providing the strongest control on FDR but with the low-
est power. Alternative methods like those in [101–115] were proposed to estimate
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π0 and control FDR based on an estimated π0 (Figure 1.6a). However, these estima-
tions are based on the assumption that f0 is uniformly distributed. This is not true in
datasets with large scale strong correlations where the observed f0 severely deviate
from uniform, causing π0 estimation methods to become very unstable which in turn
makes FDR estimation unreliable [107]. The effect of correlation on simultaneous
significance tests was previously studied theoretically in [116–118]. Improved tech-
niques have been developed such as in [67] where re-sampling strategies were used
in strongly correlated simulated dataset and the estimations of π0 is reported greatly
improved. After the original FDR paper Benjamini and Hochberg (1995) [93], there
were increasingly interests in developing methodologies for controlling the FDR under
different model assumptions, instead of the independent assumptions. In a later paper,
Benjamini and Yekutieli (2001) (hereafter called BY) [119] relaxed the independence
assumption to certain dependence structures, that is, when the underlying statistics are
positive regression dependent on a subset of the true null hypotheses. A conservative
step-up procedure controlling the FDR was developed to control the FDR in the strong
sense without relying on the independence assumption. The BY procedure was used
as the default method for multiple hypothesis correction for all the result presented in
the thesis.
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(a) (b)
Figure 1.6: Two methods for FDR estimation. a) FDR is estimated by assuming a uni-
form distribution of the test statistic, for example, p-value. The top histogram shows the
uniform distribution which is likely to be seen in an experiment where there is no sig-
nificant changes. Note that even if there are no significant changes in the experiment,
it is still expected, by chance, to get p-values<0.05 (in red). In the bottom histogram,
significant changes are observed (in green), some might be false positives. Based on
the uniform distribution assumption, a line can be drawn where the p-value distribution
flattens out which helps to estimate how many significant values are actually false pos-
itives (the red portion of the green bar). b) FDR is estimated against an empirical null
distribution. The empirical null distribution is usually derived by re-sampling or perform-
ing a permutation of the dataset. For a given threshold (vertical line), the shaded area
represents all data that is considered significant (All discoveries, R in table 1.1) while
the overlapping area (in red) represents false discoveries (type I errors, V in table 1.1).
The ratio of these two areas is then used to estimate the FDR. (the figure shows the
idealized distribution, the actual distribution would usually be depicted with a histogram
or bar graph)
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Other methods are available to compute the FDR. For example, instead of using
the distribution of the test statistics, calculating it directly from the dataset using re-
sampling/permutation based algorithms such as SAM [120], dChip [121] and GSEA
[38]. In theses methods, the FDR is computed against an empirical approximation of
the null distribution ( f0) which naturally considered the correlation between the tests
(fig. 1.6b). However, these methods usually require a large amount of sample data to
compute a reliable null distribution which is a limitation especially in the context of
biological experiments. In addition, like methods by Benjamini et al [93, 119], these
permutation based algorithms do not estimate π0, thus the FDR control is considered
to be overly conservative especially in datasets with a large number of true alternative
hypothesis (H1).
Multiple hypothesis correction has been studied for many years and it is, not just
in the context of enrichment analysis, but in general still a very active field. It is
very important to be aware of such problems when doing multiple hypothesis tests but
there is not much evidence of how much of an improvement in discovery sensitivity
and specificity can be achieved by applying these methods in real-life practice in en-
richment analysis. By comparing various common correction methods that are with
real-life datasets in Gene Ontology enrichment analysis, [122] concluded that com-
mon multiple testing correction methods that are overly conservative approaches for
enrichment analysis involving thousands of annotation terms, may negatively affect
specificity rather than improve it. As pointed out by [16], enrichment analysis results
are influenced not only by the statistical methods used, but also by the algorithms and
data sources used. This can not simply be fixed by multiple testing correction, sug-
gesting that efforts to improve sensitivity and specificity should first be fundamentally
addressed before refining statistical approaches.
4. ID Mapping
Annotation databases typically provide annotations for genes using some kind of gene
identifiers such as the EntrezGene ID [123] or HGNC gene symbol. High throughput
technologies like microarrays use their own probe names to identify specific nucleotide
sequences, which map to specific genes. Thus, in order to perform enrichment anal-
ysis for a list of differentially expressed genes, an essential first step is to effectively
translate the list of probe IDs into a list of corresponding gene IDs that matche the
annotation source. For proteins id such as those from UniProt [124], genes need to
be further mapped to proteins. The success of such ID-to-ID and ID-to-annotation
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mappings have a large impact on subsequent enrichment analyses.
Currently, identifiers for genes and proteins are spread out across a number of
databases and other resources and maintained by various independent bioinformatics
organizations/groups/companies that often have very different interests and research
foci. As a result, these resources often use their own identifiers. Cross referencing
these identifiers is still challenging. For example, Entrez Gene does not cover PIR ID
while UniProt does not reference RefSeq ID. Even between the most commonly used
gene identifiers Entrez Gene and Ensembl Gene, there are not always perfect matches.
Such ID mapping issue becomes crucial when mapping from one type of identifier to
another is not one-to-one. For example, some Entrez Gene IDs are mapped to multiple
Ensembl Gene IDs and vice versa which may cause confusion and lead to incorrect
interpretation in the following analysis. What’s more, low-resolution mapping results
in loss of important information. For example, XRN2a , a variant of XRN2, is mainly
expressed in human tissues, whereas another variant of the same gene, XRN2b is found
expressed in blood leukocytes [125]. Only XRN2 exists in the Entrez Gene database
with an Entrez gene id of 22803. Tissue-specific information, and possibly condition-
specific information, provided by the two variants, will be lost during the ID mapping.
Another out-standing issue is to map identifier across model species. This is usually
done by using orthologues genes but may suffer from low coverage or high noise
(many-to-many mapping) issue discuss previously in section 2.3.5.
The increase of the id mapping can also result in an increase of the annotation
content, as reported in [126] that 10-20% more GO terms were able to be assigned
to the corresponding genes in DAVID after a process called the DAVID Gene Con-
cept, a single-linkage algorithm to agglomerate redundant gene IDs into the DAVID
gene clusters in order to improve cross-referencing capability across several indepen-
dent database sources, particularly between NCBI and UniProt systems. Even though
efforts have been made to improved the ID-to-ID and ID-to-annotation mapping and
tools have been developed such as Onto-Translate [54], MatchMiner [127], IDCon-
verter [128] and DAVID ID Converter [129], the ID mapping problem is yet to be fully
solved and is still a burden left entirely on the shoulders of the researchers. More effort
is still needed from the major bioinformatics organizations to improve the quantity and
quality of their cross mapping data.
To sum up, despite the usefulness of these tools and the different statistic algo-
rithms used for finding the enriched ontology terms, most of them only work for a
specific type of ontology, GO in the majority cases, even though the general under-
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lying enrichment analysis process is similar. The difference in statistical algorithms,
parameters setting make it not intuitive to compare the enrichment results generated by
these tools under the same environment. A standard framework for general ontology
enrichment analysis is needed, which is, alongside the lack of ontology annotation,
another limitation for the use of newly emerging ontologies.
Therefore, my main motivation of the work presented in this thesis can be sum-
marized as follows: Ontologies are semantic frameworks upon which biological data
can be structured and have grown to be one of the great enabling technologies of mod-
ern bioinformatics. The transformation of unstructured to structured data using data
mapped to ontologies has largely been achieved in a time-consuming manner which
relies on human experts. Such manual data curation is accurate but hard to scale
and unable to keep pace with the rapid expansion and refinement of both ontologies
and the data that we would like to annotate to them. Many bioinformatic tools only
support analysis using the Gene Ontology because it is the best annotated and is the
most widely used and cited. The delay annotating new ontologies and the lack of sup-
port for them in existing analytical tools to aid biological interpretation of data has
become a major limitation to their utility and uptake. Thus, I propose that automatic
approaches are needed to facilitate the transformation of unstructured data to unlock
the potential of all ontologies, with corresponding bioinformatics tools to support their
interpretation.
1.3 Organization of the Thesis
This thesis is divided into three major chapters, two methodological and one applica-
tion based. In chapter 2, I acknowledge the problem of unstructured gene annotation
and the limitation of manual curation. I propose a methodology to ameliorate the
problem based on natural language processing techniques (and related implementa-
tions) which generates ontology based annotation by mining biomedical text corpora.
I discussed the design/implementation details, strengths and weaknesses of the ap-
proach and applied the method to generate human gene disease annotation with hu-
man disease ontology (HDO). I evaluate the method by validating the generated HDO
annotation data with a discussion of extending the annotation of other species. and
evaluate/analyse the resulting annotation data.
In chapter 3, I review current enrichment analysis algorithms and tools, and pro-
pose an R package that integrates a range of statistical algorithms and topological
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methods for ontology based enrichment analysis. Detailed implementation and valida-
tion are discussed, and usage of the package is demonstrated by analyzing the activity-
regulated cytoskeleton-associated protein (ARC) complex.
In chapter 4, I utilize the data produced with the methodology presented in chap-
ter 2, and the tool discussed in chapter 3 to enrich the understanding of human disease
by integrating heterogeneous data in a disease context. I demonstrated the power of the
methodologies by 1) building a disease profile for 277 gene classes constructed from
three ontologies, and 2) building an disease environment for 1310 human diseases.
A final overall remarks is provided in a concluding chapter in chapter 5, with a
discussion of limitations and possible future works.

Chapter 2
Mapping text corpora to ontology
terms using natural language
processing tools
2.1 NLP in biomedical text mining
Ontology based annotation is a key component in enabling data integration and a wide
range of data analysis techniques. However, to annotate genes with a newly devel-
oped ontology is time consuming and currently the burden falls to the corresponding
ontology consortium. There are numerous text based gene annotation resource freely
available from individual labs or from central bioinformatics organization like NCBI or
EBI (European Bioinformatics Institute), but it is still a challenge to automate the an-
notation process with these data. Natural language processing (NLP) has been proved
to be a reliable and accurate method to identify and extract relevant data from text
corpora. A consecutive series of 18,453 pathology reports were evaluated by Bravo et
al. [45] and showed that NLP methods correctly detected 117 out of 118 patients (99.1
%) with prostatic adenocarcinoma after TRUS-guided prostate biopsy.
Concepts (ontology terms), however are difficult to recognize in text due to a dis-
connect between what is captured in an ontology and how the concepts are expressed
in text [130]. Not only the concepts themselves can be expressed in text with a huge
amount of variability, ambiguity and underspecification (see above examples), but also
the relations among them are vague and rarely described explicitly [131]. Thus, a
general approach for concept recognition is still an open research problem.
Ontologies provide a set of terminological resources and semantic constraints,
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which are used in a wide range of dictionary-based concept recognition tools. There
are recognizers for specific ontologies which are used to address specific categories
of terms such as genes or gene products [132], protein mutations [133] or diseases
[134, 135], but these recognizers require targeted training material and cannot generi-
cally be applied to recognize arbitrary terms from text. Two of the most widely used
dictionary-based generic tools for biomedical text mining are the MetaMap [136] de-
veloped by the National Library of Medicine (NLM) and the NCBO Annotator [137]
developed by the National Center for Biomedical Ontology which are considered the
state of the art in the field. Other tools including Whatizit [138], KnowledgeMap [139],
CONANN [140], IndexFinder [141], Terminizer [142] and Peregrine [143] are either
not freely available or appear not to be in widespread use [144].
MetaMap
The MetaMap [145] is a highly configurable program developed at the National Li-
brary of Medicine (NLM) to map biomedical text to the UMLS Metathesaurus or,
equivalently, to discover Metathesaurus concepts referred to in text. MetaMap can run
locally on a Linux machine. It parses input text into noun phrases and generates their
variants including alternate spellings, abbreviations, synonyms, inflections and deriva-
tions. A candidate set of Metathesaurus concepts were identified and scored based
on the strength of mapping from the variants to each candidate concept. MetaMap
natively works with UMLS Metathesaurus, but can be optionally configured to work
on any ontology. The data file builder (DFB) [146] provided by MetaMap allows the
transformation of an ontology into UMLS database tables which is the default dictio-
nary format used by MetaMap.
NCBO Annotator
The NCBO Annotator (formerly referred to as the Open Biomedical Annotator (OBA)),
is an ontology-based Web service [52] that annotates textual meta data with biomedical
ontology concepts (terms). It allows users to tag their data automatically with ontol-
ogy concepts. These concepts come from National Center for Biomedical Ontology
(NCBO) BioPortal [22], an ontology repository containing more than 500 ontologies
(September 2016). The input text is fed into a concept recognition tool developed
by the University of Michigan called MGREP and ontology annotations are produced
only when finding an exact-match. Despite a RESTFUL web service, NCBO also pro-
vides a virtual machine which contains a pre-installed, pre-configured version of the
2.1. NLP in biomedical text mining 35
NCBO Annotator that can be run locally on a Linux operating system. It simulates an
environment which provides all the pre-requirements (scripts, libs etc.) for the NCBO
Annotator and provides the same service locally to the user with a shorter response
time. Ontologies that are currently not in the NCBO BioPortal repository can also be
added locally.
2.1.1 Comparison of concept recognition tools
Funk et al. [144] carried out a detailed evaluation of the performance of MetaMap,
NCBO Annotator and ConceptMapper (CoM) [147], a tool dictionary-base recognizer
that was not specifically developed for biomedical term recognition. The Colorado
Richly Annotated Full-Text (CRAFT) Corpus [148] was used, containing 67 docu-
ments (articles) fully annotated with nine biomedical ontologies and terminologies:
the Cell Type Ontology, the Chemical Entities of Biological Interest ontology, the
NCBI Taxonomy, the Protein Ontology, the Sequence Ontology, the entries of the En-
trez Gene database, and the three sub ontologies of the Gene Ontology. The study
evaluated the tree recognizers using eight out of the nine ontologies (excluding the
Entrez Gene database) in terms of precision and recall under different parameter set-
tings and showed that the best concept recognizers varied from ontology to ontology.
They concluded that the generic ConceptMapper, even though not developed for use in
the biomedical domain, generally provided the best performance. MetaMap tends to
produce the highest recall (five out of eight ontologies tested) but its precision suffers
because it finds the most errors; while NCBO annotator produces the highest precision
(four out of eight ontologies tested) but falls behind in the recall because it is unable
to recognize plurals or variants of terms. As a summarize, the best performance for
all tools on all ontologies tested in [144] are shown in fig. 2.1. Besides performance,
the study also provided general suggestions on the parameter setting to optimize the
performance of the recognizers.
The tool underlying NCBO Annotator, MGREP, has been directly compared against
the MetaMap on several term recognition tasks [149–151]. These studies reach a sim-
ilar conclusion as those in [144] that MGREP outperforms MetaMap in terms of pre-
cision of matching while MetaMap produced more annotations. The actual recall rate
was not given in either study because the test corpora used were not fully annotated.
This is because MetaMap generates lexical variants on ontology terms during its pre-
processing of the ontology while MGREP uses exact match. For the same reason,
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MetaMap suffers from slow speed which makes it unsuitable for many real-time appli-
cations or for applications in which either the data sources or the dictionary changes
frequently. On the other hand, MGREP has extremely fast execution speed, which
makes it possible to process large datasets, that require large dictionaries, or that in-
volve frequent reprocessing.
Many previous studies have been done using NLP tools in the biomedical domain.
In terms of disease, MeSH terms [152–155] or OMIM [156,157] were used for mining
human diseases. Rappaport et. al. used an in house process to integrate 44 disease
sources into 16919 disease entries named ‘disease cards’ [46]. These ‘disease card’
were substantially used in annotating genes based on the information provided by ‘gene
cards’ [158], a similar concept as the ‘disease cards’ that was used to represent genes
and the relevant genomic related information. More recent studies have begun to use
the Human Disease Ontology (HDO). Osborne et al. [3] used MetaMap and mapped
human disease to HDO terms from the NCBI GeneRIF database, which is a curated
database linking genes to short functional annotations and the corresponding publi-
cations in the PubMed database. A truth table of the Homayouni gene collection [51]
was constructed manually using GeneRIF and OMIM texts as sources which were then
used as validation data to evaluate the disease annotation to these two databases. The
result reported a 91% recall rate and 97% precision rate of disease annotation using
GeneRIF, in contrast with a 22% recall and 98% precision using OMIM suggesting
that GeneRIF is a great source for mining gene disease association. LePendu et al. [4]
instead used the NCBO Annotator to automatically generate human disease annota-
tion from already existing GO annotations, based on the hypothesis that if a disease
term is mentioned in the abstract of the article based on which a GO annotation is
created for a gene product, then that disease term is likely to be associated with that
gene product. The resulting gene disease annotation dataset was not directly assessed
quantitatively but qualitatively with several domain experts by 1) inspecting the re-
capitulation of known disease associations on well studied genes and 2) examining
disease enrichment analysis results for a set of known aging related genes using the
generated disease annotation data.
Due to the lack of disease annotation in the CRAFT corpus, it cannot be used to
evaluate the performance of the concept recognition tools in terms of finding disease
names. In order to assess such feature for MetaMap, NCBO Annotator, and Con-
ceptMapper, an HDO annotated corpus is needed, which is not obviously available.
However, such corpus can be generated indirectly, often based on other manually cu-
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Figure 2.1: Maximum F-measure for concept recognizer-ontology pair. A wide range of
maximum scores is seen for each concept recognizer within each ontology [144].
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rated resources via annotation cross references. One of such resources is the NHGRI-
EBI GWAS Catalog [159], which contains manually curated genome-wide association
studies annotated with the Experimental Factor Ontology (EFO) [160]. EFO is a super-
set of the HDO, making the GWAS Catalog a good resource for generating high-quality
HDO annotated corpus.
GWAS Catalog data was downloaded on 28 July 2017, which contained 3050
unique publications annotated with 1576 unique EFO terms, out of which, 304 can
be mapped to HDO via EFO-HDO cross references using the EBI Ontology Xref
Service [161]. This result in 1548 GWAS publications annotated with HDO terms,
from which two HDO annotated corpora (gold standard annotation) are derived: 1) a
corpus containing 1535 publication abstracts (13 publication does not have abstract),
referred to as GWAS Abstract; and 2) a corpus containing gene rifs(Gene Reference
Into Function) from 522 publications from the NCBI GeneRIF database, referred to as
GWAS GeneRIF.
The relatively small amount of mapped HDO from EFO is because that EFO covers
domains that are not captured in the HDO, i.e, EFO contains not just disease terms, but
also terms used to represent other experience factors, for example measurement terms
such as ‘EFO 0004467 insulin measurement’ or biomarkers such as ‘EFO 0006842
diabetes mellitus biomarker’. These EFO terms were thus removed from the annota-
tion.
In order to evaluate the performance of MetaMap(MeM), NCBO Annotator(NcA)
and ConceptMapper(CoM), HDO terms was used as dictionaries to mine GWAS Abstract
and GWAS GeneRIF. The resulting annotation was compared to the gold standard. All
comparisons were performed using three comparators: 1) a STRICT comparator (SC),
which means that ontology terms generated by each concept recognizer must match
the gold-standard annotation exactly to be counted correct; 2) a HIERARCHICAL de-
scendants comparator (HDC), which on top of the STRICT comparator, also counts
correct if the ontology terms generated by each concept recognizer are the hierarchical
descendants of the gold-standard annotation(see section 1.1.1.4 on page 6 for details of
ontology structure); and 3) a HIERARCHICAL comparator (HC) which on top of the
HDC, also counts correct for any ancestors of the gold standard. As an example, for the
gold standard annotation ‘DOID:9351 diabetes mellitus’, both ‘DOID:4194 glucose
metabolism disease’(ancestor) and ‘DOID:9744 type 1 diabetes mellitus’(descendant)
will be counted correct by HC. Only the latter one will be counted correct by HDC
while both will be counted incorrect when using SC.
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The performance of the three concept recognizers were measured in terms of true
positives (TP), false positives (FP), and false negatives (FN) as well as precision (P),
recall (R), and F-measure (F) (see Equation 2.1), which are calculated over all an-





















The evaluation result for each concept recognizers-corpus pair with HDO is pre-
sented in fig. 2.2 and table 2.1. The three concept recognizers, within each comparator,
have very similar performance in finding HDO terms from the two corpora tested. The
best F scores are from the HC comparator, ranging from 0.76 to 0.82 which the worse
F scores are from the SC, ranging from 0.42 to 0.52. In general, similarly to the result
from Funk et al. [144], CoM slightly out performed the other two, but the difference
between F scores is subtle, ranging from 0.004 (found between MeM and CoM with
GWAS GeneRIF SC) to 0.065 (found between CoM and NcA with GWAS GeneRIF
HDC).
Interestingly, NcA received the lowest F score among the three when using SC and
HDC, but the highest score when using HC, indicating that NcA often finds HDO terms
from the corpora that are the ancestor terms(less specific) of the gold standard. This is
partly due to the characteristics of the HDO terms where disease names often consist
other less specific disease names, such as ‘breast cancer’ and ‘cancer’. Recognizing
‘cancer’ is partially correct but such finding of less specific term is not desired. Thus,
the HC is likely to be over optimistic, therefore, the result form HD should be consider
with caution.
It was also observed that the performance of the concept recognizers vary between
corpus. Receiving similar F scores, a higher precision rate was observed for each con-
cept recognizers when annotating GWAS GeneRIF, which suggests that using semi-
curated corpus is likely to increase the performance over pure text base corpora such
as PubMed abstracts or full text.
In this thesis I use both MetaMap and the NCBO Annotator for NLP analysis of text
corpora and integrate them into the same framework to automate the ontology annota-
tion process. Since the two tools have their own advantages and disadvantages, the re-
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Figure 2.2: Comparison of MetaMap, NCBO Annotator and Concept Mapper in the task
of finding Human Disease Ontology terms from publication abstracts and GeneRIFs.
Three type of comparators were used to assess the performance, STRICT comparator
(SC), HIERARCHICAL descendants comparator (HDC) and HIERARCHICAL compara-
tor (HC). The two HIERARCHICAL comparator correct the result base on the ontology
hierarchical structure, thus generated a higher F score than the STRICT comparator.
MetaMap NCBO Annotator Concept Mapper
P R F P R F P R F
SC 0.3336 0.6578 0.4427 0.3125 0.6654 0.4253 0.3727 0.6584 0.4760
GWAS Abstract HDC 0.3954 0.7149 0.5092 0.3525 0.7043 0.4699 0.4207 0.7057 0.5271
HC 0.6674 0.8840 0.7606 0.7429 0.9057 0.8163 0.7335 0.8882 0.8035
SC 0.5519 0.4672 0.5060 0.4355 0.4948 0.4632 0.5741 0.4741 0.5193
GWAS GeneRIF HDC 0.5967 0.5034 0.5461 0.4597 0.5153 0.4859 0.6096 0.5025 0.5509
HC 0.8676 0.6960 0.7724 0.8740 0.7669 0.8170 0.8914 0.7034 0.7863
Table 2.1: Precision, Recall and F score of the result from MetaMap, NCBO Annotator
and Concept Mapper on GWAS Catalog corpus with HDO
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sulting ontology based annotations can be post-processed based on ontology properties
to increase performance. The reason to include MetaMap and the NCBO Annotator
in the initial implementation of the framework is that a) they are the most widely used
generic ( not limited to certain ontology) concept recognizers for biomedical text min-
ing tasks [144] and b) they are being actively developed and are well maintained. Con-
cept Mapper was potentially another powerful concept recognizer, which performed
slightly better than the MeM and NcA (A different in the f score ranging from 0.004 to
0.065 across the corpora tested), but not included in the initial implementation consid-
ering that there is no available documentation and the tool has not been updated since
24 Aug 2011 1. It, however, will be added to the framework in the next version.
2.1.2 Organization of the chapter
This chapter introduces OntoSuite-Miner, a framework composed of a set of Linux
shell scripts, Perl/R scripts and two concept recognizers, the MetaMap and the NCBO
Annotator, working together to automate the creation of ontology based annotation
from publicly available data repositories. What differentiates my method from other
approaches is that 1) I use two of the most popular concept recognizer in biomedi-
cal text mining with the potential of adding extra recognizers, for example the Con-
ceptMapper, into the OntoSuite-Miner framework without too much effort and 2) I
reused publicly available curated gene annotation databases as a basis to provide reli-
able data quality. To demonstrate the feasibility of our method, I generated a Human
Disease Ontology (HDO) annotation from three publicly available gene annotation
databases including OMIM, GeneRIF and Ensembl variation. HDO is used because 1)
disease information is a very interesting and important aspect of gene annotation, but
the HDO consortium does not provide gene annotations and 2) the HDO is a good can-
didate ontology for automatic annotation because disease terms are frequently men-
tioned in the biomedical text copora (46% more often than GO terms in MEDLINE
abstracts [4]), thus the automated annotation process in theory could work better for
annotating genes with disease ontology terms than for performing automatic annota-
tion on other ontologies like GO.
In the following sections I provide implementation details of OntoSuite-Miner, a
discussion of the main design decisions and a number of validation approaches for the
generated ontology base annotations. The main output of this chapter are: 1) a general
1https://mvnrepository.com/artifact/org.apache.uima/ConceptMapper/2.3.1
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framework, which uses unstructured semi-curated gene annotations as a starting point
for creating ontology based annotation and 2) a human disease annotation dataset using
HDO which enables a wide range of computational analyses and graph/network based
analyses for human disease such as disease enrichment analysis.
2.2 Implementation of OntoSuite-Miner
2.2.1 Overview
The OntoSuite-Miner toolkit is composed of a set of linux shell scripts, perl/R scripts
and two text annotators, MetaMap and NCBO Annotator. A high-level schematic de-
scribing the implementation of the OntoSuite-Miner is shown in fig. 2.3. The main
purpose of the toolkit is to link genes with ontology terms given their free text annota-
tion from a variety of sources.
In order to use OntoSuite-Miner, the initial dataset must be preprocessed into a list
of EntrezGene IDs with the corresponding annotation text in a tabular form stored in
a text file. The toolkit provides two methods to input the text, through an interactive
command-line accepting one text at a time and return the results ‘on the fly’(a user
friendly web interface is also available) and, through a command-line batch request
which processes all text in a file. Despite the different input methods, the toolkit uses
the same underlying methods to process the input data.
The processes can be time consuming depending on the amount of inputted text.
Having obtained the text file, a programming model conceptually similar to MapRe-
duce [162] was implemented to speed up the process. Firstly, a work dispatcher unit
receives the text file and splits the file into smaller slices. Each slice is then fed to a
worker unit (a thread in a multi-core machine or a machine in a cluster) which initiates
the mapping process. The work unit dispatches the received text to the two annotators
and starts the mapping processing with a set of predefined parameters and a preselected
ontology. Once all the work units finish processing the text, the mapping results are
collected, merged and indexed by distinct annotation text. A filter is implemented to
post process the mapping results with the aim of removing annotation errors occur-
ring in the previous processes (detail discussed below). Finally, EntrezGene IDs are
linked to ontology terms through their annotation text and stored in a SQLite relational
database. The details of the implementation are described in the following sections.
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2.2.2 Description/preprocessing of annotation sources
Annotation source data were taken on 04 Jan 2016 unless otherwise specified. Entrez-
Gene id was used as the primary index for genes.
GeneRIF
GeneRIFs (Gene Reference Into Function) are short annotations of the functions (in-
cluding diseases) of genes in the NCBI Gene database. A GeneRIF contains a con-
cise phrase describing a function or functions of a gene that exist in the NCBI Gene
database. The phrase is restricted to 425 characters in length and requires a published
paper in PubMed which describes that function. An example GeneRIF looks like this:
A high expression of CCL19 was a good prognostic factor of lung adenocarcinoma.
GeneRIFs are created by NCBI users who are willing to provide their email address.
This Wiki-type resource offers high accuracy and allows a rapid update by the research
community [163].
GeneRIF data was downloaded from the NCBI ftp site. Deprecated genes were
removed from the data while genes with discontinued id were replaced with the corre-
sponding EntrezGene id according to the discontinued records provided by the NCBI
gene history file. There are 369234 distinct geneRIFs referencing 334891 distinct
PubMed articles and 16359 distinct genes in the GeneRIF dataset. This represents
86% of the roughly 19,000 protein coding genes estimated to exist in the human
genome [164].
OMIM
The Online Mendelian Inheritance in Man (OMIM) database is part of NCBI which is
manually curated and contains information on human genes and genetic disorders. Hu-
man genes and disorder were indexed with OMIM’s own access number, locus mim acc
and disorder mim acc. A typical OMIM entry is as follows: “602290-615988-Bardet-
Biedl syndrome 11”, which indicates that gene with locus mim acc 602290 is associ-
ated with Bardet-Biedl syndrome 11 with disorder mim acc 615988. OMIM’s manual
curation process makes its data very precise, and is an excellent source for mining gene
disease associations. However, there is a noticeable delay in updating the database and
a limited gene/disease coverage because the curation process is extremely time con-
suming.
OMIM data was taken from the NCBI ftp site. Genes with locus mim acc were
mapped to EntrezGene id according to the mapping provided in the mim2gene.txt file
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of OMIM. Those genes without a mapping to an EntrezGene entry were removed.
As a result, 3596 distinct genes were annotated with 4482 disorders in the OMIM
dataset. However, subtypes between the same disorder in OMIM are considered as
different disease entities. For example, Bardet-Biedl syndrome 11 and Bardet-Biedl
syndrome 12 in OMIM are considered two disorder entities instead of a single Bardet-
Biedl syndrome entity. Thus, the number of distinct disorder in OMIM is far less than
4482 and the actual number of distinct disorder is hard to be determined.
Ensembl variation
Genetic recombination is an event naturally occurring during meiosis. It is facilitated
by chromosomal crossover where homologous chromosomes tightly pair together and
exchange genetic information (fig. 2.4). These exchanges increase genome diversity
and are essential for proper chromosome segregation at the first meiotic division. re-
combination can occur with small probability at any location along chromosome and
the frequency of recombination between two locus depends on the distance between
them. Therefore, Recombination will rarely separate loci that lie closely together on
a chromosome because it is unlikely that a crossover is located in such a small space
between the two loci. Thus, sets of alleles on the same small chromosomal segment
tend to be transmitted as a block through generations. Therefore, SNPs are likely to
be inherited together with their closely located up-stream/down-stream genes during
evolution. Most SNPs are found located between genes, which act as good biomark-
ers of diseases. The other SNPs occur within genes or in regulatory regions near genes
which may play a more direct role in disease by affecting directly on the genes’ func-
tion. Since the completion of the human genome and following various technolog-
ical advances, an increasing number of GWAS studies identified SNPs which pro-
vided evidence for possible disease association of many previously uncharacterized
genes [165, 166]. Such data is potentially a very good resource for mining gene dis-
ease association.
Ensembl variation [168] stores areas of the genome that differ between individ-
ual genomes (”variants”) and, where available, their associated disease and phenotype
information. Different types of variants exist including SNP, Insertion/Deletion and
more complicated structural variants. I am interested in SNP data in this project be-
cause SNP is the most dominant type of variants in human (fig. 2.5, ‘SNV’ is the
corresponding term for SNP in Sequence Ontology), accounting for 89% of all types
of variants. As the number of GWAS studies is growing rapidly, a lot of new SNPs
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Figure 2.4: Genetic recombination event during meiosis. It is facilitated by chromoso-
mal crossover where homologous chromosomes tightly paired together and exchange
genetic information [167].
are being associated with diseases, which provides a great resource for linking these
diseases to genes. For example, SNP rs1333049 is located on chromosome 9 and has
been found to be associated with coronary heart disease. Gene ‘CDKN2B-AS1’ and
‘RP11-408N14.1’ are the closest up- and down-stream genes of the SNP so it can be
inferred that they are potentially associated with coronary heart disease.
Figure 2.5: Human variant type distribution with Sequence Ontology(SO) terms in the
Ensembl variation database. SNV is the corresponding term for SNP in SO.
Not all SNPs have diseases/phenotypes associated with them. The Ensembl varia-
tion database uses a concept ‘variant sets’ to group variants that share some property
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together. I used BioMart [169] to search and download all of the human SNPs which
are in the variation set ‘All phenotype/disease-associated variants’, that is all the SNPs
that have at least one disease/phenotype associated with them. These SNPs were gath-
ered from 11 different sources (fig. 2.6) including ClinVar [170], NHGRI-EBI GWAS
Catalog [165] and OMIM [86]. As shown in table 2.2, the majority of these GWAS
studies were cancer studies including breast cancer, ovarian cancer and colorectal can-
cer. This is because, compared to the traditional candidate gene approach, GWAS
provides a powerful approach to identify common disease loci without prior knowl-
edge of gene, location or function, thus are particular useful in the study of polygenic
diseases. In total, 74715 unique SNPs were found in the variation database and 17088
unique genes were identified as the most up-stream/down-stream genes or the overlap-
ping genes of the SNPs.
Figure 2.6: Source distribution in the Ensembl variation database. SNPs data were
integrated from 11 sources with more than half of the SNPs from the ClinVar database
[170].
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Phenotype count
1 Hereditary cancer-predisposing syndrome 27885
2 Familial cancer of breast 13748
3 Breast-ovarian cancer familial 2 7269
4 Lynch syndrome 6882
5 Cardiomyopathy 6657
6 Tuberous sclerosis syndrome 6072
7 Breast-ovarian cancer familial 1 5535
8 CYSTIC FIBROSIS 3532
9 Height 3372
10 Cardiac arrhythmia 3276
11 Familial colorectal cancer 2970
12 Congenital long QT syndrome 2327
13 Obesity-related traits 2154
14 Thoracic aortic aneurysms and aortic dissections 2058
15 Rasopathy 1705
16 Severe myoclonic epilepsy in infancy 1690
17 Alport syndrome X-linked recessive 1539
18 BRCA1 and BRCA2 Hereditary Breast and Ovarian Cancer 1458
19 Malignant tumor of prostate 1370
20 Primary familial hypertrophic cardiomyopathy 1109
Table 2.2: Top 20 phenotypes annotated in the Ensembl variation database. The ma-
jority of the studies were cancer studies including breast cancer, ovarian cancer and
colorectal cancer.
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The Independence between sources
Even through the three data sources discussed above, namely GeneRIF, OMIM and En-
sembl variation, are created and maintained independently by different bioinformatics
organizations, there are overlapping information among them. In order to assess the
degree of independence between the sources, gene/pubmed pair was used to identify
overlapping data entities. GeneRIF and Ensembl variation store pubmed id in their
data entities whenever they are available, but OMIM does not contain such data. Thus,
the assessment was carried out only between GeneRIF and Ensembl variation.
GeneRIF contains 482084 unique gene/pubmed pairs while the corresponding num-
ber in Ensembl variation is 71909, among which 1830 are share between them. Such
a small overlapping indicates that the two data sources are reasonably independent.
Further assessment is needed to evaluate the dependence of OMIM against the other
two, when such data become available from OMIM.
2.2.3 Annotator setup/configuration
Two publicly available dictionary-based annotators were implemented locally on a
Linux server, NCBO Annotator [137] and MetaMap [136]. These two annotators are
both able to produce annotations for ontologies but differ in their underlying imple-
mentation and amount of configurable parameters. Funk et.al [144] evaluated three
annotators including NCBO Annotator and MetaMap on eight biomedical ontologies
in the Colorado Richly Annotated Full-Text(CRAFT) Corpus [171]. Over 1000 pa-
rameter combinations were examined by Funk et.al and best-performing parameters
for each ontology were presented. Despite the small difference between ontology-
parameter pairs, a general guild-line for choosing parameters was discussed and sug-
gestions for choosing the best parameters based on ontology characteristics were pre-
sented. The parameters of NCBO Annotator and MetaMap in OntoSuite-Miner were
set up based on the best-performing parameters with modification (see below for de-
tails) to suit the Human Disease Ontology used in this project.
2.2.3.1 NCBO-Annotator
The NCBO Annotator provides a RESTFUL web service2, as well as a virtual machine
which contains a pre-installed, pre-configured version of the NCBO Annotator running
on a Linux operating system. It stimulates an environment which provide all the pre-
2https://bioportal.bioontology.org/annotator
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requirements(scripts,libs, etc.) for the NCBO Annotator and provides the same service
locally to the user. NCBO virtual machine (hereby referred to as NcA) version 2.4
was integrated locally in OntoSuite-Miner, because the following reasons: 1) A local
implementation provides a shorter response time compared to using the RESTFUL
web service remotely; 2) The user has full control of the annotator’s configurations; 3)
having the annotator service locally ensures that the general maintenance on the NCBO
Annotator web service does not interrupt OntoSuite-Miner; and 4) The RESTFUL
web service alway use the most updated ontologies, thus may produce inconsistence
mapping result due to the update of ontologies. Having a local service allows the user
to precisely control the ontology version for consistent performance, as well as the
possibility of using customized ontology that does not exist in the NCBO ontology
repository.
In order to keep ontologies consistent within OntoSuite-Miner, instead of using the
ontologies provided by NCBO directly, ontology data were manually parsed into NcA
following the instructions described on the NCBO virtual machine wiki3. This also
enables customized ontologies to be used in NcA. In this project, the Human Disease
(HDO) and Human Phenotype (HPO) ontologies were downloaded (04-12-2015) and
parsed into NcA.
NcA is highly configurable and the parameter settings can make a significant dif-
ference to its performance. According to [144], a general rule for NcA was that only
whole words should be matched and synonyms of terms should be used. Thus, pa-
rameter whole word only was set to true and parameter exclude synonyms was set to
false. The Minimum term size was reported not to effect the matching of terms but to
act as a filter to remove matches of less than a certain length. A safe value of one or
three was suggested to remove only very small words. However, in the case of HDO,
diseases sometimes contains synonyms of abbreviation which were frequently used
in biomedical text. For example, AD for Alzheimer’s disease in the sentence These
results suggest that variants of APOA1 might influence the onset and the risk for AD
and COPD for chronic obstructive pulmonary disease in the sentence The CYP2E1 and
NAT2 variants associated with COPD. Such information would be omitted if a min-
imum term size was set to one or three. Thus, based on the characteristic of HDO,
parameter minimum match length was set to 0. Note that having a 0 minimum match
length increases the chance of identifying ontology concepts in a sentence with the
price of introducing abbreviation annotation error, which is discussed further in sec-
3http://www.bioontology.org/wiki/index.php/Virtual Appliance FAQ
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tion 2.3.4.1 on page 76. Other parameters that did not impact the performance of NcA
were set to their default value and a set of default stop words were used and can be
found on the NCBO annotator documentation website4.
2.2.3.2 MetaMap
MetaMap is a highly configurable program designed to work with the UMLS Metathe-
saurus, but can be optionally configured to work on ontology. The data file builder
(DFB)5 provided by MetaMap allows the transform of UMLS-like database tables into
a dictionary format used by MetaMap. Thus, Perl scripts were written in OntoSuite-
Miner to convert ontology from a standard OBO format to UMLS database tables
following the specification in the DFB, which is subsequently used in the MetaMap.
In contrast to a web service like NCBO Annotator, MetaMap runs natively on a
Linux machine. MetaMap v.2013 was installed and integrated in OntoSuite-Miner and
hereby referred to as MeM. The Human Disease (HDO) and human Phenotype (HPO)
were downloaded (04-12-2015) and parsed into UMLS database tables using the Perl
scripts. DFB was used to load the ontologies into MeM.
Parameters were set according to [144] for best performance. Gaps between words
(parameter −g) was not allowed when matching. Two data models are available in
MeM, the Strict model and the Relaxed model which differs in the way MeM par-
titions its dictionary. The Relaxed Model is a proper superset of the Strict Model,
and typically contains dictionary strings containing internal syntactic structure, such
as conjunction like ‘arms and legs’. The STRICT model, on the other hand, performs
an extra filtering step on the dictionary terms (ontology terms), which was reported to
increase precision without losing recall for two out of eight ontologies tested in [144]
(no difference in the other six ontologies). It is also documented to produce the highest
level of accuracy and is used as the default model by MeM. Therefore, Strict model
was used in the current implementation of MeM in OntoSuite-Miner. Enabling re-
ordering (parameter−i) of words in the terms is another way to configure MetaMap to
recognize more complex terms but was discouraged because a drop of precision was
observed without an increase in recall [144].
One unique feature of MeM is that it is able to compute acronym and abbreviation
variants when mapping text to the dictionary terms (ontology terms). It is observed
that the use of all acronym/abbreviations (parameter −a) introduced many erroneous
4http://data.bioontology.org/documentation
5https://metamap.nlm.nih.gov/DataFileBuilder.shtml
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matches, resulting in a decrease in precision without an increase in recall [144]. The
use of acronym/abbreviation that has unique expressions (parameter −u) was thus rec-
ommended and configured in MeM. Minimum term size, acts exactly like textitmini-
mum match length of the NcA parameter, was set to 0 due to the same reason discussed
early in the parameter setting of NcA.
MeM can be configured to generate derivational variants which help to identify
different forms of terms, for example, ‘cancer-cancerous’ as a noun-adjective deriva-
tional. The aim of using derivational is to increase recall without introducing ambigu-
ous terms. There are three values (all, none,and ad jnounonly) for this parameter and
it produces the most varied results. The default value ad jnounonly was suggested
in [144] if most of the ontology terms could be expressed as nouns or verbs, other-
wise hurts the performance if ontology terms do not follow traditional English rules,
like gene/protein names. Human disease ontology belongs the former, thus generating
derivational variants was allowed for ad jnounonly.
MeM produces a score for each of its mapping result in the range of 0 to 1000, with
1000 being the most confident. A threshold of the score can be used to filter results.
A high threshold (only keep high scored mapping) results in a high precision with low
recall while a threshold of 0 returns all mappings, resulting in the highest recall with
the lowest precision. Performance is best on all ontologies tested in [144] when using
most of the mapping found by MeM, so a score of 0 is suggested, thus implemented
MeM. Other parameters that did not impact the performance of MeM were set to their
default value as documented by MetaMap6.
2.2.3.3 The worker thread
MeM and NcA are coordinated by a work worker thread. After text corpora are loaded
into OntoSuite-Miner, a work dispatcher split the corpora into a number (10 in the cur-
rent implementation) of smaller pieces containing part of the text corpora. Each piece
is then dispatched to a worker thread (a thread in a multi-core machine or a machine
in a cluster) where the annotation process is initiated. With in a worker thread, Linux
shell scripts are used to dispatch received text corpora to MeM and NcA simultaneously
and gather the outputs. Worker threads perform the annotation process in parallel and
results were merged when all the worker threads finish.
6https://metamap.nlm.nih.gov/Docs/MetaMap13 Usage.shtml
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2.2.4 The filtering process
As shown in fig. 2.3, an extra filtering step was implemented to post-process the
merged annotation. The filtering process was not designed to discover more anno-
tations but to remove unwanted annotations and possible errors. For a particular an-
notation, firstly, the filter checks if the annotated term was present in a predefined list
of unwanted terms. The unwanted term list for HDO contains two terms, ‘DOID:4
disease’ and ‘DOID:225 syndrome’. Secondly, the annotation was filtered based on
the annotator used to produce the annotation. If the annotation was found by both
MeM and NcA, it would be kept under the rationale that an annotation agreed by both
annotators was more reliable. MetaMap computed a score for each annotation based
on the strength of the mapping, thus the annotation was kept if it was found solely
by MeM and was the top ranked annotation. NcA did not provide any score for its
result, and it is generally more accurate then MeM, thus all annotations from NcA
were kept at this stage. Finally, the annotation was examined, together with other an-
notations that passed the filter previously, for their relationship within the ontology
structure hierarchy. Ancestor terms (more generic terms) were removed if there was
an offspring term (more specific terms) present, ensuring that only the most specific
(informative) terms were kept. For the Human Disease Ontology it is very common
that some disease names partly compose other disease names. Some of these diseases
have a parent-child relation in the ontology hierarchy, for example, ‘DOID:162 can-
cer’ and ‘DOID:1612 breast cancer’ which is a type of cancer. However, this is not
always the case, for example, ‘DOID:1091 tooth disease’ which is a dental disorder
and a completely different disease ‘DOID:10595 Charcot-Marie-Tooth disease’ which
is a neuromuscular disease. Such characteristics of disease names usually confuses
the annotators, leading to an annotation error called coordinating conjunctions (Detail
discussed in section 2.3.4.1 on page 76. This final filtering step, accounting for the
ontology structure, was therefore implemented to deal with such errors. An example
of the filter process was shown in fig. 2.7.
2.2.5 Data storage
OntoSuite-Miner use portable SQLite database to store the final annotation as well as
all the intermediate results that are needed to trace back any annotation to its source.
R scripts implemented in the OntoSuite-Miner allow a user to pull all of the evidence
associated with a particular gene disease association (fig. 2.8). A gene disease asso-
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Figure 2.7: An example of the filtering process. A GeneRIF was fed into OntoSuite-
Miner and 2 HDO terms were found by MeM and 4 HDO terms by NcA. ‘DOID:225
syndrome’ was a predefined unwanted term and was removed. ‘DOID:0060058 LYM-
PHOMA’ was removed because it is a parent term of ‘DOID:8567 Hodgkin lymphoma’.
As a result, two HDO terms were annotated to this GeneRIF, ‘DOID:8567 Hodgkin lym-
phoma’ and ‘DOID:1184 NEPHROTIC SYNDROME’.
ciation file was pre-computed that provides only the gene disease association without
evidence for easy access.
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2.3 Application of OntoSuite-Miner
2.3.1 Evaluating the performance of OntoSuite-Miner
In order to demonstrate the performance improvements of OntoSuite-Miner, over MetaMap
or NCBO Annotator alone, they are used to annotate the GWAS Abstract and the
GWAS GeneRIF corpus (see section 2.1.1 for a description of the corpus and com-
parison methods) corpus with Human Disease Ontology. The results were three HDO
annotation data set generated from MeM, NcA and OntoSuite-Miner respectively. Be-
cause OntoSuite-Miner implemented multiple concept recognizers, a high confident
subset, supported by all implemented concept recognizers in OntoSuite-Miner (re-
ferred to as OntoSuite-Miner MN) were extracted from the OntoSuite-Miner result
and included in the substantial evaluation.
The above four HDO annotation data sets were assessed in terms of precision, re-
call and F scores (see eq. (2.2) on page 39) using the STRICT Comparator (SC) and
the HIERARCHICAL Descendants Comparator (HDC). The HIERARCHICAL Com-
parator was overly optimistic, thus not included here. The detail comparison methods
were described previously in section 2.1.1. The result was shown in fig. 2.9 and ta-
ble 2.3.
The best F score (0.6153) was generated from OntoSuite-Miner MN from mining
GWAS Abstract corpus with the HIERARCHICAL Descendants Comparator (HDC)
while the best precision rate was reported in also from OntoSuite-Miner MN from min-
ing GWAS Abstract with the HDC, where 78% of the mapping are correct. OntoSuite-
Miner MN was able to recover 72% of the annotation from GWAS Abstract but around
50% of the mapping generated were false positives. An improved F score was observed
in all cases from OntoSuite-Miner (also its high confident subset) comparing to using
MeM or NcA along, suggesting the an increasing performance from the integration of
multiple concept recognizers.
MetaMap NCBO Annotator OntoSuite-Miner OntoSuite-Miner MN
P R F P R F P R F P R F
GWAS
Abstract
SC 0.3336 0.6578 0.4427 0.3125 0.6654 0.4253 0.3969 0.6233 0.4849 0.5621 0.5488 0.5554
HDC 0.3954 0.7149 0.5092 0.3525 0.7043 0.4699 0.4752 0.7271 0.5748 0.6252 0.6057 0.6153
GWAS
GeneRIF
SC 0.5519 0.4672 0.5060 0.4355 0.4948 0.4632 0.6452 0.5017 0.5645 0.7387 0.4241 0.5388
HDC 0.5967 0.5034 0.5461 0.4597 0.5153 0.4859 0.6984 0.5403 0.6092 0.7807 0.4482 0.5695
Table 2.3: Precision, Recall and F score of the result from OntoSuite-Miner, MetaMap
and NCBO Annotator on GWAS Catalog corpus with HDO
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Figure 2.9: Comparison of the performance of OntoSuite-Miner, MetaMap and NCBO
Annotator in the task of finding Human Disease Ontology terms from testing corpus of
publication abstracts and GeneRIFs generated from the GWAS Catalog. Two type of
comparators, a STRICT comparator (SC) and a HIERARCHICAL descendants com-
parator (HDC)(see section 2.1.1, were used to assess the performance in terms of
Precision, Recall and F score. A high confident subset of the annotation generated
by OntoSuite-Miner, referred to as OntoSuite-Miner MN is also assessed. An overall
higher F score was observed suggesting from OntoSuite-Miner, suggesting the im-
provement of the result by integrating multiple concept recognizers. ).
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2.3.2 Creating the Human Disease Gene Database (HDGDB)
I applied OntoSuite-Miner on three publicly available data sources described early
including OMIM, GeneRIF and Ensembl variation, to find HDO terms in the gene
annotation text corpora. As a result, three HDO based gene annotation datasets were
produced, one for each of the three sources. The transformation of the unstructured,
text based annotation to HDO base annotation allows easy comparison and integration
of the annotation. Therefore, a comprehensive disease annotation database named
Human Disease Gene Database (HDGDB) was created, by merging the three HDO
annotations datasets. EntrezGene id was used as the primary index of the annotation.
In the following sections, I will report the disease annotation from each source, and
from HDGDB.
OMIM
There are 5267 distinct OMIM disease entities referencing 3596 distinct genes in the
OMIM database. OntoSuite-Miner was able to find 1248 unique HDO term in 3971
(75.39%) OMIM disease entities, annotating 2914 distinct human genes with at least
one HDO term, generating in total 4759 unique gene disease associations. On average,
1.18 HDO terms were found for each OMIM disease entity. The top 20 most annotated
genes and diseases in OMIM are shown in table 2.4.
GeneRIF
There are 369102 distinct geneRIFs referencing 334789 distinct PubMed articles and
16103 genes in the NCBI GeneRIF database (data taken on 16 Feb 2015). OntoSuite-
Miner was able to find 3303 unique HDO term in 154202 (41.78%) rifs, annotating
10977 distinct human genes with at least one HDO term, generating in total 111875
unique gene disease associations. On average, 1.25 HDO terms were found for each
RIF of the mapped RIFs. The top 20 most annotated genes and diseases in the GeneRIF
database are shown in table 2.5.
Ensembl variation
There are 10707 distinct disease entities referencing 17085 distinct genes in the En-
sembl variation database. OntoSuite-Miner was able to find 1421 unique HDO term
in 6267 (58.53%) disease entities, annotating 13853 distinct human genes with at least
one HDO term, generating in total 39993 unique gene disease associations. On aver-
age, 1.19 HDO terms were found for each disease entity. The top 20 most annotated























1 intellectual disability 81
2 retinitis 68
3 retinitis pigmentosa 67
4 autosomal recessive nonsyndromic deafness 54
5 cataract 49
6 Charcot-Marie-Tooth disease 46
7 tooth disease 46
8 hereditary spastic paraplegia 46
9 autosomal dominant cerebellar ataxia 42
10 carcinoma 41
11 congenital disorder of glycosylation 38
12 autosomal dominant non-syndromic intell... 36
13 microcephaly 36
14 dilated cardiomyopathy 36
15 myopathy 34
16 Alzheimer’s disease 33
17 colorectal cancer 33
18 autosomal dominant nonsyndromic deafness 31
19 Ohtahara syndrome 31
20 schizophrenia 29
Table 2.4: HDO annotation produced by OntoSuite-Miner from the OMIM database.
The top 20 most annotated genes in the table on the left and the top 20 most annotated
diseases in the table on the right. The ‘Count’ is the number of unique gene/disease
a disease/gene is annotated with. ‘Intellectual disability’ received the most research
attention together with diseases like ‘Retinitis pigmentosa’, reflecting the fact that OMIM
focuses on studies of Mendelian disorders.
genes and diseases in the Ensembl variation are shown in table 2.6.

























3 breast cancer 2815
4 hepatocellular carcinoma 1919
5 prostate cancer 1789
6 lung cancer 1742
7 colorectal cancer 1587
8 squamous cell carcinoma 1442
9 adenocarcinoma 1310
10 ovarian cancer 1186
11 melanoma 1172
12 malignant glioma 1024
13 Alzheimer’s disease 1011
14 pancreatic cancer 999
15 schizophrenia 933
16 colon cancer 927
17 hepatitis 822
18 non-small cell lung carcinoma 761
19 rheumatoid arthritis 759
20 esophageal carcinoma 667
Table 2.5: HDO annotation produced by OntoSuite-Miner from the GeneRIF database.
The top 20 most annotated genes in the table on the left and the top 20 most annotated
diseases in the table on the right. The ‘Count’ is the number of unique gene/disease a
disease/gene is annotated with. Various cancers like ‘breast cancer’ and ‘lung cancer’
and their corresponding genes were found frequently in the database. Other diseases
like ‘Alzheimer’s disease’ and ‘schizophrenia’ also attracted a lot of research attention.


























4 bipolar disorder 911
5 Alzheimer’s disease 557
6 attention deficit hyperactivity disorder 555
7 breast cancer 519
8 lateral sclerosis 489
9 major depressive disorder 488
10 prostate cancer 478
11 intellectual disability 457
12 rheumatoid arthritis 457
13 Usher syndrome 448
14 multiple sclerosis 437
15 amyotrophic lateral sclerosis 432
16 Crohn’s disease 385
17 inflammatory bowel disease 355
18 long QT syndrome 345
19 chronic obstructive pulmonary disease 332
20 ulcerative colitis 330
Table 2.6: HDO annotation produced by OntoSuite-Miner from the Ensembl variation
database. The top 20 most annotated genes in the table on the left and the top 20
most annotated diseases in the table on the right. The ‘Count’ is the number of unique
gene/disease a disease/gene is annotated with. Diseases like ‘obesity’, ‘schizophre-
nia’, ‘bipolar disorder’ and cancers were popular topics in GWAS studies, thus have
most support in the Ensembl variation database. Interestingly, many uncharacterized
gene(symbol starts with ‘LOCL’ followed by a number) were found and annotated with a
lot of diseases. This is because, compared to the traditional candidate gene approach,
GWAS studies usually identify a large number of SNPs for the disease under study,
thus generating interesting and novel gene candidates that may have never been linked
to the disease before.
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Human Disease Gene Database (HDGDB)
The results from the above three data sources were merged into a comprehensive hu-
man disease gene data base, named HDGDB. The overlap between genes, diseases
and gene-disease associations between the three sources are shown in fig. 2.10. I will
introduce HDGDB in the following paragraphs from three perspectives, it’s gene fea-
tures, disease features and the gene-disease association(GDA) features. The validation
of HDGDB are then performed both quantitatively and qualitatively and possible im-
provements are discussed.
Figure 2.10: Venn diagram showing the overlaps between genes, diseases and GDAs
in HDGDB according to source. Only 1.8% (2881) the GDAs are common to all of the
data sources, while in the case of genes and diseases the overlap is 14% (2504) and
32.2% (1101) respectively. Such small overlaps between data sources highlights the
importance of data integration.
Gene features
Reactome pathway database [172] provides pathway annotation for genes while the
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Panther Protein Class Ontology classify genes (gene products) into different classes
[173, 174]. Genes in HDGDB are thus classified with 1) 24 top-level pathways from
Reactome database and 2) 29 top-level classes from Panther Protein Class Ontology
to explore the composition of genes in terms of pathways and protein classes. The
result is shown in fig. 2.11. The best-represented pathways are ‘Signal Transduc-
tion’ and ‘Metabolism’, comprising 10% of the disease genes each, followed by ‘Im-
mune System’ (7%), ‘Gene Expression’ (5.5%) and ‘Metabolism of proteins’ (5%).
In HDGDB, over 80% of genes (14306 genes) are protein-coding genes (calculated
based on UniProt Swiss-Prot manually reviewed records on 1 Feb 2016). The remain-
ing 20% belong to pseudogenes, ncRNA and other categories. There are estimated
19000 protein-coding genes in the human genome [164], of which roughly 75% are
annotated with at least one disease in HDGDB. In terms of protein class, the best-
represented are ‘nucleic acid binding’, comprising nearly 12% of all disease proteins
followed by ‘receptor’ (9%), ‘hydrolase’ (8.5%), and ‘transcription factor’ (8.2%).
The next best-represented protein classes are ‘enzyme modulator’, ‘transferase’ and
‘signaling molecule’ comprising approximately 7% each. Note that more than half of
the genes in HDGDB do not appear in any pathways and about 40% of the proteins
encoded by the disease genes are not covered by the Panther Protein Class Ontology
(‘Unclassified’). The numbers are even higher in the Ensembl variation data. This is
possibly due to the fact that the pathways and protein classes are manually annotated
and have limited gene coverage. Some of the recent discoveries are not included in
these manually curated datasets but captured by OntoSuite-Miner.
As shown in fig. 2.12a, most of the genes have only a few disease annotations
while only a few genes have been linked to a large number of diseases. The same
can be observed when analyzing diseases and their associated genes (fig. 2.13a). The
most well-annotated genes in HDGDB are ‘TNF tumor necrosis factor’ (Entrez id
7124), ‘VEGFA vascular endothelial growth factor A’ (Entrez id 7422) and ‘TP53 tu-
mor protein p53’ (Entrez id 7157) which have been linked to 427, 414 and 401 diseases
respectively. The ‘TNF’ gene is involved in the regulation of a wide range of biologi-
cal processes including cell proliferation, differentiation, apoptosis, lipid metabolism,
and coagulation and implicated in a variety of diseases, including autoimmune dis-
eases, insulin resistance, and cancer [175, 176]. The ‘VEGFA’ gene is up-regulated
in many known tumors and its expression is correlated with tumor stage and progres-
sion [177,178]. The ‘TP53’ gene is a well-studied tumor suppressor where it’s encoded
proteins bind to DNA and regulate other gene expressions to prevent mutations. It has
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been classified as the most frequently mutated gene (>50%) in human cancer, indi-
cating its crucial role in cancer formation [179]. In total, on average 8 diseases were
annotated to each gene in HDGDB.
(a) (b)
Figure 2.12: (a) Distribution of the number of associated HDO terms per gene in
HDGDB. Most of the genes have only a few disease annotations while a few genes
have been linked to a large number of diseases. (b) Word cloud plot of the number of
disease annotation for each gene in HDGDB.
Disease features
Genes are annotated with disease terms from HDO. Similar to the above gene analysis,
most of the diseases were annotated with only a few genes while a few diseases (mostly
cancers) were linked to a large number of genes (fig. 2.13a). The distribution of top-
level HDO terms in the HDGDB is shown in fig. 2.14. The largest disease category
is ‘disease of anatomical entity’. 70% of the genes are annotated within this category.
The second largest disease categories are ‘disease of cellular proliferation’, covering
57% of the genes, ‘disease of metabolism’ and ‘disease of mental health’ annotated
to 27% of the genes each. ‘syndrome’ and ‘physical disorder’ are the least annotated
disease category being only 5% each. In terms of individual disease, the top annotated
diseases are mostly cancers, for example, ‘breast cancer’ has been linked to over 3000
genes and ‘prostate cancer’ has been linked to 2000. Other diseases like ‘obesity’,
‘schizophrenia’ and ‘Alzheimer’s disease’ are also near the top of the list.
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(a) (b)
Figure 2.13: Distribution of the number of genes associated with each HDO term in
HDGDB. Most of the diseases have only a few gene annotations while a few diseases
have been linked to a large number of genes. (b) Word cloud plot of the number of
annotated genes for each HDO term in HDGDB
Gene-Disease association feature
The current release of HDGDB contains 147023 unique GDAs identified by OntoSuite-
Miner from three sources including GeneRIF, OMIM and Ensembl variation. GDAs
supported by multiple sources and/or identified by both annotators are more reliable
than those with less supporting evidence. In order to indicate the level of confidence
in each association, a confidence score is implemented. The score takes into account
the number of data sources (GeneRIF, OMIM and/or Ensembl variation) that report the
association, the number of evidences (text corpora reporting the GDA) in each sources
and the number of annotators reporting the annotation. It is calculated as follows:
Let S be the score for a GDA.
S = ∑Ssource = SOMIM +SGeneRIF +SEnsemblvariation (2.3)
The score for an individual source is defined:
Ssource =Wsource · f (n) (2.4)
where n is the number of evidence (text corpora reporting the GDA) in the source. The
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Figure 2.14: Disease category distribution of all diseases in HDGDB using the top-level
HDO terms. ‘disease of anatomical entity’ is the largest disease category, annotated
with 70% of all the genes in HDGDB while ‘syndrome’ and ‘physical disorder’ are the
least annotated disease categories (5% each).
68Chapter 2. Mapping text corpora to ontology terms using natural language processing tools
sources are equally weighted in the current implementation:
Wsource =WOMIM =WGeneRIF =WEnsemblvariation =

0.2 if GDA is from MeM and NcA
0.06 if GDA is from MeM or NcA
0 otherwise
(2.5)
The weight of the annotator was designed so that a) Wsource is always smaller than
1 and b) annotations found by two annotators were scored higher than those found
by one annotator. The function f (n) is an arbitrary increasing function depend on
the number of evidence n in the source. It is designed to distinguish the existence
of evidence while preventing the score being dominant by the unbalanced number of
evidence across different sources. The rationale behind f (n) is that a GDA is more
reliable if it is supported by multiple sources than a single source for multiple times.
Thus, f (n) increases very fast when n is small while creating a long tail toward 1.
k can be adapted to control the influence of n to a desired degree. For example, as
shown in fig. 2.15, when k = 0.2, f (n) start from 0.83, which means when there is any
evidence exists, 83% of the corresponding source weight is counted. As n increase,






Given the above equations, for example, gene A2M was found to be linked to
‘DOID:10652 Alzheimer’s disease’ in HDGDB. Multiple sources of evidence exist





OMIM 0 0 1
GeneRIF 5 1 7
VAR 0 0 2

The score for this GDA is calculated as follow:
SOMIM = 0.2 f (1) = 0.167
SGeneRIF = 0.2 f (7)+0.06 f (1)+0.06 f (5) = 0.302
SVAR = 0.2 f (2) = 0.182
S = ∑Ssource = SOMIM +SGeneRIF +SVAR = 0.651
The GDA score ranges from 0 to 1. It can be used to assist in the prioritization,
weighting and navigation of the GDAs since it indicates their level of confidence. For
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Figure 2.15: How k affect the source score f (n) = nn+k . The function f (n) is an arbitrary
increasing function depend on the number of evidence n in the source. It is designed
to distinguishe the existence of evidence while preventing the score being dominant by
the unbalanced number of evidence across different sources. f (n) increases very fast
when n is small while creating a long tail toward 1. k can be adapted to control the
influence of n to a desired degree. In the currently implementation, k is set to be 0.2.
example, associations found in one source by both annotators (0.166 ≤ S ≤ 0.2) have
higher scores than those only found by one annotator(0.083 ≤ S ≤ 0.1). Associations
found by both annotators in two sources(0.332 ≤ S ≤ 0.4) have a higher score than
those found in a single source.
The sources were weighted equally in the currently implementation. The gene-
disease associations identified in human curated data sources such as OMIM, are likely
to be more precise than sources such as GeneRIF. However, the latter may provide
useful information for genes when there is no curated data available or for those that
are very recently identified. Thus, the annotation score could be refined base on the
confidence/quality of the source, but it is unclear how to assign the weights to the
sources when there is no obvious training data available.
In HDGDB, most of the GDAs were scored at around 0.2 which indicated that
most of them were found only in a single source. This is because the focus of the three
data sources are different. OMIM focuses on human genes and genetic phenotype; En-
sembl variation database contains mainly GWAS studies for cancers while GeneRIF
is a bit of both but focuses more on gene function. Their differing objective for de-
scribing gene-disease relationships may result in a low overlap between sources but
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does not imply error. For example, NAT 2 is linked to ‘DOID:9352 type 2 diabetes
mellitus’ with a score of 0.05, having only one supporting evidence from a relatively
recent paper published in 2013 [180] and contributing to HDGDB by a from GeneRIF
entity. This association is not captured in OMIM nor Ensembl variation but it is a cor-
rect association. In fact, it is these low sored GDAs that are more likely to bring new
insight into the understanding of complex diseases. On the other hand, 4% (5979) of
GDAs scored over 0.3, supported by at least two sources. The top-50 scoring GDAs
(table 2.7) are very well-studied gene-disease associations. For example, ‘retinitis pig-
mentosa’ with RPGR (retinitis pigmentosa GTPase regulator); ‘Alzheimer’s disease’
with PSEN1 (Presenilin-1), APP (Amyloid precursor protein) and APOE (Apolipopro-
tein E); ‘Wilson disease’ with AT P7B. The top ranked GDA in HDGDB is the associa-
tion of ‘breast cancer’ and BRCA2 (breast cancer 2) gene. BRCA2 is a tumor suppressor
gene found in all humans. It encodes a protein, called by the synonym breast cancer
type 2 susceptibility protein, is responsible for repairing DNA or destroying cells if
DNA cannot be repaired. If BRCA2 itself is damaged by a mutation, damaged DNA is
not repaired properly, and this increases the risk for breast cancer [181]. The second
ranked GDA is the association of ‘pulmonary hypertension’ and BMPR2 (Bone mor-
phogenetic protein receptor type II ) gene. It has been shown that BMPR2 mutations
are present in more than 70% of familial cases of relatives of patients with idiopathic
pulmonary hypertension [182]. BMPR2 functions to inhibit the proliferation of vascu-
lar smooth muscle tissue. When it is inhibited, vascular smooth muscle proliferates and
can result in ‘pulmonary hypertension’. The association of ‘melanoma’ and CDKN2A
(cyclin-dependent kinase Inhibitor 2A) gene ranked the third in HDGDB. CDKN2A
codes two proteins, p16 and p14ar f , which act as tumor suppressors. p16 binds to
the cyclic dependent kinases CDK4 to inhibit their ability to create tumors, but when
inactivated the suppression no longer occurs [183], thus starting the development of
melanoma. CDKN2A is estimated to be the second most commonly inactivated gene
in cancer after p53 and it’s mutation has been associated with melanoma in many pre-
vious studies [184–186]. These GDAs were supported by multiple evidences from
different sources and therefore obtained the highest scores.
The confidence score is especially useful in annotation generated by automatic
methods such as the HDGDB by OntoSuite-Miner. It provides a reference to rank/weight
the associations based on evidence and assists in the prioritization and navigation of
the GDAs. In addition, the score can be applied in analysis such as gene set enrich-
ment analysis (discussed in the next chapter) so that those highly ranked GDAs are to
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Figure 2.16: Violin plot of the distribution of GDA scores in HDGDB. 64% of the GDAs
were scored at within the range of [0.15,0.2] which indicated that they were found only in
a single source, indicating the small overlap between the three sources, namely OMIM,
GeneRIF and Ensembl variation.
be weighted more then other.
OMIM did not provide data linking their entities to literature but all the entities in
GeneRIF and most of the entities in Ensembl variation database have references (usu-
ally papers in PubMed database) attached as supporting evidence. Thus, Almost all
of the GDAs (98.47%) in HDGDB can be linked back to the sources and the corre-
sponding papers. For those GDAs that have no references, the original entities in the
corresponding sources are provided. Remarkably, 82.48% of the articles supporting
the GDAs in HDGDB have been published in the last 10 years, 58.74% in the last 5
years (fig. 2.17). This indicates that OntoSuite-Miner is able to pick up GDAs from
some of the most recent studies.
2.3.3 Updating HDGDB
HDGDB is a gene disease association database containing GDAs from OMIM, GeneRIF
and Ensembl variation databases. table 2.8 displays the statistics of the current database,
v3.0, generated on 2016.01.05, compared with the previous ones v1.0 on 2014.09.04
and v2.0 on 2015.02.17. As shown in fig. 2.18, the OMIM database only has a
small change because of the time consuming nature of the expert-curation processes.
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DOID Disease Gene Score Score.o Score.g Score.v #Evidence(o/g/v)
1 DOID:1612 breast cancer BRCA2 0.84 0.217 0.319 0.259 2/273/2466
2 DOID:6432 pulmonary hypertension BMPR2 0.83 0.217 0.312 0.257 2/48/34
3 DOID:1909 melanoma CDKN2A 0.83 0.232 0.313 0.258 3/87/43
4 DOID:1099 alpha thalassemia HBA1 0.83 0.217 0.31 0.256 2/26/32
5 DOID:10584 retinitis pigmentosa RPGR 0.83 0.217 0.309 0.253 2/26/27
6 DOID:2352 hemochromatosis HFE 0.78 0.167 0.318 0.256 1/105/29
7 DOID:893 Wilson disease ATP7B 0.78 0.167 0.307 0.259 1/63/141
8 DOID:3490 Noonan syndrome PTPN11 0.78 0.167 0.307 0.259 1/40/114
9 DOID:1485 cystic fibrosis CFTR 0.78 0.217 0.316 0.2 2/289/1186
10 DOID:0050773 paraganglioma SDHD 0.78 0.217 0.254 0.256 2/25/51
11 DOID:0050773 paraganglioma SDHB 0.78 0.217 0.256 0.253 2/34/21
12 DOID:1099 alpha thalassemia HBA2 0.77 0.217 0.31 0.256 2/21/32
13 DOID:9253 gastrointestinal stromal tumor KIT 0.77 0.167 0.315 0.253 1/93/14
14 DOID:9255 frontotemporal dementia VCP 0.77 0.217 0.254 0.255 2/16/18
15 DOID:9253 gastrointestinal stromal tumor PDGFRA 0.77 0.167 0.313 0.255 1/46/19
16 DOID:649 prion disease PRNP 0.77 0.167 0.314 0.245 1/41/9
17 DOID:9255 frontotemporal dementia TARDBP 0.77 0.167 0.312 0.249 1/44/16
18 DOID:14686 Axenfeld-Rieger syndrome FOXC1 0.77 0.217 0.248 0.253 2/8/14
19 DOID:13628 glucose-6-phosphate dehydroge-
nase deficiency
G6PD 0.77 0.188 0.307 0.257 3/36/46
20 DOID:3012 Li-Fraumeni syndrome TP53 0.77 0.167 0.305 0.258 1/21/92
21 DOID:4252 Alexander disease GFAP 0.77 0.167 0.303 0.257 1/36/32
22 DOID:1909 melanoma MITF 0.77 0.167 0.31 0.217 1/50/2
23 DOID:2739 Gilbert syndrome UGT1A1 0.77 0.167 0.306 0.253 1/15/14
24 DOID:1921 Klinefelter’s syndrome FGFR1 0.76 0.167 0.292 0.257 1/7/39
25 DOID:0050773 paraganglioma SDHC 0.76 0.217 0.248 0.24 2/8/7
26 DOID:10632 Wolfram syndrome WFS1 0.76 0.217 0.248 0.255 2/22/19
27 DOID:14261 fragile X syndrome FMR1 0.76 0.217 0.305 0.182 2/53/2
28 DOID:0050589 inflammatory bowel disease NOD2 0.76 0.167 0.304 0.251 1/17/12
29 DOID:3612 retinitis RPGR 0.76 0.217 0.247 0.241 2/24/27
30 DOID:0060241 3-M syndrome CUL7 0.76 0.167 0.282 0.254 1/4/15
31 DOID:0060472 Kindler syndrome FERMT1 0.76 0.167 0.296 0.244 1/13/6
32 DOID:13636 Fanconi’s anemia FANCA 0.76 0.167 0.296 0.248 1/11/20
33 DOID:11105 fundus albipunctatus RLBP1 0.75 0.217 0.236 0.239 2/4/6
34 DOID:9993 hypoglycemia ABCC8 0.75 0.217 0.225 0.242 2/7/51
35 DOID:0050439 Usher syndrome PDZD7 0.74 0.217 0.236 0.217 2/4/2
36 DOID:10652 Alzheimer’s disease APOE 0.72 0.167 0.319 0.198 1/301/20
37 DOID:10652 Alzheimer’s disease APP 0.72 0.167 0.32 0.199 1/420/28
38 DOID:1612 breast cancer ESR1 0.72 0.167 0.318 0.196 1/373/11
39 DOID:10652 Alzheimer’s disease PSEN1 0.72 0.188 0.318 0.199 3/133/69
40 DOID:1926 Gaucher’s disease GBA 0.72 0.192 0.257 0.259 5/42/161
41 DOID:1307 dementia MAPT 0.72 0.167 0.258 0.256 1/55/27
42 DOID:1612 breast cancer TP53 0.72 0.167 0.317 0.167 1/221/1
43 DOID:1919 Lesch-Nyhan syndrome HPRT1 0.72 0.167 0.249 0.258 1/9/57
44 DOID:8997 polycythemia vera JAK2 0.72 0.167 0.317 0.182 1/86/2
45 DOID:10487 Hirschsprung’s disease RET 0.72 0.167 0.258 0.258 1/48/68
46 DOID:3490 Noonan syndrome SOS1 0.72 0.167 0.251 0.258 1/12/59
47 DOID:10283 prostate cancer AR 0.71 0.167 0.315 0.196 1/280/10
48 DOID:9256 colorectal cancer TP53 0.71 0.167 0.316 0.188 1/81/3
49 DOID:9263 homocystinuria CBS 0.71 0.167 0.251 0.257 1/12/52
50 DOID:14330 Parkinson’s disease SNCA 0.71 0.182 0.314 0.198 2/236/23
Table 2.7: The top 50 scored gene disease associations in the Human Disease Gene
Database
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Figure 2.17: Violin plot of the distribution of publication year of the publications in
HDGDB and their supported GDAs in GeneRIF and VAR. Any papers published before
1995 were binned as 1995. OMIM does not provide a reference for their data, thus it
was not included in the figure. The red line in the box plot indicates the mean. The
paper time line clearly shows that the GeneRIF dataset has been continually increasing
since 2001 while the Ensembl variation database started to expand from 2007 when
Genome Wide Association studies became more popular. In total, 82.48% of the GDAs
were supported by papers from the last 10 years.
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GeneRIF has increased constantly. A sharp increase of the Ensembl variation database
between v1.0 to v2.0 is the result of an major update which added in a number of re-
cent GWAS studies. Despite the number of entities in each source increasing, a small
drop in GDAs were observed. This is because of the implementation of a filter (see
section 2.2.4) between v2.0 and v3.0 which removed some of the erroneous GDAs to
increase mapping accuracy. For example, in v2.0, a GeneRIF Overexpression of serum
A1BG is associated with non-small cell lung cancer was mapped to both ‘lung cancer’
and ‘cancer’ creating two GDAs due to an annotation error referred to as a coordinating
conjunctions(see section 2.3.4.1). The filter removed the latter, keeping only the most
specific annotation ‘lung cancer’. Thus the total GDAs decreased but the accuracy was
improved. OntoSuite-Miner allows regular updating of the data sources, thus keeping
the database up-to-date with the most recent findings.
source
Genes Diseases Associations # corpora in source
v1.0 v2.0 v3.0 v1.0 v2.0 v3.0 v1.0 v2.0 v3.0 v1.0 v2.0 v3.0
Generif 10376 10466 10977 2774 2810 3003 99393 112818 111875 397403 439114 484340
OMIM 2628 2770 2914 1057 1142 1210 4244 5146 4759 5339 5504 5724
Var 4829 13980 13853 385 1063 1359 8452 39133 39993 34790 229777 337731
HDGDB 12964 17547 17731 2841 2917 3140 108010 147823 147023 563141 674395 827795
Table 2.8: The number of gene, disease and gene-disease association between differ-
ent version of HDGDB.
2.3.4 Validation of HDGDB
In order to validate the HDGDB, I evaluated the gene disease association data in several
ways. First, I manually reviewed 900 HDO mappings randomly taken from HDGDB,
300 from each source including OMIM,GeneRIF and Ensembl variation. Precision
rates were calculated to measure the accuracy of the dataset. Errors/mismatches were
identified and classified into four different groups and possible solutions were dis-
cussed. Next I compared HDGDB against an OMIM ‘gold standard’ dataset generated
by using HDO term’s cross references features (see section 2.3.4.2). Finally, two well
studied gene sets, an aging related gene set from GenAge database [187] and a cil-
iopathy related gene set from Cildb [188], were examined with HDGDB, to explore
their gene disease relations by running over-represented disease ontology enrichment
analysis.
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Figure 2.18: Number of gene, disease, GDA and the number of corpus between major
updates. A small drop in GDAs were observed. This is because of the implementation
of a filter (see section 2.2.4) between v2.0 and v3.0.
76Chapter 2. Mapping text corpora to ontology terms using natural language processing tools
2.3.4.1 Dealing with annotation errors
Annotation errors from OntoSuite-Miner may arise from a variety of sources includ-
ing the two NLP annotators used in the task, the ontology itself and errors induced
by the original text sources. Some errors are inevitable in an automated process like
OntoSuite-Miner but some of them can be avoided or corrected. Due to the lack of a
standard labeled HDO annotation, there is not an obvious way to evaluate the quality
of HDGDB. As a rule of thumb, manual inspection is the most accurate way to eval-
uate the performance of NLP based methods. Thus, I reviewed 900 HDO mappings
(referred to as ALL) randomly taken from HDGDB, 300 from each source including
OMIM, GeneRIF and Ensembl variation (not available in the thesis but provided as
supplementary file on the attached disk). As shown in fig. 2.19, a small proportion
of these 900 mapping were found solely by one of the annotators while the majority
were found by both of the annotators. This applied to the results across all of the three
data sources and ALL, suggesting that most of the time, the two annotators perform
similarly.
By manually inspecting the accuracy of the mapping, precision rates were calcu-
lated for mappings from each of the data sources and for the overall 900 mappings as
a whole. The precision rate is calculated as follows:
Precision = (Number of correct mapping)/(Total number of mappings) (2.7)
It is difficult to estimate the recall rate in this case since it is extremely time consuming
and requires the involvement of domain experts. Therefore, only precision rates are
measured and used for the purposes of evaluation. As shown in fig. 2.20, the highest
precision rates are from those mappings generated by both MeM and NcA, 95.15%
in ALL. In terms of the performance of each annotator, MeM slightly out performed
NcA across all sources. However, when looking at those mappings generated solely
by one annotator, MeM largely out performed NcA, correctly identifying 85% of the
mappings in ALL while NcA only identified 55.05% of them. The result suggests that
in the current configuration, MeM performs better in this specific task than NcA, while
the overlap mappings found by both of them are the most reliable.
Each annotator has its own pros and cons due to the different underlying algorithms
and configurations. They favour certain types of text input and tend to make mistakes
for others. A pattern of errors was observed, some of which have been already eluci-
dated in [189]. Four types of errors were identified among the 900 mappings inspected.
The details are shown in fig. 2.21 and table 2.9.
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Figure 2.19: The distribution of annotations by annotator in the manually inspected 900
mappings from HDGDB. More than 70% of mappings were found by two annotators,
indicating that most of the time, the two annotators’ perform similarly and the generated
mappings are trustworthy compared to those only found by one of them.
MetaMap NCBO Annotator MetaMap &NCBO Annotator
GeneRIF OMIM VAR ALL GeneRIF OMIM VAR ALL GeneRIF OMIM VAR ALL
CC 5 4 2 11 16 20 10 46 11 4 10 25
Abbr 2 1 1 4 4 0 0 2 2 0 0 4
Missing 0 0 0 0 0 0 0 0 0 1 0 1
Other 2 2 0 4 1 0 0 1 2 0 0 2
Table 2.9: he number of error identified in 900 mapping from the Human Disease Gene
Database
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Figure 2.20: Precision rate of 900 manually inspected mappings from HDGDB. Pre-
cision rates were calculated based on the annotator that generated the mapping. The
precision of those mappings generated solely by NcA or MeM were plotted as only.n
and only.m. all.n and all.m indicates the precision of all mappings found by NcA or
MeM respectively, including those found by both. Precision for the mappings found
by both annotators is plotted as m&n while overall is the overall precision for the 900
mappings regardless of the annotator. Mapping source is indicated by shape while a
ALL represent all 900 mappings. It is observed that mapping precision rates are the
lowest when the mappings are only supported by NcA. In general, MeM out performed
NcA in all three data sources. Those mappings supported by both MeM and NcA were
found the most reliable. An overall 88.89% of mapping were found correct amount the
900 mappings.
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Figure 2.21: Distribution of the four types of annotation errors identified among the 900
mappings inspected from HDGDB. The most common type of errors, composed 82%
of all the errors in ALL, were coordinating conjunctions (CC), the discovery of HDO
terms with only a partial or ambiguous part of the input text. Other errors include those
caused by abbreviation in the source text or errors due to missing concepts/synonyms
in the Human Disease Ontology were identified but only composed 11% of all the errors
in ALL. 7% of the errors were classified as ‘Others’, which were mainly caused by inap-
propriately handled prepositions of the source text or the inability to extract relationships
between entities in the source text.
Mapping error due to Coordinating conjunctions The most significant problem
contributing to the majority of errors (82% of all errors in the ALL) was the discovery
of HDO terms which indicated a partial or ambiguous part of the input text. This type
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of error, referred to as coordinating conjunctions in [189], occurs when the input text
has complex syntax or contains an arbitrary way of stating multiple thoughts. This
type of error can be further classified into two subcategories:
1)Wrongly split phrases. Some text have a complex syntax which confused the an-
notator’s decision on how to split the text into phrases. This resulted in the using of the
wrong parts of the text and consequently assigning the wrong HDO terms to the text.
For example, A protein encoded by this locus was found to be differentially expressed
in postmortem brains from patients with atypical frontotemporal lobar degeneration
was wrongly assign to the HDO term ‘DOID:1443 brain degeneration’. Genetic vari-
ation may affect severity of disease for X-linked retinitis pigmentosa was mapped to
‘DOID:630 genetic disease’ and GLUTATHIONE SYNTHETASE DEFICIENCY OF
ERYTHROCYTES HEMOLYTIC ANEMIA DUE TO was mapped to ‘DOID:13121 de-
ficiency anemia’. Despite the fact that the correct HDO terms have been identified(not
shown here) for the most of the text of this type, this was still a frequent source of
mismatches.
2)Matching a partial of the sentence. This was the most prevalent source of er-
rors, caused by recognizing only a partial of the sentence/phrase. Example includ-
ing Dyserythropoietic anemia with thrombocytopenia being mapped to ‘DOID:1588
thrombocytopenia’ and To analyze the expression of Syk tyrosine kinase during the
multi step development of human breast carcinoma being mapped to ‘DOID:305 car-
cinoma’. This type of text shared a similar pattern. They either used a disease name
as descriptive text(adjective), for example, anemia with thrombocytopenia to empha-
size the condition/type of anemia, or include disease name that contain other disease
names(usually more general disease), for example, carcinoma in breast carcinoma.
Unfortunately, this pattern appear very frequently in medical text, thus making it one
of the most prevalent source of errors in HDGDB. However, such error is not necessar-
ily wrong in term of disease annotation. In the above case, it is reasonable to link the
gene to ‘thrombocytopenia’ as well as ‘anemia’. It is also true that the gene involved
in the development of breast carcinoma is involved in carcinoma in general. Note that
similar disease name does not always mean relevant disease. For example, Charcot-
Marie-Tooth disease, axonal, type 2V, also known as ‘CharcotMarieTooth(CMT) neu-
ropathy’ which is a nervous system disease characterized by progressive loss of muscle
tissue and touch sensation across various parts of the body. The above text was wrongly
assigned the term ‘DOID:1091 tooth disease’ which is a completely irreverent disease
of dental disorder in mouth.
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The HDO annotation was generated from sources including GeneRIF, OMIM and
Ensembl variation, all of which provide short sentences/phrases to describe genes.
Coordinating conjunctions will become more problematic when using longer, more
complicated texts such as those in abstract/full-text documents of scientific literature.
In terms of the performance of the two annotators, MeM tends to make the ‘wrongly
split phrase’ mistake because it takes into account the gaps between words. In contrast,
NcA only searches for exact matches, thus is unlikely to make such mistakes but is
more likely to match a part of the sentence to HDO terms. In most cases in HDGDB,
errors of this type result in less accurate matches that usually identify high level terms
which are either direct or indirect ancestor terms of the correct term, for instance,
‘DOID:162 cancer’ and ‘DOID:1612 breast cancer’. The effect of these errors varies
depending on the type of analysis performed. For example, when constructing a gene-
disease network, wrongly assigned high level terms may result in misleading high
connectivity degree nodes. In other cases, such as testing for disease enrichment of a
set of genes, these mappings are normally inconsequential to the overall enrichment
result because high level terms will tend to have a large count in the background set
and are therefore unlikely to be enriched in the study set (see chapter 3 on page 113
for detail).
An extra filtering process was implemented in the OntoSuite-Miner pipeline by
taking into account the ontology hierarchy to minimize errors caused by coordinating
conjunctions (see section 2.2.4 on page 53). Errors caused by coordinating conjunc-
tions could also be rectified by analyzing the dependency grammar (see review [190])
of the text sentence. The idea is that the syntactic structure of a sentence consists
of binary asymmetrical relations between the words of the sentence. A dependency
parser can break the sentence into words connected according to their relationships.
Such relationships can be visualized hierarchically where nodes represent words and
edges represent relationships. As shown in fig. 2.22, cat is the syntactic subject of the
sentence. white and black eyes are descriptive pieces of text (adjectival modifier or
amod) that are used to modify/complete the meaning of cat. Such dependency trees
can be used to guide the selection of the most relevant parts of the sentence. The words
can be prioritized by their distance to the ROOT, that is the words that are closer to the
ROOT have a higher priority. This word ranking can be fed into the annotators to avoid
coordinating conjunctions to a certain degree.
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Figure 2.22: Dependency tree for the sentence white cat with black eyes. Each vertex in
the tree represents a word (except ROOT), child nodes are words that are dependent on
the parent. Edges are labelled by the relationship. The subscript indicates the position
of the word in the sentence. The word white and black eyes are adjectival modifier
(amod) and noun modifier (nmod) respectively which serve to modify the meaning of
the noun phrase cat. In this example, cat is closer to the ROOT, indicating that it is
the syntactic subject of the sentence. amod white is directly modifying the syntactic
subject, thus has a closer relation to it than the nmod eyes. In this case, if to prioritized
the words, white will have a higher priority than eyes and cat with eyes.
Mapping error due to Abbreviation The use of abbreviation in source texts results
in annotators choosing the wrong HDO term because the meaning of the abbreviation
is ambiguous. This can be further classified into three types of abbreviation error:
(1) gene/protein name wrongly interpreted as disease abbreviation. Examples in-
cluding WT1 expression is down-regulated in the ovulatory polycystic ovary syndrome
endometrium being wrongly mapped to ‘DOID:5183 WT1 hereditary Wilmsś tumor’
because of an exact synonym of the term being ‘WT1’, and, due to the same reason,
CRF does have a role to play in determining BDNF control of dendritic spines being
wrongly mapped to ‘DOID:784 chronic kidney failure (CRF)’ when it was referring to
‘corticotrophin releasing factor’ in the text.
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(2) abbreviations being ambiguous when they are considered in a disease con-
text. For example, In amnion cells EGFR clustering induced by 50-Hz MF depends
on acid sphingomyelinase activity being mapped to ‘DOID:8691 mycosis fungoides
(MF)’ when the MF means ‘magnetic field’.
(3) ambiguous disease abbreviations. For example, dlgap1 showed the highest
association, of snps examined, with ocd was wrongly annotated to ‘DOID:84 osteo-
chondritis dissecans (OCD)’ when the ocd in the text was referring to ‘obsessive-
compulsive disorder’. familial cold autoinflammatory syndrome 2 was incorrectly
assigned the term ‘DOID:3083 chronic obstructive lung disease (COLD)’. Another ex-
ample would be Emery-Dreifuss muscular dystrophy 2, AD being mapped to ‘DOID:10652
Alzheimer’s disease(AD)’ when the AD was short for ‘autosomal dominant’.
These types of errors suggest that further research needs to be done into the devel-
opment of the HDO. Great care needs to be taken when defining synonyms/concepts to
avoid ambiguous/duplicated terms. In terms of approaches to improve the results, these
types of errors can be reduced by applying a technique called WSD, that is word-sense
disambiguation (see survey [191] for more details). WSD is a technique to identify the
intended sense of a word (i.e. meaning) used in a sentence when the word has multi-
ple meanings. It is still an open research area in NLP and different variants of WSD
exist. The general procedure of WSD can be summarized as follows: given a set of
words (e.g., a sentence or a bag of words), a technique is applied which makes use of
one or more sources of knowledge to associate the most appropriate senses with words
in context. The knowledge source is a fundamental component of WSD, providing
data which are essential to associate senses with words. For example, the word AD in
AD patients with an atypical onset have significantly higher levels of total tau is more
likely to refer to Alzheimer’s disease due to the presence of the ward tau, which is a key
protein involved in the disease. Thus, given enough knowledge sources, WSD might
be able to distinguish ambiguous words’ meaning in different contexts and assign the
right HDO term to the text. NcA did not implement WSD but provides a parameter to
specify the minimum match length which can solve some of the problems caused by
abbreviations with the cost of possible loss of recall. However, it is unclear what the
optimal match length is. A large minimum match length may result in a reduction of
NcA’s detection power while a small one may not make any difference to the results.
MeM has its own WSD procedure but does not provide any appropriate disease knowl-
edge sources as training set for the WSD. The errors caused by abbreviations is likely
to be reduced if when such training data become available.
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Mapping error due to Missing concepts/synonyms in HDO There were also rare
cases where a particular concept was not in the Human Disease Ontology (once in the
900 mappings examined). For example, Auditory neuropathy, autosomal dominant, 1
representing Auditory neuropathy (AN), a variety of hearing loss in which the outer
hair cells within the cochlea are present and functional, but sound information is not
faithfully transmitted to the auditory nerve and brain properly. There is no HDO term
for AN. The most relevant HDO terms were ‘DOID:2742 auditory system disease’
and ‘DOID:870 neuropathy’, of which the later was identified by both MeM and NcA.
The lack of synonyms of HDO terms caused a lot of mismatches especially in disease
contexts where disease names were highly variable in free text. For example, the word
‘OCD’ is frequently used as ‘obsessive-compulsive disorder’ but is not present as a
synonym of that term. This type of error requires additional development research
of the ontology to address. HDO is being actively updated, and new terms are being
added to better represent human disease domain knowledge. The performance of the
annotators is likely to be improved as this process continues. Data generated from
OntoSuite-Miner identified such problem in ontologies, thus suggesting its potential
role in aiding the developing/refining of ontologies.
Others There were several cases where an exact surface form in the text corpus
was obvious but were missed by both MeM and NcA. For example, ciliary dyskinesia
primary 21 should be mapped to ‘DOID:9562 primary ciliary dyskinesia’ but neither
of the annotators was able to find this term. This is likely caused by inappropriately
handled prepositions. Another type of error occurs where some of the text describes
a week, null or negative relationship between a gene and a disease, but the current
implementation of OntoSuite-Miner does not capture this information, resulting in the
generation of an incorrect gene-disease link. For example, No association with ovarian
cancer risk for BRCA1 or BRCA2 mutation carriers or with breast cancer risk for
BRCA1 mutation carriers was observed describes no association between the genes
and ovarian cancer, but OntoSuite-Miner would generate a link between them. No
association with psoriasis susceptibility is another example of this kind. This is not
an error made by the annotator itself but extra work needs to be done to handle the
relation between gene the disease. A simple solution would be to ignore text that
contains a predefined set of keywords indicating negative relationships, for example,
‘not’,‘unlikely’,‘without’,‘no’,‘infrequent’,‘low’ and ‘unaffected’. A more reasonable
solution would be to consider the level of certainty of the relation and extract such
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information implied in the text with relation extraction (RE) methods similar to the
approach by Bravo et.al [45].
Summary Errors in the HDGDB arise from a variety of sources. Some errors are
inevitable in an automated process like that used by OntoSuite-Miner, but some can
be avoided or corrected. These errors have different impacts based on how the data is
used. In the case of enrichment analysis discussed in chapter 3 on page 113, because
the errors affect both the set of interest and the reference set equally, the errors will
most likely cancel each other out when computing statistical enrichment, though this
is not guaranteed. In other cases like studying relationships between diseases, these
errors may bring in false positive links which may have negative effects. Fortunately,
the succinctness and accuracy of the curated databases used as sources for the HDGDB
mean that annotation errors occur less frequently than, for example, using abstracts or
full paper text as sources, which may be more complex and error prone since, for
example, diseases may be mentioned but not directly related to the gene under study.
2.3.4.2 Validation of HDGDB against an OMIM ‘gold standard’ dataset
Ontology terms are usually created with external cross references to other ontologies
or resources. The HDO term ‘DOID:106052 Alzheimer’s disease’, for example, has
in total 36 external cross references including the KEGG database (‘KEGG:05010
Alzheimer’s disease pathway’), the OMIM database (‘OMIM:104300 ALZHEIMER
DISEASE; AD’) and the ICD10 database (‘ICD10CM:G30 Alzheimer’s disease with
early onset’). These cross references are created manually by domain experts and con-
sidered very reliable. The absence of a gold standard HDO annotation makes it hard to
evaluate any newly created HDO annotations. Thus, I used the HDO to OMIM cross
references and created an annotation dataset referred as ‘OMIM-GOLD’, which was
used as a test dataset to validate the newly generated HDGDB.
In HDO, there are 1349 (19.78%) HDO terms that have at least one OMIM refer-
ence and in total 2622 (58.5%) out of 4482 unique disorder entries in OMIM database
were referenced with at least one gene annotation. OMIM disorders are manually an-
notated with genes. These genes were transfered to HDO terms via their OMIM cross
references (HDOOMIM disordergenes) to form the ‘OMIM-GOLD’ dataset.
‘OMIM-GOLD’ contained 1052 HDO term annotated with 2333 unique genes,
forming 3222 gene disease associations (GDAs). As shown in fig. 2.23, OntoSuite-
Miner was able to recover 66.48%, 76.47% and 64.84% of the ‘OMIM-GOLD’ GDAs
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by mining GeneRIF, OMIM and Ensembl variation databases separately. This in-
creases to 90.32% when these data were merged into HDGDB. Most of the GDAs were
found by both annotators, indicating that they are high confidence discoveries. Even
though GDAs identified solely by one annotator are less trustworthy, they contribute
to more than 10% of the correct mappings in HDGDB when compared to ‘OMIM-
GOLD’.
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Figure 2.23: The validation of HDGDB by comparing to the ‘OMIM-GOLD’ HDO anno-
tation dataset (1052 HDO term annotated with 2333 unique genes forming 3222 GDAs)
created using OMIM cross-references to HDO terms. HDGDB was able to recover
90.32% of ‘OMIM-GOLD’ GDAs, indicating a high recall rate while most of the GDAs
were found by both annotators, indicating that they are high confidence mappings. Even
though GDAs identified solely by one annotator are less trustworthy, they contribute to
more than 10% of the correct mappings in HDGDB when compared to ‘OMIM-GOLD’.
The increased percentages of GDAs recovered from HDGDB compared to the tree
individual source highlights the advantages of the data integration.
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2.3.4.3 Validation of HDGDB against DisGeNet
Similarly, instead of using OMIM-HDO cross references, as a further validation, I
compared HDGDB with the DisGeNet [192], which is an integrated knowledge base
containing human gene disease association from a variety of sources. However, Dis-
GeNet and HDGDB are not directly comparable due to the differences of sources
used, but one of the data sources from DisGeNet, the Literature-derived Human Gene-
Disease Network (LHGDN) [193], is derived from the GeneRIF database, making it
an ideal resource for validating HDGDB and the performance of OntoSuite-Miner on
recovering gene disease association, also from the GeneRIF database.
Recall that in the GeneRIF database, a Pubmed id is indexed with genes and rifs
(short sentences submitted by authors that describe the functions of the genes studied
in the publication). Each GeneRIF entity thus links one gene to one rif from one
publication. LHGDN and HDGDB(GeneRIF subset) are both derived by linking such
gene/publication pair to disease terms base on its rifs, thus they are comparable. In the
following validation process, the LHGDN is considered as a test data set to evaluate
HDGDB.
LHGDN data was downloaded from DisGeNet website on 28 July 2017. UMLS
[10] id was used to represent disease. To enable the comparison, the UMLS ids were
mapped to HDO using EBI Ontology Xref Service [161]. Out of the 52828 gene dis-
ease associations in LHGDN, 16500(31%) cannot be mapped to HDO, thus removed
from further testing. Three categories, identical, better, and missed were used during
the assessment. For each gene/publication pair in LHGDN, if HDGDB(GeneRIF sub-
set) contains a) the same disease annotation, it is assigned identical; b) more specific
diseases, it is assigned better; c) otherwise, it is assigned missing. The result is shown
in fig. 2.24.
HDGDB is able to recover in total 30233(88.2%) of the 34288 gene/publication
pairs in LHGDN, out of which, 2561(7.47%) contains more specific disease terms. For
example, gene HGFAC(Entrez gene id 3083) is indexed with Pubmed paper 16189274
[194] with a rif ‘HGF/MET signaling and aberrant HGF-activator expression is as-
sociated with diffuse large B-cell lymphoma’. LHGDN annotated this gene with
‘DOID:707 B-Cell Lymphomas’, while HDGDB annotated the same gene with ‘DOID:0050745
diffuse large b-cell lymphoma’, which is a direct child term of the previous in the
HDO hierarchy. Another example would be gene HOXD13 (3239) which is indexed
with Pubmed paper 18566322 [195] with a rif ‘transgenic mice expressing NUP98-
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HOXD13 (NHD13) fusion gene develop myelodysplastic syndrome, and more than
half eventually progress to acute leukemia’. In this case, both LHGDN and HDGDB
corrected annotated the gene with ‘DOID:0050908 myelodysplastic syndrome’. How-
ever, another disease term ‘DOID:1240 leukemia’ was annotated to the gene in LHGDN,
while in HDGDB, one of its direct child term ‘DOID:12603 acute leukemia’ was found
instead.
HDGDB failed to recover 4055(11.8%) annotation for the gene/publication pair
compared to LHGDN. However, since LHGDN is a text-mining derived dataset ex-
tracted from GeneRIF, it itself contains errors. Thus, there are cases in the 4055 anno-
tation where HDGDB correctly identified the annotation while LHGDN did not. The
precedent of such cases is however unknown. In another word, the 11.8% missing rate
is an upper bound of the error rate while the actual error rate is lower. As an example,
gene CPE(1363) wan annotated wrongly to ‘DOID:169 Neuroendocrine Tumors’ in
LHGDN base on the rif ‘cDNA microarray analysis led to the identification of 2 novel
biomarkers that should facilitate molecular diagnosis and further study of pulmonary
neuroendocrine tumors’ from Pubmed paper 15492986 [196], while HDGDB was able
to pick up the correct disease term ‘DOID:5410 pulmonary neuroendocrine tumor’.
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Figure 2.24: The validation of HDGDB (GeneRIF subset) against the DisGeNet
LHGDN dataset. For each gene/publication pair in LHGDN, it is assigned a) identi-
cal if HDGDB(GeneRIF subset) contains the same disease annotation; b) better if
HDGDB(GeneRIF subset) found more specific diseases, and c) missing otherwise.
HDGDB agrees 80.7% of the GDAs in LHGDN, indicating a high recall rate. 7.47%
of the gene/publication pair were annotated with more specific HDO terms in HDGDB,
while 11.83% were annotated with different HDO terms.
2.3.4.4 Validation of HDGDB against genes from GenAge
I used a set of 305 human genes(build 18, release on October 11, 2015) from the
GenAge database [187], which are known to be associated with aging. HDGDB was
able to annotate 303 (99.34%) of these genes with human disease ontology terms. For
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this subset, I ran enrichment analysis with the topOnto R package (see chapter 3 on
page 113) and obtained the top 50 enriched HDO terms (table 2.10). Most of the
enriched diseases are different types of cancer. This agrees with the date published
by Cancer Research UK [197] that peak rate of cancer cases, 2012-2014, UK was in
people aged 85+ while half of all cancer cases in the UK are diagnosed in people aged
70 and over. Other diseases such as ‘Alzheimer’s disease’, ‘type 2 diabetes mellitus’
and ‘Parkinson’s disease’ are also known to increase with age.
TERM.ID TERM.NAME Annotated Significant Expected elim-p elim-p-BY
1 DOID:1909 melanoma 1248 142 21.33 1e-30 5.69e-28
2 DOID:684 hepatocellular carcinoma 1951 167 33.34 1e-30 5.69e-28
3 DOID:1749 squamous cell carcinoma 1518 153 25.94 1e-30 5.69e-28
4 DOID:10283 prostate cancer 2261 190 38.64 1e-30 5.69e-28
5 DOID:8567 Hodgkin’s lymphoma 519 85 8.87 1e-30 5.69e-28
6 DOID:299 adenocarcinoma 1465 142 25.03 1e-30 5.69e-28
7 DOID:10652 Alzheimer’s disease 1511 122 25.82 1e-30 5.69e-28
8 DOID:0050865 tongue squamous cell carcinoma 636 84 10.87 1e-30 5.69e-28
9 DOID:769 neuroblastoma 620 83 10.6 1e-30 5.69e-28
10 DOID:768 retinoblastoma 306 65 5.23 1e-30 5.69e-28
11 DOID:5520 head and neck squamous cell carcinoma 336 63 5.74 1e-30 5.69e-28
12 DOID:1036 chronic leukemia 465 71 7.95 1e-30 5.69e-28
13 DOID:8552 chronic myeloid leukemia 364 64 6.22 1e-30 5.69e-28
14 DOID:9538 multiple myeloma 534 74 9.13 1e-30 5.69e-28
15 DOID:2237 hepatitis 950 95 16.23 1e-30 5.69e-28
16 DOID:657 adenoma 575 76 9.83 1e-30 5.69e-28
17 DOID:9261 nasopharynx carcinoma 436 66 7.45 1e-30 5.69e-28
18 DOID:2043 hepatitis B 460 67 7.86 1e-30 5.69e-28
19 DOID:1712 aortic valve stenosis 353 60 6.03 1e-30 5.69e-28
20 DOID:1936 atherosclerosis 565 72 9.66 1e-30 5.69e-28
21 DOID:289 endometriosis 458 71 7.83 1e-30 5.69e-28
22 DOID:1612 breast cancer 3487 229 59.59 1e-30 5.69e-28
23 DOID:9119 acute myeloid leukemia 674 86 11.52 1e-30 5.69e-28
24 DOID:3070 malignant glioma 1357 146 23.19 1e-30 5.69e-28
25 DOID:3347 osteosarcoma 522 71 8.92 1e-30 5.69e-28
26 DOID:3910 lung adenocarcinoma 485 66 8.29 1e-30 5.69e-28
27 DOID:4362 cervical cancer 702 94 12 1e-30 5.69e-28
28 DOID:3717 gastric adenocarcinoma 243 50 4.15 1e-30 5.69e-28
29 DOID:0050908 myelodysplastic syndrome 231 48 3.95 1e-30 5.69e-28
30 DOID:9952 acute lymphocytic leukemia 605 69 10.34 1e-30 5.69e-28
31 DOID:1115 sarcoma 463 72 7.91 1e-30 5.69e-28
32 DOID:11054 urinary bladder cancer 796 99 13.6 1e-30 5.69e-28
33 DOID:3068 glioblastoma multiforme 359 55 6.13 1e-30 5.69e-28
34 DOID:3008 invasive ductal carcinoma 376 56 6.43 1e-30 5.69e-28
35 DOID:0050866 oral squamous cell carcinoma 504 63 8.61 1e-30 5.69e-28
36 DOID:219 colon cancer 1137 118 19.43 1e-30 5.69e-28
37 DOID:14221 metabolic syndrome X 425 57 7.26 1e-30 5.69e-28
38 DOID:0050745 diffuse large B-cell lymphoma 254 46 4.34 1e-30 5.69e-28
39 DOID:10286 prostate carcinoma 220 49 3.76 1e-30 5.69e-28
Continued on next page
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Table 2.10 – continued from previous page
TERM.ID TERM.NAME Annotated Significant Expected elim-p elim-p-BY
40 DOID:10236 exhibitionism 209 42 3.57 1e-30 5.69e-28
41 DOID:2394 ovarian cancer 1486 148 25.39 1e-30 5.69e-28
42 DOID:11714 gestational diabetes 147 37 2.51 1e-30 5.69e-28
43 DOID:9352 type 2 diabetes mellitus 298 48 5.09 1e-30 5.69e-28
44 DOID:3770 pulmonary fibrosis 268 46 4.58 1e-30 5.69e-28
45 DOID:4001 ovarian carcinoma 470 74 8.03 1e-30 5.69e-28
46 DOID:12704 ataxia telangiectasia 78 29 1.33 1e-30 5.69e-28
47 DOID:326 ischemia 388 66 6.63 1e-30 5.69e-28
48 DOID:3908 non-small cell lung carcinoma 1117 126 19.09 1e-30 5.69e-28
49 DOID:12603 acute leukemia 271 45 4.63 1e-30 5.69e-28
50 DOID:643 progressive multifocal leukoen-
cephalopathy
138 35 2.36 1e-30 5.69e-28
Table 2.10: Enrichment analysis for Aging-related genes from the GenAge database
HDGDB and topOnto R package (see chapter 3 on page 113). The enriched dis-
ease make biological sense. Most of these disease such as different types of cancer,
neurodegenerative disease such as ‘Alzheimers disease’ and ‘Parkinsons disease’ are
diseases primarily associated with older people with incidence rates increasing with
age.
2.3.4.5 Validation of HDGDB against genes from Cildb
Cilia are tiny hair-like organelles formed on the surface of cells and are present on
almost all polarized cell types of the human body and are involved in various cellular
functions. Cilia can either be motile or immotile (sometimes refered to as sensory cilia
or primary cilia). Ciliary motility is required to move extracellular fluid while immotile
cilia are thought to have sensory and signaling roles. Ciliary dysfunction causes a
number of diseases in humans from development defects to defects in vision, smell,
and hearing. Well known cilia-related diseases includes ‘primary ciliary dyskinesia
(PCD)’, ‘situs inversus totalis’ and ‘Nephronophthisis’ are referred to as ciliopathies,
and the number of diseases caused by ciliary dysfunction is expected to increase (see
review paper in [198, 199]).
As part of the validation of the HDGDB data generated by OntoSuite-Miner, I first
explored HDGDB for known ciliopathies to ensure that the data recapitulated known
disease associations. Six well known ciliopathies were picked and the number of genes
annotated to each disease from each source were calculated (Table 2.11). Some GDAs
were identified by multiple sources while others were only found in a single source.
By integrating such information into HDGDB, the inter-connection between these dis-
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eases was revealed (Figure 2.25). For example, ‘primary ciliary dyskinesia’ shares no
genes between any of the diseases in OMIM , GeneRIF or Ensembl variation database
but is linked to ‘polycystic kidney disease’ by gene CCDC151 in HDGDB.
OMIM GeneRIF Ensembl variation HDGDB
primary ciliary dyskinesia 26 22 27 56(17)
Joubert syndrome 23 2 68 75(23)
Bardet-Biedl syndrome 21 23 72 76(23)
Senior-Loken syndrome 7 3 13 16(5)
polycystic kidney disease 3 47 14 57(17)
polycystic liver disease 2 5 6 9(3)
Table 2.11: Number of genes annotated to six well known ciliopathies. Some genes
were identified by multiple sources while others were only found in a single source. The
number in the bracket indicates the number of false positives estimated base on the
result (Precision rate 69.84% on GWAS GeneRIF(HDC)) from section 2.3.1.
As a further validation of the utility of the HDGDB, I performed disease enrich-
ment analysis with topOnto R package (discussed in the chapter 3 on page 113) on
a set of cilia-related genes from Cildb [188]. The gene data, comprised 3133 human
genes having at least one piece of evidence of association with cilia and was taken from
from Cildb on 25/04/2016. 446 diseases were enriched with p≤ 0.05. For readability,
the top 50 significant enriched terms are shown in table 2.12 while the full list can be
found as supplementary information in Cildb enrichment.csv (attached disk).
TERM.ID TERM.NAME Level Annotated Significant elim-p elim-p-BY
1 DOID:684 hepatocellular carcinoma 9 1951 406 4.0e-20 1.21e-15
2 DOID:9562 primary ciliary dyskinesia 5 56 36 3.3e-18 4.98e-14
3 DOID:1749 squamous cell carcinoma 7 1518 326 3.4e-17 3.42e-13
4 DOID:9261 nasopharynx carcinoma 8 436 118 8.2e-14 5.53e-10
5 DOID:1909 melanoma 6 1248 263 9.8e-14 5.53e-10
6 DOID:1612 breast cancer 7 3487 671 1.1e-13 5.53e-10
7 DOID:219 colon cancer 10 1137 255 3.3e-12 1.42e-08
8 DOID:0050865 tongue squamous cell carcinoma 9 636 150 6.4e-12 2.41e-08
9 DOID:1324 lung cancer 7 2427 474 8.9e-11 2.98e-07
10 DOID:299 adenocarcinoma 7 1465 300 1.7e-10 5.13e-07
11 DOID:3008 invasive ductal carcinoma 10 376 97 2.5e-10 6.54e-07
12 DOID:3498 pancreatic ductal adenocarcinoma 10 304 83 2.6e-10 6.54e-07
13 DOID:1107 esophageal carcinoma 8 789 179 3.1e-10 7.19e-07
14 DOID:3969 papillary thyroid carcinoma 9 244 70 6.4e-10 1.38e-06
15 DOID:0050866 oral squamous cell carcinoma 8 504 119 9.5e-10 1.91e-06
Continued on next page
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Table 2.12 – continued from previous page
TERM.ID TERM.NAME Level Annotated Significant elim-p elim-p-BY
16 DOID:768 retinoblastoma 11 306 81 2.1e-09 3.96e-06
17 DOID:10283 prostate cancer 8 2261 406 1.8e-08 3.19e-05
18 DOID:4001 ovarian carcinoma 11 470 122 2.5e-08 4.19e-05
19 DOID:8469 influenza 5 240 65 3.1e-08 4.83e-05
20 DOID:10619 lymph node cancer 8 205 58 3.2e-08 4.83e-05
21 DOID:2876 laryngeal squamous cell carcinoma 9 194 55 6.6e-08 9.48e-05
22 DOID:1115 sarcoma 6 463 103 3.0e-07 4.11e-04
23 DOID:305 carcinoma 6 4065 768 3.4e-07 4.46e-04
24 DOID:3910 lung adenocarcinoma 10 485 106 5.1e-07 6.41e-04
25 DOID:3565 meningioma 8 152 44 7.0e-07 8.45e-04
26 DOID:3068 glioblastoma multiforme 8 359 83 8.2e-07 9.51e-04
27 DOID:8567 Hodgkin’s lymphoma 9 519 114 9.3e-07 1.04e-03
28 DOID:3113 papillary carcinoma 7 67 25 1.2e-06 1.29e-03
29 DOID:11054 urinary bladder cancer 7 796 173 1.6e-06 1.66e-03
30 DOID:0050639 primary cutaneous amyloidosis 6 272 66 1.9e-06 1.91e-03
31 DOID:2394 ovarian cancer 8 1486 309 2.2e-06 2.14e-03
32 DOID:3114 serous cystadenocarcinoma 9 145 41 3.2e-06 3.02e-03
33 DOID:0050777 Joubert syndrome 5 75 26 3.6e-06 3.29e-03
34 DOID:10459 common cold 6 156 43 3.9e-06 3.46e-03
35 DOID:4450 renal cell carcinoma 9 759 148 4.1e-06 3.53e-03
36 DOID:1712 aortic valve stenosis 8 353 79 5.6e-06 4.57e-03
37 DOID:657 adenoma 6 575 117 5.6e-06 4.57e-03
38 DOID:1793 pancreatic cancer 7 1392 283 6.0e-06 4.76e-03
39 DOID:0050569 Seckel syndrome 7 32 15 6.2e-06 4.80e-03
40 DOID:3144 cutis laxa 6 29 14 8.3e-06 6.25e-03
41 DOID:0050576 Senior-Loken syndrome 7 16 10 8.5e-06 6.25e-03
42 DOID:8552 chronic myeloid leukemia 10 364 80 9.9e-06 7.11e-03
43 DOID:1485 cystic fibrosis 7 269 63 1.1e-05 7.54e-03
44 DOID:0050908 myelodysplastic syndrome 9 231 56 1.1e-05 7.54e-03
45 DOID:2871 endometrial carcinoma 10 343 76 1.2e-05 8.04e-03
46 DOID:1935 Bardet-Biedl syndrome 7 76 25 1.6e-05 1.05e-02
47 DOID:9538 multiple myeloma 10 534 108 1.7e-05 1.09e-02
48 DOID:0050902 medulloblastoma 10 240 57 1.8e-05 1.13e-02
49 DOID:769 neuroblastoma 9 620 122 1.9e-05 1.15e-02
50 DOID:4610 intestinal benign neoplasm 7 228 58 1.9e-05 1.15e-02
Table 2.12: Enriched diseases resulting from an enrichment analysis using topOnto
and the HDGDB for a list of 3133 human genes from CilDB. f‘Level’ indicates the depth
of the disease term in the Human Disease Ontology hierarchical structure. The total
number of gene annotated to a term in HDGDB and the number of overlapping genes
in the CilDB gene list is shown in the ‘Annotated’ column and the ‘Significant’ column. A
number of different types of cancer including lung/breast/prostate/pancreatic/skin carci-
noma, lymphoma, leukemia and sarcoma were significantly enriched. This result sug-
gests that cilia may play an important role under the common theme of cancer where
each different type of cancer shares a subset of overlapping developing mechanism
which require the involvement of cilia.
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(a) OMIM (b) GeneRIF
(c) Ensembl variation (d) HDGDB
Figure 2.25: Known ciliopathies and their annotated genes in OMIM,GeneRIF,Ensembl
variation and HDGDB. Green nodes represent diseases while red nodes represent
genes. Genes were connected to diseases by edges based on their sources. (a)
and (b) shows the gene disease network built on GDAs from the OMIM and GeneRIF
databases. The networks are relatively small and there are not many connections be-
tween diseases. (c) shown the network built using the Ensembl Variation database
which consists mostly of data from GWAS studies. GWAS is able to pick up a lot of
potential genes for diseases, thus have a better recall but bigger noise. As a result,
many more genes were identified from the Ensembl Variation database but some dis-
eases are still orphan. (d) The network built using HDGDB. All of the diseases are
now connected by at least one gene. Edge color indicates the number of sources con-
tributing to the annotation. Interestingly, ‘primary ciliary dyskinesia’ shares no genes
with any of the diseases in OMIM, GeneRIF or Ensembl variation database but is linked
to ‘polycystic kidney disease’ by gene CCDC151 in HDGDB.
96Chapter 2. Mapping text corpora to ontology terms using natural language processing tools
Interestingly, on examining the list of enriched diseases, I found that a number
of different types of cancer including lung/breast/prostate/pancreas/skin carcinoma,
lymphoma, leukemia and sarcoma were significantly enriched. This result suggests
that cilia may play an important role in cancer-related processes where each different
type of cancer shares a subset of overlapping mechanisms which involve of cilia. In
fact, the relationship between cilia and cancer is an emerging research area (see a
recent review by Cao et. al. [200]). Cilia are required to promote the formation of
the spindle during mitosis thus play a role in control of cell division, cell polarity and
cell migration. They can suppress abnormal cell growth and proliferation by affecting
the cell cycle. Dysfunction of cilia has been proposed as a prerequisite step for cancer
development [201] and has been observed in multiple cancer types [202]. Despite a
much-improved understanding of the relationship between cilia and cancer relation
and association, little is known of their direct role in tumorigenesis.
Next, I examined a list of 9 known ciliopathies and 14 suspected ciliopathies
from [203] and their enrichment status in the enrichment results from Cildb genes.
HDO was not used in [203], thus ciliopathies from [203] were manually mapped to
HDO terms based on their names. For example, ‘Dandy-Walker malformation’ was
mapped to the HDO term ‘Dandy-Walker syndrome’. 7 out of 9 known ciliopathies
were found to be significantly enriched but there was no statistical support for the en-
richment of ‘Alstrom syndrome’ or ‘orofaciodigital syndrome I’ (table 2.13). Among
the 14 suspected ciliopathies, 6 were found to be enriched. Note that ‘diabetes mellitus’
was not enriched when using OMIM, GeneRIF or Ensembl Variation alone, but was
found to be enriched using HDGDB, illustrating the advantage of integrating multiple
data sources to increase the statistical power of enrichment analysis. What’s more,
general term ‘diabetes mellitus’ was enriched but none of its children terms ,for ex-
ample type I diabetes or type II diabetes, were enriched, indicating indicating that the
enrichment was the join result of all children terms of diabetes, which would have been
missed without the topology information (see chapter 3 on page 113 for details.) As
potentially more data from other sources being integrated into HDGDB in the future,
the enrichment result of Cildb genes is likely to confirm other suspected ciliopathies or
revealing possible diseases that have not been previously linked to cilia dysfunction.
Disease network analysis has emerged as a powerful way of studying inter-connections
between diseases [204–206]. Such networks of diseases and disease genes offers a
platform to explore all known diseases and disease gene associations in a single graph
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TERM.ID TERM OMIM GeneRIF Ensembl variation HDGDB
Known Ciliopathies
1 DOID:0050473 Alstrom syndrome - Y - -
2 DOID:1935 Bardet-Biedl syndrome Y Y Y Y
3 DOID:0050777 Joubert syndrome Y Y Y Y
4 DOID:0050778 Meckel syndrome Y Y Y Y
5 DOID:12712 nephronophthisis Y Y Y Y
6 DOID:0060316 orofaciodigital syndrome I - - - -
7 DOID:0050576 Senior-Loken syndrome Y Y Y Y
8 DOID:898 polycystic kidney disease - Y - Y
9 DOID:9562 primary ciliary dyskinesia Y Y Y Y
Suspected Ciliopathies
1 DOID:4626 hydranencephaly - - - -
2 DOID:2785 Dandy-Walker syndrome - - - -
3 DOID:9351 diabetes mellitus - - - Y
4 DOID:12714 Ellis-Van Creveld syndrome - - - -
5 DOID:409 liver disease - - - -
6 DOID:0050592 asphyxiating thoracic dystrophy - Y - Y
7 DOID:0060172 juvenile absence epilepsy - - - -
8 DOID:9970 obesity - - - -
9 DOID:1148 polydactyly Y Y - Y
10 DOID:11162 respiratory failure - - - -
11 DOID:10003 sensorineural hearing loss - - - Y
12 DOID:758 situs inversus Y - Y Y
13 DOID:10584 retinitis pigmentosa - Y - Y
14 DOID:0080016 spina bifida - - - -
Table 2.13: Enrichment analysis for known and suspected Ciliopathies taken from [203].
Enrichment analysis was carried out with TopOnto and the p-value was calculated us-
ing Fisher’s exact test with the elim method. A term is considered to be enriched with
p ≤ 0.05. Seven out of 9 known ciliopathies were found to be significantly enriched
but there was no statistical support for the enrichment of ‘Alstrom syndrome’ and ‘oro-
faciodigital syndrome I’. Among the 14 suspected ciliopathies, 6 were found to be en-
riched. Note that ‘diabetes mellitus’ was not enriched when using OMIM, GeneRIF or
Ensembl Variation alone but was enriched with HDGDB, indicting the advantage of in-
tegrating multiple data sources to increase the statistical power of enrichment analysis.
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theoretic framework, and has already been used to reveal the common genetic origin
of many diseases as well as predict potential disease gene candidates [204, 206, 207].
In order to explore the inter-connections of ciliopathies, a disease network was con-
structed with the top enriched diseases from the Cildb enrichment analysis (fig. 2.27,
to reduce the complicity and increase the visibility as a graph in the thesis, only the
top 100 enriched diseases were used). Nodes in the network represent diseases. Two
nodes are connected by a weighted edge if they share CilDB gene(s) with the weight
of the edge equal to the number of common genes. With the rationale that ciliopathies
are a collection of related diseases, they are likely to share similar molecular mecha-
nisms and group together in the same community in the network. Thus, the commu-
nity detection algorithm spinglass.community was applied to the network to identify
ciliopathy communities. A community is defined as a set of nodes with many edges
inside the community and few edges outside it (i.e. between the community itself and
the rest of the network). The community which contains the largest number of known
ciliopathies is referred to as a ciliopathy community. In total, 9 known ciliopathies










DOID:9562 primary ciliary dyskinesia
DOID:3083 chronic obstructive pulmonary disease
Table 2.14: 9 known ciliopathies that were enriched in the Cildb genes.
An argument, gamma, is defined to control the community detection algorithm,
specifying the balance between the importance of edges in a community. The default
value of 1.0 makes existing and non-existing edges equally important. Roughly, small
gamma values generate a few big communities while larger gamma values generate
more communities (fig. 2.26).
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To determine the appropriate gamma value for the disease network, I define n(γ) the
number of community generated for a give γ, Ni(γ) the number of known ciliopathies
in the ith community, Si(γ) the size of the ith community. Let j be the index of the
ciliopathy community for a give γ, so N j is the number of ciliopathy disease in the
ciliopathy community while S j is the size of the ciliopathy community. The Objective




s.t. S j(γ) = max(S1(γ) . . .Sn(γ)) (2.9)
where N j(γ) = max(N1(γ) . . .Nn(γ)) (2.10)
To determine the appropriate gamma value for the disease network, the algorithm
was applied to the network with a range of predefined gamma values in order to find
the one that generates a maximum N j(eq. (2.9)) subjecting to eq. (2.9). The resulting
ciliopathy community size and the number of known ciliopathies in that community
is shown in fig. 2.26b. The best result (referred to as the ciliopathy community) was
generated with a gamma value equal to 1.3, and comprised 17 diseases, including all
9 known ciliopathies, forming the largest community in the network (fig. 2.27). Note
that when gamma value equal to 1, the generated ciliopathies community size is larger
than the one when gamma value equal to 1.3, but this ciliopathies community is not
the largest community in the network, i.e. there were other larger non-ciliopathies
communities in the network.
In addition to the 9 known ciliopathies, the ciliopathy community also contained
8 novel enriched diseases. Some of these diseases are known to involve cilia function
while others have either little or no association with cilia. Respiratory system disease
like common cold was enriched and fell into the ciliopathy community. In human,
cold viruses are transported by nasal cilia to the front of the nasal passages where
they infect nasal cells. Loss of cilia and ciliated cells was observed and suggested
to be responsible for the impaired mucociliary function in patients with common cold
[208]. Numerous cilia-related diseases have been described in [198] that are associated
with developmental defects or degeneration affecting the central nervous system which
explain the enriched diseases including ‘cerebral degeneration’, ‘Alzheimer’s disease’,
‘frontotemporal dementia’ in the ciliopathy community. The occurrence of ischemia
and Diamond-Blackfan anemia (DBA) in the community is very interesting. Same
evidence has shown that the change of functional cilia length/mass is associated with
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(a) (b)
Figure 2.26: Testing different gamma values for community detection applied to the cil-
iopathy disease network. Small gamma values generate a few big communities while
larger gamma values generate more smaller communities. (a) gamma affects the num-
ber of communities in the network and (b) network and ciliopathy community (the largest
number of known ciliopathies) size under different gamma settings.
ischemia [209, 210] but to the best of this author’s knowledge, there is no previous
evidence supporting the association of DBA to cilia. DBA is a congenital erythroid
aplasia that usually presents in infancy, causing low red blood cell counts (anemia)
[211]. Its gene signature is similar to some of the known ciliopathies suggesting a
common underlying molecular mechanism but its connection with cilia function is
still unknown and requires further investigation.
Another interesting member found in the ciliopathy community is cutis laxa, a
group of rare connective tissue disorders in which the skin becomes inelastic and hangs
loosely in folds. The loose skin is often most noticeable on the face but can also affect
internal organs including lungs and heart when it is severe. It has not been classified as
a ciliopathy. A search in the Pubmed database with keyword ‘cutis laxa’ and ‘ciliopa-
thy’ returned only 5 recent papers, all of which reported evidence of having cutis laxa
as a comorbidity of other cilia-related diseases. For example, Alazami et al. reported
a very rare autosomal recessive disorder, Cranioectodermal dysplasia (CED), charac-
terized by a recognizable craniofacial profile in addition to ectodermal manifestations
involving the skin, hair, and teeth [212]. It is highly likely that CED is a ciliopathy
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(a)
(b)
Figure 2.27: (a) a disease network comprising the top 100 enriched diseases from
enrichment analysis of a list of cilia-related genes from CilDB. Nodes in the network
represent diseases. Two nodes were connected by weighted edge if they shared CilDB
gene(s), the weight of the edge is equal to the number of common genes. The network
community was generated using the spinglass.community algorithm from igraph with
a gamma value of 1.3. The ciliopathy community (yellow) community is the largest
community in the network with 17 members containing all 9 master ciliopathy diseases.
(b) Diseases in the ciliopathy community. The width of the edge represent the weight
(genes in common between two nodes). High resolution gene disease network of the
ciliopathy community available in the attached disk.
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because four genes involved in the ciliary intraflagellar transport were known to be
mutated in this disorder. In the report, typical CED features were observed in a mul-
tiplex consanguineous family in addition to intellectual disability and markedly lax
skin with joint laxity fulfilling the clinical definition of cutis laxa. However, none
of the studies had linked cutis laxa directly to cilia dysfunction. According to the
disease annotation data from HDGDB, cutis laxa was annotated with genes including
ALDH18A1, ELN and FBLN5 which have been found associated with multiple known
ciliopathies including chronic obstructive pulmonary disease, cystic fibrosis and jou-
bert syndrome [213–216]. Such overlapping suggested that cutis laxa may be another
undiscovered family member of ciliopathies.
Summary Cilia are located on almost all polarized cell types of the human body.
The malfunction of cilia can result in a number of human disorders and the list is
expected to grow. By running enrichment analysis with cilia-related genes with our
automatic generated disease annotation database, I demonstrated that HDGDB is able
to capture most of the well known ciliopathies as well as novel diseases that have not
yet been connected with ciliopathies. Our results suggest that abnormal function of
the cilia plays an important role in diseases like cutis laxa and provides insight into the
molecular mechanism of these diseases.
2.3.5 Extending annotation to model species
Model organisms are widely used to understand biological phenomena. Functional
information can often be transfered between human genes a genes in model organisms
so that discoveries made in the model organism can provide insight into the workings
of the human diseases. A possible scenario would be the identification of a set of
differentially expressed genes between pathological and control states, e.g., disease
vs. healthy phenotypes. These genes may then be mapped from the model species to
their homolog genes in the human to reveal information relevant to human health and
disease.
Homologous relationships are used to follow gene functions between different
species, however, not all the homolog can be used in this way. As shown in fig. 2.28,
there are two main homology types: Orthologues and Paralogues.
Orthologs are genes in different species that have evolved from a common ances-
tral gene by specification. Paralogs are genes related by duplication within a genome
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which can happen in the same species or across different species. Orthologs are genes
in different species that descend by speciation from the same gene in the last com-
mon ancestor [217]. Orthologs are generally assumed to retain equivalent functions in
different organisms and to share other key properties even if they have diverged since
the speciation event [218]. While orthologs generally retain the same function through
the course of evolution, paralogs often evolve new functions, so in the case of transfer,
functional information between human and model organisms, orthologs are considered
more suitable.
Figure 2.28: Different homology types [219]. Genes in different species and related by
a speciation event are defined as orthologs. 1:1, 1:many and many:many relationships
are defined depending on the number of genes found in each species. Genes of the
same species and related by a duplication event are defined as paralogs.
Orthologs can be further classified into one-to-one orthologues, one-to-many or-
thologues and many-to-many orthologues. When mapping human genes to model or-
ganisms, for example Drosophila melanogaster, a one-to-one orthology relationship
means that a human gene has only one ortholog in Drosophila which is a good indica-
tion that the gene function is likely to be conserved and can be transferred. A one-to-
many relation means a single human gene is orthologous to several Drosophila genes.
In this case it is very likely that one or several of the Drosophila genes shares the same
function (or part of it) as the human genes (the fewer in-paralogs the more likely they
share the function in Drosophila). These annotations could also be transferred with the
cautionary note that they are based on one-to-many relationships. Functional transfers
with many-to-one and many-to-many orthology relationships are less certain but can
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still be informative. HDGDB contains integrated disease annotation for human genes.
Such information can be transfered to different model organisms. In order to extend
the use of such annotations, I mapped these annotations to different model species us-
ing homology data from NCBI HomoloGene [123]. Many-to-one and many-to-many
orthology relationships were removed to keep the annotation as accurate as possible.
A pipeline (fig. 2.29) was implemented to automate the mapping and updating process
due to the fact that the homology data are continually changing and evolving in a fast
speed.
Figure 2.29: Pipeline implemented in OntoSuite-Miner to transfer ontology based an-
notation across species. EntrzGene id is used as the primary index for gene. Ontology
base annotation are projected from human to model species with ortholog data col-
lected form the NCBI HomoloGene database.
2.3.5.1 Drosophila melanogaster
Drosophila is a model organism that has been utilized to model a number of human
diseases. For example, Drosophila have been used to model and study a wide variety
of brain diseases [220]; heart disease [221]; various muscular dystrophies [222–224];
multi-symptom inherited disorders [225]; responses to infection by human pathogens
[226–228] and cancer [64, 229]. Drosophila is also used as model of asthma [230],
lipotoxicity [231] and metabolism [232, 233]. The conservation of gene function be-
tween human and Drosophila makes Drosophila an excellent model to study human
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diseases.
To map fly genes to human ones, homolog data were taken from the Ensembl
database using Biomart [169] on 10/05/2016. One-to-one and one-to-many orthologs
were used to map human genes to fly genes. As a result, 4675 fly genes were anno-
tated with at least one HDO term. Among the 49823 GDAs found in fly, 2977(6%)
were scored above 0.3 which indicated that they were from at least two sources. On
average, each fly gene was annotated with 10 HDO terms.
This fly gene disease annotation was automatically created and stored in a tab de-
limited text file. Other model organism GDAs like mouse, rat and zebrafish can easily
be added to the pipeline to transfer human gene annotations. When HDGDB releases
a new update, the fly gene annotation will be automatically updated, as well as anno-
tation data for other future added model species in the pipeline.
2.4 Conclusions and Future work
In this chapter I have presented a methodology to annotate genes by mining biomedi-
cal texts for ontology terms of interests. I implemented the method into a framework
named OntoSuite-Miner with a set of scripting languages including R, Perl and Linux
shell command. Most the scripts are available on github (https://github.com/statbio/OntoSuite-
Miner) but the two annotators, MeM (10GB) and NcA (7.4gb) are too big in size, thus
stored locally on a Linux server. The framework is highly configurable and customiz-
able, it (a) automatically connects to data source ftp to retrieve up-to-date gene an-
notation texts, (b) integrates two of the most popular NLP-annotators, MetaMap and
the NCBO-annotator, (c) can be configured to auto-run in a preferable time interval to
keep track of the latest gene annotations and (d) stores the result in a portable SQLite
database allowing easy access within the context of pipeline-based workflows of wider
scope. In addition, OntoSuite-Miner also provides an easy to use interface allowing
users to submit a text, choose an ontology and get the results ”on the fly”. Moreover,
OntoSuite-Miner is extensible. Potentially, more annotators,for example, the The Con-
ceptMapper [147], could be included in the framework to improve accuracy and cov-
erage. OntoSuite-Miner has been designed to be generalizable so it works uniformly
on different ontologies but the performance may vary depending on the ontology used.
I have demonstrated the usage of OntoSuite-Miner by mining gene annotation data
from three sources including the OMIM, GeneRIF and Ensembl Variation databases
for gene-disease associations using the human disease ontology. A gene disease anno-
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tation database named HDGDB was created and validated quantitatively and qualita-
tively. Firstly, I analyzed different types of errors in HDGDB. By sampling and man-
ually inspecting errors from 900 annotations from HDGDB, errors were summarized
into four types, namely, coordinating conjunctions, abbreviations. Missing concept-
s/synonyms and others. Coordinating conjunctions were found to be the main sources
of error. Possible improvements/solutions were discussed for each type of error in
section section 2.3.4.1 on page 76. Secondly, I validated HDGDB against a gold stan-
dard. This showed that HDGDB was able to recover 90.32% of the gold standard
annotation a very high recall rate. Finally, I examined the annotations of known aging
genes from GenAge database [187] and known cilia-related genes from Cildb [188].
In particular, for the cilia-related gene set, I ran enrichment analysis and looked more
closely at a number of subsets of the enriched disease terms and built a network of the
inter-connections between diseases based on their shared genes. I utilized a network
community algorithm spinglass.community and identified a smaller sub-network for
which there was a strong biological support for a set of diseases called ciliopathies.
The usage of HDGDB, in combination with these analysis and selection techniques,
allowed the identification of several novel links that interconnected known ciliopathies
in biologically meaningful communities, as well as a number of novel diseases with no
previous known link to cilia.
A confidence score have been implemented, indicating the level of certainty of each
gene disease association(GDA). The score takes into account the number of sources,
the amount of evidence that support the association and the number of annotators that
map the association. It provides a way to rank/weight the associations based on the
evidence and assists in the prioritization and navigation of the the GDAs. In addition,
the score can be applied in analysis such as gene set enrichment analysis (discussed in
the next chapter) so that highly ranked GDAs can be preferentially weighted.
Next, I discussed the usefulness and corresponding methodology for extending
HDGDB to model species. A pipeline was implemented to transfer human gene an-
notations to model species using one-to-one and one-to-many orthologs. Drosophila
melanogaster (fruit fly) which has long been utilized to model a number of human dis-
eases, was used to demonstrate the usage of the pipeline. As a result, 4675 fly gene
were annotated with at least one HDO term. On average, each fly gene was annotated
with 10 HDO terms. Whenever HDGDB releases a new update, the fly data will be
update automatically to capture the latest changes. Note that other model organisms
can easily be added to the system.
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A few points about the implementation and methodology need further discussion.
OntoSuite-Miner is designed to extract gene associations from plain text. However,
the text corpus sometimes describes gene associations, such as‘unaffected’, which ex-
presses a negative relationship. Gene association can also be unqualified or not spec-
ified at the semantic level, e.g. ‘Gene A is associated with disease B’ or semantically
specified, e.g. ‘Gene A is over expressed in disease B’. Moreover a gene association
may be described with a level of certainty; that is whether the association is phrased as
a fact or proven experimental observation or, alternatively, as a hypothesis or specula-
tion. e.g. ‘Gene A might be associated with disease B’. The current implementation of
OntoSuite-Miner does not capture this type of information, thus the resulting data does
not provide the causality of gene association. Several approached have been proposed
to overcome this problem in the field of relation extraction (RE) including rule-based
approaches [133, 234], co-occurrence based statistic approaches [154, 235, 236], ma-
chine learning [45, 237–240] and NLP-based systems [241, 242]. Supervised learning
approaches have shown good performance identifying relations between entities in
text [243]. These approaches usually classify text based on how the relationship is
represented [244,245] using a variety of features including word frequencies, sentence
structure or dependency trees. Adding these approaches to OntoSuite-Miner would al-
low the capture of an extra layer of data of the gene association and potentially increase
the usefulness of the resulting gene annotation data.
There are other aspects of the implementation that could be improved. In sec-
tion 2.2.2, genes were linked to diseases by SNP based on their location on the chro-
mosome. The closest up/down stream and the overlapping genes of a SNP were con-
sidered important for the disease/phenotype. This sequence level prediction assumes
that sets of alleles on the same small chromosomal segment tend to be transmitted as
a block through generations thus SNPs are likely to be inherited together with their
closely located up-stream/down-stream genes during evolution. The current imple-
mentation uses the closest stream/down-stream genes regardless their distance to the
SNP. This could be improved by adding a score to such link, taking into account the
distance. On the other hand, instead of using sequence level information, transcript
level or protein level prediction could also be integrated to improve the quality of the
data but is not currently implemented. It would be interesting to incorporate such
information and there are many tools available for this task. Variant Effect Predic-
tor(VEP) [246] uses a rule-based approach to predict the effects that each allele of the
variant may have on the transcript using a set of consequence terms from the Sequence
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Ontology(SO) [247]. SnpEff [248] predicts the effects of variants on genes. SIFT [249]
predicts whether an amino acid substitution is likely to affect protein function based on
sequence homology and the physico-chemical similarity between the alternate amino
acids. Other protein level predictions tools including PolyPhen [250] (predicts the SNP
effect on the structure and function of a protein) and PANTHER Coding SNP Anal-
ysis tool [251] (estimates the likelihood of a SNP causing a functional impact on the
protein) are freely available to use.
Lastly, the ontology used by OntoSuite-Miner can affect the performance and as
a result, affect the resulting annotation dataset. Thus, there is always room for im-
provement and refinement of the ontology itself. In this project, the Human disease
Ontology was used to represent disease concepts. HDO was developed based on a sub-
set of the UMLS disease concepts. It is a relatively new ontology (published in [39]
in 2012) aiming to provide an open source ontology for the integration of biomed-
ical data that is associated with human disease. Thus, it is frequently updated and
refined in both terms and the ontology structure itself. New terms may be added
while existing terms may be refined to better represent the disease concept. For ex-
ample, the disease term ‘DOID:10652 Alzheimer’s disease’ was a child term (more
specific term) of ‘DOID:680 tauopathy’ and ‘DOID: dementia’ but was removed from
the later after HDO version 1.2 release on 2015-12-04 (Firgure fig. 2.30 on the fac-
ing page); ‘pericentral pigmentary retinopathy’ was added to term ‘ DOID:10584 re-
tinitis pigmentosa’ as an exact synonym. Moreover, some of the errors identified by
HDGDB in this thesis suggest that additional research is needed into the definition of
the ontology to eliminate ambiguities. For example, ‘OCD’ for DOID:84 osteochon-
dritis dissecans(OCD) and ‘obsessive-compulsive disorder’ or ‘AD’ for DOID:10652
Alzheimers disease(AD) and autosomal dominant. These changes in the ontology not
only have an impact on OntoSuite-Miner, but also affect some of the algorithms in
OntoSuite-Analytics (discussed in the next chapter) where ontology structure is taking
into account, for instance, when using the elimination algorithm in enrichment anal-
ysis. Therefore, a corresponding update needs to be scheduled when either the data
sources or the ontology have a major new release.
Other potential usage of HDGDB
Ontology based gene annotation enables a wide rage of modern bioinformatics
analysis. HDGDB potentially could be used in other disease network analysis which
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Figure 2.30: ‘Alzheimer’s disease‘ in HDO ontology (a) before and (b) after version 1.2
release on 2015-12-04. HDO is frequently updated and refined, and changes to the
ontology structure were made. New terms may be added while existing terms may be
refined to better represent disease concepts.
may provide insights into the interconnections between human diseases. We are cur-
rently witnessing a shift from a ‘single gene single disease’ paradigm towards an ‘in-
terplay of different disease modules’ [204, 205]. It is difficult to consider diseases as
being invariably independent of one another. In fact, disease modules can overlap, so
that the underlying molecular mechanism causing one disease can affect other disease
modules. Disease network analysis has emerged as a powerful way of studying the
inter-relationship between diseases and their associated genes. Such networks of dis-
eases and disease genes offers a platform to explore all known diseases and disease
gene associations in a single graph theoretic framework, and has already been used to
reveal the common genetic origin of many diseases as well as predict potential disease
gene candidates [204, 206, 207].
In a typical disease network, nodes represent diseases and links represent vari-
ous molecular relationships between them. Some commonly used relationships which
are based on shared features between diseases include their shared causal genes, their
shared regulatory microrRNAs, related pathways and various other external influences.
Details of some of these approaches have been discussed by Barabasi et al. in [204].
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Shared Gene approach A gene associated with two different diseases is often an
indication that the two diseases have a common genetic origin. Disease nodes in the
network are linked if they share one or several genes. Goh et al. [206] used data from
the OMIM database to build a network of disease containing 1284 diseases, out of
which 867 were linked to one or more other diseases. 516 diseases were found in a
single disease cluster, forming the largest connected component in the disease network.
It was observed that similar diseases from the same class (indicated by color in the fig-
ure) were more likely to share genes than diseases that belong to a different class. For
example, cancers form a tightly interconnected sub-cluster by a small group of genes
associated with multiple cancers including P53,KRAS,ERBB2 or NF1. Indeed, Park
et al. [252] showed co-morbidity between linked diseases from the observation that
patients with a primary disease are twice as likely to develop a secondary disease if the
secondary disease shares genes with the primary one. However, such compatibility is
not guaranteed between linked diseases. This was partly attributed to different contex-
tual scenarios of their genetic mutations where mutations on the same gene can have
different effects on the function of the gene product or on its organ-based expression.
On the other hand, a gene network can be constructed with a similar approach
where nodes in the network represent genes and they are linked if they associate with
the same disease(s). Such networks have been explored and have resulted in a number
of different finding regarding predicting biological functions, for example, in recent
studies by Gillis and Pavlidis in [253–255].
Shared metabolic pathway approach An enzymatic defect that affect a metabolic
reaction may potentially affects all downstream metabolic reactions in the same path-
way, leading to metabolically-induced disease phenotypes. This is particularly true for
metabolic diseases. In this scenario, nodes in the network represent diseases and two
diseases are linked if the enzymes associated with them catalyze adjacent reactions.
Such a network has been used to study disease co-morbidity. For example, Lee and
Chung [256] constructed a metabolic disease network(MDN) and showed a 1.8-fold
co-morbidity increase in diseases linked in this network when compared to those that
are not.
Shared microRNAs approach A microRNA (abbreviated miRNA) is a small non-
coding RNA molecule that functions in RNA silencing and post-transcriptional reg-
ulation of gene expression. A signal miRNA down-regulates potentially hundreds of
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target mRNAs, and often play a key role in cellular functions such as development,
differentiation, proliferation, apotheosis and metabolism. Recently, Lu et al. [257] im-
plemented miRNA regulation into disease networks, where disease nodes were linked
when their associated genes are regulated by one or more shared miRNAs. The re-
sulting network showed segregated disease clusters at the miRNA level for cancer and
cardiovascular diseases.
Such ‘guilt by association’ approaches link two diseases in the network by some
type of shared feature between them. The shared gene approach is an excellent ap-
proach to explore the inter-relation between human diseases and the corresponding
disease genes for gene disease association data like HDGDB. A human disease net-
work (HDN) and disease gene network (DGN) can be constructed by building a bi-
partite graph linking diseases to genes using HDGDB. The bipartite graph contains
two sets of nodes, disease nodes and gene nodes, such that every edge in the graph
connects a disease node to a gene node. From this bipartite graph, two projections
can be made: 1) HDN, where nodes are disorders and a pair of disorders is linked if
they share at least one associated gene is known to be involved in both disorders and
2) DGN, where nodes are genes and a pair of genes is linked if they are both involved
in at least one shared disorder. The resulting HDN and GDN can be used to explore




An R package for generalized
ontology term enrichment analysis
3.1 Background
The development of high-throughput genomic, proteomic and bioinformatics scanning
approaches allow researchers to simultaneously measure the properties of genome-
wide genes and proteins across entire genomes. Large interesting gene lists are often
generated from these high-throughput approaches, but the biological interpretation of
these potentially interesting genes is still a challenging and daunting task. The gene-
annotation enrichment analysis is a promising strategy for functional analysis of such
gene lists, making it possible to systematically dissect them to gain biological insight,
and has became a standard practice in the downstream analysis of high-throughput
approaches.
Several bioinformatics enrichment tools have been developed during the last decade.
In a survey, Huang et. al. [16] identified and reviewed at least 68 different enrichment
methods. Despite the distinct features of the different enrichment tools, the general
procedure for the enrichment analysis is similar and can be summarized into three
parts:
1. Preparation of the backend annotation database. This usually refers to ontology
based annotation where genes are annotated with predefined ontology terms. For
example, the Gene Ontology [20] represents over 40,000 biological concepts,
describing how genes encode biological functions at the molecular, cellular and
tissue system levels. The GO annotation links genes with GO terms indicating
the various functions that a particular gene may have.
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2. Calculation of enrichment (algorithm and statistics) against a reference set; For
example, if 20% of the genes under study are found to be annotated with “synapse
complexity” compared to 8% of the genes in the human genome, this enrichment
can therefore be assessed by some kind of statistical methods. The pre-eminent
statistical test is the Fisher’s exact test from which an enrichment p-value is cal-
culated indicating the statistic power of the test. Thus a conclusion may be drawn
that “synapse complexity” is an enriched annotation and therefore may play an
important role in the system.
3. Post-process and presentation of results.
The Gene Ontology has been, and is still the most, if not the only ontology used in
enrichment analysis largely due to the limitation of annotation coverage discussed ear-
lier. The GO Consortium’s AmiGO [258] is provided as a web application that allows
functional enrichment analysis for user uploaded gene lists. DAVID [53] provides a
comprehensive set of functional annotation tools the interpretation of biological mean-
ing behind list of genes, including identifying enriched biological themes, particularly
GO terms A set of related bioinformatics tools such as the Gene ID Conversion Tool is
also freely available as a web application. These tools provide easy to use enrichment
analysis for users but are limited for advanced usage scenarios such as batch analysis
or when parameters need to be customized. Various programming packages support
enrichment analysis, such as topGO [33], GOstats [90], CompGO [259] for GO terms,
GAGE [72] and Pathview [260] for pathways and DOSE [261] for the diseases. These
tools play an important and successful role in functional analysis of gene lists for var-
ious biological studies [49, 53–59].
Despite the usefulness of existing enrichment analysis tools and the different sta-
tistical algorithms used for finding enriched ontology terms, they mostly only work
for a specific type of ontology, GO in the majority of cases, even though the general
underlying enrichment analysis process is in principle similar for any ontology. A stan-
dard framework for general ontology enrichment analysis is needed. In the following
sections, I proposed topOnto, an analytic R package, integrating a range of statistical
algorithms and topology methods for ontology enrichment analysis that aims to ame-
liorate the current limitations of enrichment tools, and facilitate generalized ontology
enrichment analysis.
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Figure 3.1: (a) The GO term enrichment analysis provided by Amigo and (b) the enrich-
ment result of a toy example gene list.
3.1.1 Organization of the chapter
In this chapter, in order to adjust the second part of the TBI challenge which is the
availability of the appropriate bioinformatics tools for the analysis and exploitation
of human disease data, I proposed the second part of the OntoSuite framework, the
OntoSuite-Analytics, which consists of a set of R packages including topOnto and the
corresponding data packages for the ontologies. I provided implementation details,
the main design decisions and a number of validation approaches for the package.
I discussed statistical limitations, back-end annotation database, multiple hypothesis
correction and the key design decisions to ameliorate them. A modified GSEA algo-
rithm, named GSEA-CSW was proposed for gene set enrichment analysis. The al-
gorithm was implemented and tested with syntactic gene expression data. A practical
use-case example of the tool was presented with the investigation the activity-regulated
cytoskeleton-associated protein (ARC) complex followed by a conclusion section.
3.2 Implementation of topOnto
topGO is a powerful gene list enrichment analysis package, available from R/Biocon-
ductor, designed to facilitate semi-automated enrichment analysis for Gene Ontology
(GO). It provides unified enrichment analysis framework that facilitates comparison
between different enrichment methodologies. In addition, it implements a set of topo-
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logical algorithms proposed by Alexa et al. [33] which calculate enrichment for GO
terms while accounting for the topology of the GO graph. The package has been
widely used and plays an important and successful role in various high-throughput
biological studies [262–265]. However, topGO only supports Gene Ontology analy-
sis. As discussed before, the ability of using different ontologies would be beneficial
for biological interpretation. Cross comparison of results across several ontologies
can provide further evidence of important biological processes if those processes are
represented in different ontologies. Fortunately, ontologies are usually defined in a
similar structure and stored in text files following the same standard OBO format. This
motivated me to adapt topGO to topOnto, extending of all the functionalities of the
origin topGO to any ontology of interest. Because topOnto was implemented on top
of topGO, there is a large amount of code being reused and adapted from topGO. The
detailed implementation of the topGO has already been described by its author Alexa
in [266], thus not repeatedly described in this thesis. I will only focus on the implemen-
tation and usage of topOnto that differs from the topGO. topOnto is freely available
on github (https://github.com/statbio/topOnto). A high-level schematic describing my
implementation of the topOnto package is shown in fig. 3.2. The work flow of to-
pOnto can be divided into four steps: i) Ontology preparation; ii) Data preparation; iii)
Running the enrichment tests and iv) Analysis/comparison of the results.
Figure 3.2: The work flow of topOnto can be divided into four steps: i) Ontology prepara-
tion; ii) Data preparation; iii) Running the enrichment tests and iv) Analysis/comparison
of the results.
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3.2.1 Ontology preparation
To use topOnto for enrichment analysis, firstly one needs to decide what ontology
to use and prepare the corresponding ontology objects. The ontology is usually de-
fined in an OBO flat file. Scripts are provided by topOnto to extract information from
the OBO file and store it in a SQLite database following the AnnotationDbi bimaps
database schema [267]. For example, the SQLite table term stores the ontology term
id, name and definition while the tables parents and offspring store the interrelation-
ships between terms. The ontology package implements the AnnotationDbi interface,
which serves as an abstraction layer above the underlying SQLite database, providing
methods to query the database and generate objects that allow easy access from within
R. Objects such as ONTTERM, ONTANCESTOR and ONTCHILDREN are provided to
represent the ontology hierarchy. The ontology package is named topOnto.X.db, where
X stands for the name of the ontology, indicating that this is an ontology package pro-
viding information needed by the topOnto package. For example, topOnto.HDO.db
for the Human disease ontology.
The advantage of using such an abstraction layer is that, regardless of the different
ontologies, the same set of objects will be generated representing the corresponding
ontology. This way, topOnto doesn’t need to know the details of the underlying SQLite
database and can work generically with a set of objects provided by the topOnto.X.db
package for each ontology. This is one of the most important features of topOnto which
making it possible to apply the same set of enrichment methods to different ontologies.
3.2.2 Data preparation
An R object of class topONTdata was defined in topOnto, which is designed to be a
master object that stores the ontology, gene annotations and test statistic. To construct
this object, one first needs to define the list of genes of interest. This can be a prese-
lected list of gene ids or gene expression data with a criteria for selecting genes based
on their scores. Secondly, a gene universe is to be defined which serve as a reference
background when calculating the terms enrichment statistics. See section 1.2 for how
to define a proper gene universe. Next, the ontology is loaded into the topONTdata
from topOnto.X.db packages where the ontology is internally represented as a directed
acyclic graph (DAG) (fig. 3.3). In the ontology DAG, individual terms are represented
as nodes connected, by directed edges, to more specific nodes, such that each node is
a more specific child of one or more parents. Note that for such a graph, the notion
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of child and parent can be used, where a child term is more specific than its parent.
Directed edges between nodes represent their relationship. The ontology based gene
annotation can be loaded into the DAG from a tab delimited file in which each row
represents an ontology term and its annotated genes. topOnto currently provides an-
notation for Human Disease Ontology (HDO), Human Phenotype Ontology (HPO),
Gene Ontology (GOBP, GOCC, GOMF)1, the Reactome Pathway Ontology (RPO)2,
Panther protein class Ontology (PCO)3 and the Chromosome Ontology (CO)4. The
HDO and HPO annotations were generated by OntoSuite-Miner while the others were
taken from their website. Note that strictly speaking, the RPO and CO is not a for-
mally defined ontology but a list of controlled vocabularies structured hierarchically. It
has the basic structure of an ontology (terms, relationship between terms) which makes
it possible to apply the same methodologies as for a standard ontology.
In the following sessions, I will be using a small part of the Human Disease Ontol-
ogy as an example to illustrate the different methods and algorithms implemented in
topOnto. There are 21 nodes and 20 links in this sub HDO DAG. Each node represents
a HDO term and each the link represents a ‘is a’ relationship. The directed edges are
pointing from parent nodes to child node. The DAG has 8 levels and 5 leaf nodes. The
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Figure 3.3: DAG structure showing part of the Human Disease Ontology. There are 21
nodes and 20 links in this sub HDO DAG. Each node represents a HDO term and each
the link represents an ‘is a’ relationship. The directed edges point from parent node to
child node. The DAG has 8 levels and 5 leaf nodes. The root node is ‘all’.
Gene are assigned to the nodes in the DAG according to the gene annotation pro-
vided, followed by a ‘roll-up’ procedure in which a gene assigned to a node, will also
be assigned to all its direct parent nodes. This result expands the gene annotation
base on the hierarchical structure of the ontology DAG, aggregating genes from the
bottom (specific nodes) to the top (general nodes) of the structure. The ‘roll-up’ pro-
cess is based on the True Path Rule of the ontology definition where an annotation
for a term(node) in the ontology hierarchy is transferable to its ancestors (transitivity).
Thus, if a gene is annotated to a term(node), it is also implicitly associated with all the
terms on its True Rule (see section 1.1.1.4 on page 6) [268]. In the Gene Ontology
biological process, for example, if a gene is involved in ‘developmental programmed
cell death’, then it is reasonable to say that it is also involved in the parents process
such as ‘cellular developmental process’ or ‘cell death’. Due to the unbalanced nature
of research interests, some areas are better studied than others. In addition, genes are
sometimes annotated with different granularities; a gene associated with Parkinson’s
disease may be annotated with a specific type of Parkinson’s disease, for example au-
tosomal dominant Parkinson disease 1, or with a more general disease category like
neurodegenerative disease or nervous system disease. This results in an unbalanced
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ontology annotation where some of the less studied terms are poorly annotated, thus
unlikely to be identified as enriched in the analysis. The ‘roll-up’ process was designed
to avoid this problem by aggregating the effect of poorly annotated terms to their par-
ent terms so that these joint effects are more likely to be identified. However, the True
Path Rule introduces dependency into the ontology terms which was referred to as the
‘inheritance problem’ by Grossmann et al. in [269] , which may result in some of the
statistical methods producing misleading results.
By default, all terms available in the ontology are used to construct ontology DAG.
Optionally, topOnto allows the user to define a domain specific subset of ontology
terms (a ‘clip’) before constructing the ontology DAG so that all the following statisti-
cal analyses are performed with this subset rather than the full ontology. The advantage
of using a more specific pruned ontology in enrichment analysis was discussed in sec-
tion 1.1.1.5.
A single R object of class topONTdata contains the gene data (genes of interest/-
gene universe), ontology data and gene annotations. Arguments are available for con-
trolling the construction of the topONTdata object. For example, the argument on-
tology specifies which ontologies to be used while the argument nodeSize is used to
prune the ontology hierarchy of terms which have only a few, for example, less than
10, annotated genes. A summary of the topONTdata object can be seen by typing the
object name at the R prompt. Having all the data stored in this single object facilitates
easy access to identifiers, annotations and to basic data statistics.
3.2.3 Running the enrichment tests
Once a topONTdata object has been created, it is possible to process it with a number
of different statistical algorithms and topology methods. The statistical algorithms
are used to measure the significance (p-value) of the enrichment while the topology
methods aim to reduce the number of false positive results by rating into account the
ontology structure. topOnto currently supports statistical algorithms including Fisher’s
exact test, KolmogorovSmirnov test and GSEA. Topology methods including ‘classic’,
‘elim’, ‘weight01’ and ‘parentchild’ are also available and are described further below.
table 3.1 presents the compatibility between the statistics and the topology methods.
A function runTest is implemented to apply the specified test statistic and topology
method to the topONTdata object. It returns an object of class topONTresult for each
test statistic/topology method pair. The results might be different when using different
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Table 3.1: Algorithms/topology methods currently supported by topOnto.
statistic/topology combinations. A high-level interface script run.batch is used to apply
the specified test statistics and methods to the data simultaneously across multiple
ontologies. This returns a list of results indexed by ontology names. It is up to the
user to decide which combinations are suitable for their data. A brief introduction is
given which can be used as a guide to choose statistic and topology methods and to aid
interpretation of the results.
3.2.4 Statistical algorithms
The Fishers exact test is a count based statistical significance test used in the analysis
of contingency tables. It is useful when only a list of interesting genes is provided but
no further information is available (gene scores, weighted, gene expression measure-
ments etc.). Typically this gene list is preselected from other studies such as genes
that belong to a certain cluster or top ranked genes in a microarray experiment that
are over expressed in one group against another. In the Fisher’s exact test, every gene
contributes equally. Sometimes genes expression measurements or other properties
like score or weight of the genes are available. For example, a sore can be calculated
for each gene based on the expression value in a microarray experiment. The score
indicates how distinguish/important the gene is within the two different test groups. In
this case, score based algorithms like the KolmogorovSmirnov test or GSEA are more
appropriate because these algorithms take all the gene scores into account, allowing
the more highly score genes to contribute more to the final enrichment result.
3.2.5 Topology methods
The classic,elim,weight and weight01 methods were introduced by Alexa et al. in [33].
The parentchild method is proposed by Grossmann et al. in [269].
The classic method, differs from the other methods, as it does not take the ontology
structure into account, treating all the ontology nodes as a flat list and applying the
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chosen statistical algorithm independently to each node. Another way to think of the
classic method is that when testing for a particular node, it is actually abstracting the
DAG to the level of that node with all the information below that level aggregated
to it. As a result, the top enriched nodes are usually often generic terms due to the
‘roll-up’ process. These terms reflect the joint effect of all their offspring terms and
give a top-down overview of the genes in relation to the ontology. In practice, the
classic method identifies the upper bound of the significant value of a term when there
is no gene annotated to any of its children terms. As the number of children annotated
grows, the significant value is often over-estimated because the annotations aggregated
are evaluated multiple times(see fig. 3.6 for an example).
Figure 3.4: The gene elimination algorithm [33]. Genes are removed from the node and
all its ancestors nodes in the ontology DAG when the nodes is marked significant. Thus
the algorithm always detects the most specific terms in the ontology hierarchy.
The elim method processes the ontology terms by traversing the ontology hierar-
chy from bottom to top, i.e. it first assesses the most specific (bottom-most) nodes, and
proceeds later to more general (higher) nodes. If a node is found significantly enriched,
all the gene annotated to this node will be removed from all its ancestor nodes. To be
precise, as shown in fig. 3.4, the algorithm keeps a history of the significant nodes and
their genes in markedGenes. Every time a node u is being tested, a gene elimination
process takes place before the significance test is performed, pruning the genes anno-
tated to u, denoted genes[u]. If node u is found significant then all of the genes mapped
to it are marked as removed in all the ancestor to be node u. The algorithm recursively
walks up the ontology structure until all nodes have been processed (fig. 3.5). The
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Figure 3.5: The elim method. (a) The process starts from the bottom nodes of the
ontology DAG. Since nodes from the same level share no edge, they can be investi-
gated independently. (b) For a particular node (green), genes that have been marked
as removed in a previous step are removed. A chosen statistical method is applied to
calculate the enrichment significance level, i.e. the p-value. (c) Node is marked signifi-
cant (red) if its p-value is smaller than a previously defined threshold. Genes annotated
to this node are marked to be eliminated in all of the ancestors (yellow) up to the root.
(d) The process moves to the next node.
elimination process effectively prevents genes from repeatedly contributing to the sig-
nificance of the nodes across the ontology hierarchy, thus, in another words, it always
tries to find the most specific enriched nodes. As a result, the selected enriched nodes
usually provide a bottom-up perspective regarding to the ontology (fig. 3.6). The elim
method minimizes the number of false positives. However, it does tend to miss some
true positives at higher (more general) levels of the ontology hierarchy. Another lim-
itation of the elim process is that it, on top of the ‘roll-up’ process, induces another
layer of dependence between the ontology terms, which may affect subsequence anal-
ysis such as applying multiple hypothesis testing correction on the results. The elim
method is the default method implemented in topOnto.
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(a) (b)
Figure 3.6: The comparison of enrichment result (top 10 enriched terms from the a toy
example list of genes) distribution of (a) the classic method and (b) the elim method
in the HDO ontology DAG. The color indicates the significance of the nodes. Colored
nodes are found significantly enriched with a p− value <= 0.5, while red nodes are
more significant (smaller p-value) then yellow nodes. If a term contains the same genes
as one of its children (due to the ‘roll-up’ process), the classic method always gives
the same score to both terms while the child term in this case often contains more
specific biological information, thus is likely to be more interest.. The elim method is
designed to tackle this problem, by computing the significance of a term dependent
on the significance of its children. It effectively proves the same gene contributes to
the enrichment result multiple times along the path to the ontology root. As a result,
the classic method usually generates enriched terms that are located narrowly and
vertically in the ontology DAG, while the elim method tends to identify enriched terms
that are horizontally spread in the ontology DAG(see table 3.5 for an example).
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Instead of completely removing the genes that are annotated with significantly en-
riched descendant terms, the more involved weight method uses a similar bottom-up
strategy as the elim method but assigns weights to genes as a function of the scores
of neighboring terms. The algorithm is shown in fig. 3.7. In the weight method, the
ontology terms are processed bottom-up level by level as in the elim method. Initially,
all weights for the genes annotated to a node are set to 1. For a particular term u, a
modified version of the Fisher’s exact test is used to determine the term’s significant
value. If the term is found more significant than its children terms, genes in the chil-
dren are down-weighted and significant scores are recalculated base on the new gene
weight, resulting a decreased significance of the children. On the other hand, if any of
the children are more significant than the parents u, the genes common to the child and
u are down-weighted in u and its ancestors, decreasing the significance of term u. The
principle behind the weight method is to reinforce differences in significance between
u and its neighbours, thus enhancing the ability of detecting the most significant local
terms in the ontology hierarchy. It is less strict than the elim method, and tends to
miss less true positives [33]. The weight01 method is a mixture of the elim and weight
methods. Here, the gene elimination process only happens when a term is not the most
significant local term.
The parentchild approach is developed specifically to avoid the so-call ‘inheritance
problem’ of Grossmann et al. in [269]. The rationale behind this method is that,
due to the ‘true path rule’, when multiple terms are tested simultaneously, the chance
of a term being enriched is much higher if one or more of its parental terms is also
enriched. To avoid this problem, the significance level of a given term is computed by
taking into account the immediately more general terms (the parents). This can often
produce less redundant result and lead to the removal of false positives, since some of
the more specific terms are eliminated if their parent is determined to be significant.
Note the difference between the ‘bottom-up’ methods and parentchild methods is that
the former tend to eliminate parent terms while the later tend to keep them.
Simulation results reported by Alexa et al. [33] show that the weight algorithm has
less false positives than the classic method and misses fewer true positives, while elim
has even less false positives than weight but misses more true positives. Grossmann et
al. in [269] compare the elim, weight and parentchild algorithms with simulated GO
data and conclude that each method has its own advantages in certain scenarios. The
advantage of topOnto is that it provides a platform, allowing simultaneously testing
of enrichment with different statistic/topology methods. Users can easily add new
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Figure 3.7: The weight algorithm [33]. Weights are assigned to genes as a function of
the scores of neighboring terms. If the term is found more significant than its children
terms, genes in the children are down-weighted and significant scores are recalculated
base on the new gene weight, resulting a decreased significance of the children. The
same applied when any of the children are more significant than the parents, which
results in detecting the most significant local terms in the ontology hierarchy.
3.2. Implementation of topOnto 127
methods into the platform and test them against the other methods. It is recommended
to test the same set of genes with multiple methods and consider differences in the
results when making any conclusions.
3.2.6 Analysis of the results
An object of class topONTresult is returned for each statistic/topology method pair
containing the p-values for each node in the ontology DAG. The p-values returned are
raw p-value without any multiple testing correction. This is because 1) In many cases a
FDR/FWER adjustment procedure can produce very conservative p-values and declare
no, or very few, significant terms. This can lead to an increase of false negatives,
the loss of interesting terms that contain valuable information; and 2) the gene ‘roll-
up’ process can induce dependence into the terms, thus the independent assumption
of multiple testing does not directly apply. Some of the topology methods including
elim,weight and parentchild compute the term significance conditioned on the neighbor
terms. However, the user can perform an adjustment on top of the of topONTresult
object if it is considered important for the analysis. The raw p-value was provided in
the topONTresult, together with the corrected p-value using the default method of the
Benjamini-Yekutieli(2001) [119] FDR correction.
A Function GenTable is implemented to merge the results into a summary table
where p-values for each method are put together for easy comparison (table 3.2.). Cer-
tain patterns can be found when comparing p-values across different topology methods
(see fig. 3.12a on page 145 for some examples). The significance of genes aggregate
from bottom to top due to the gene ‘roll-up’ process resulting in a vertical decrease
of significance from top to bottom of the DAG. For the classic method, this leads to
identifying significant terms located in the same vertical branch of the ontology DAG.
For to the same reason, the parentchild method usually identifies a smaller number
of low level terms that horizontally spread across the ontology DAG. The elimina-
tion methods including elim and weight01 remove significant genes from bottom to
top which usually results in a vertical increase of significance from top to bottom of
the DAG. These methods tend to identify high level enriched terms that horizontally
spread across the ontology DAG. There are circumstances when the classic approach
and the elimination approach generate the same p-value for a term. This indicates that
the topology structure has no effect on this term, either because this term is a leaf term
(has no descendants) or none of its descendants are significant. When the classic ap-
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proach identifies a significant term but the elimination approach does not, it suggests
that this term is a relatively low level term (has many descendants) and its significance
does not come from the genes annotated directly to it but the genes aggregated from
its descendants.
TERM.ID Term Level Annotated Significant classic elim weight parentchild
1 DOID:5419 schizophrenia 6 1848 48 9.6e-22 9.6e-22 9.6e-22 0.76922
2 DOID:2468 psychotic disorder 5 1858 48 1.2e-21 1.0000 1.00 5.3e-06
3 DOID:1561 cognitive disorder 4 3037 54 2.8e-17 0.6510 1.00 0.00087
4 DOID:936 brain disease 6 2001 44 6.8e-17 0.1099 1.00 9.9e-07
5 DOID:150 disease of mental health 3 4787 66 1.8e-16 0.2115 0.69 1.8e-16
6 DOID:1826 epilepsy syndrome 7 685 25 3.8e-14 0.0011 6.7e-08 0.00159
7 DOID:331 central nervous system disease 5 4834 61 8.0e-13 0.4453 1.00 0.00240
8 DOID:863 nervous system disease 4 6684 70 2.5e-11 0.0991 0.94 3.5e-07
9 DOID:1443 cerebral degeneration 7 282 14 5.4e-10 5.4e-10 3.8e-09 0.00190
10 DOID:9255 frontotemporal dementia 8 197 12 1.0e-09 1.0e-09 1.0e-09 0.24237
Table 3.2: A summary table generated by the function GenTable of topOnto. The first
row of the result can be interpreted as follows: HDO term ‘DOID:5419 schizophrenia’
is annotated to 1848 genes among which 48 appear in the given list of ‘interesting
genes’ as significant gene. p-value is calculated by Fisher exact text with four different
topology methods, namely classic,elim,weight and parentchild and present together for
easy comparison.
3.2.7 Weighted GSEA
In chapter 2 on page 33, a data mining framework is built to generate a human dis-
ease ontology (HDO) gene annotation from publicly available databases,including
GeneRIF, OMIM and Ensembl Variation. The resulting gene-HDO annotation is scored
base on a confidence level. A score of 1 means that an annotation is only found once,
in one of the three sources by either MetaMap or NCBO-Annotator, indicating that this
annotation is not reliable and should be used with caution. A higher score means more
evidence exists and the association trustworthy. This could for example mean that it
has been found in multiple corpora, multiple source, by both MetaMap and NCBO-
Annotator. Details of the annotation confidence score is described in section 2.3.2.
As discussed previously, the quality of the gene annotation has a great effect on
the final enrichment result. However, none of the currently available gene annotation
databases are complete or error free. There is always a trade off between annotation
coverage and accuracy. Manual annotations are considered accurate most of the time.
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However, because of the time lag necessary for the manual curation process, recent
annotations are missing and the overall coverage are usually low [44]. On the contrary,
annotations generated with automatic methods (without human expert involvement)
may have quality issues but usually have good coverage. For example, in the Gene
Ontology, out of 481685 total annotations available for Homo sapiens, 155499 (32%)
are inferred exclusively from electronic annotations (with Evidence Codes IEA, no
human expert involvement for checking the annotation’s accuracy). Even though some
of these IEA annotations are incorrect [84,85], the vast majority of them are reasonably
accurate [83]. However, to the best of my knowledge, at the present time, none of the
enrichment methods allow any type of weighting by annotation confidence which is
a limitation since manual curations are generally more trustworthy. In order to solve
this issue, and to make better use of the annotation data discuss in section 2.3.2 on
page 66, for the first time, I propose a modification of the original GSEA methods
referred GSEA-CSW (confidence score weighted), implemented in topOnto, allowing
the use of weighting based on the annotation confidence, which as a result, increases
the magnitude of the effect of better annotations and decreases the magnitude of the
effect of weaker ones.
The biological utility of GSEA can be improved by including additional biological
features. Utilizing more domain knowledge is likely to reveal more insights from the
analysis. In [270], Jun et.al integrate KEGG PATHWAY information to weight genes
involved in pathways. An appearance frequency (AF) is assigned to each gene based
on the number of times it appears in all of the KEGG pathways. Those genes that are
involved in many pathways are usually responsible for housekeeping functions, thus
receive a high AF whereas other genes which are more specialized and play unique
roles in one or a few pathways, receive a low AF. GSEA with the integration AF
scores is claimed to perform better both statistically and biologically [270]. Several
other recently introduced techniques incorporate concepts of gene topology, includ-
ing ScorePAGE [271], gene network enrichment analysis [272] and network topology
analysis [273]. These additional features improve the GSEA methodology not just
conceptually but practically improve the enrichment results. Similar to the above ap-
proaches, GSEA-CSW incorporates the quality of the annotation into the enrichment
analysis with the rationale that high scored genes should be contributing more to the
enrichment analysis.
Recall that in GSEA, an enrichment score (ES) is calculated by walking down a
ranked gene list L, increasing a running-sum statistic when encountering a member
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gene of set S (Phit) and decreasing it when encountering a non-member gene of set S
(Pmiss) (Equation eq. (1.1) on page 18). The magnitude of the increment during the
running-sum process is controlled by an exponent p. Typically, all genes in a gene
set S are treated equally in the analysis. However, in the case of using automatically
generated annotations, genes with a lower confidence score (CS) may not be as reliable,
thus should have less effect than those have a higher confidence score. For example,
for a gene set S, if most of the top ranked genes are low confident annotated gene, then
set S might be enriched but with a high chance of being a false positive result. GSEA-
CSW was designed to adjust the value of the exponent p according to the CS of each
gene in S, thus controlling how fast the running-sum statistic increases.
Define the exponent p
Genes with high CS should receive a smaller exponent p to increase the magnitude of
the effect whilst the ones with low CS should receive a greater exponent p to reduce
the magnitude of their effects. The exponent p is thus defined:
p(S, i) = λ(1−CSi) (3.1)
where p(S, i) is the exponent p for the ith hit gene in set S, CSi is the confidence score
of the ith gene. λ ∈ (0,1] (set as 1 as default in the current implementation) is a scaling
factor controlling the magnitude of the effect of the CS on the exponent p.
Thus Equation (1.1) can be rewrite as follows:
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where i is the position in order list L, r j is the correlation of gene g j with class C
rescaled to [-1,1] (normalized by maximum), CSi is the confidence score of gene g j
range from 0 to 1, N is the total number of genes in L and NH is the number of over-
lapping gene in S and L.
Since r j ranges from 0 to 1, the increment step (Phit(S, i)) will be bigger for genes
with a higher CS value. By adjusting the exponent p, the algorithm rewards the ‘good’
annotation while penalizes the ‘bad’ annotations. In this way, if there is a large frac-
tion of ‘bad’ genes in a particular gene set ranked at one extreme (top or bottom) of
the list, the corresponding gene set will have a smaller ES compared to the original
implemented GSEA. Note that when all genes in set S have the same confidence score
(equally weighted), the above equation will reduce the GSEA-CSW to original GSEA.
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The scaling factor λ was used to control the degree of the effect of the confidence
score. However, there is no obvious way to determine and optimize the value of λ. No
training data is available at the moment to estimate λ. Even if there is training data
available, the λ value will be optimized on that particular train data. It is possible that,
when multiple independent training data are available, a generic λ could be estimated.
Thus, when such training data become available, a better estimation of λ could be
learnt than the current implementation of λ = 1.
Topology method with GSEA-CSW
GSEA-CSW currently supports two topology methods in topOnto, classic and elim.
For a given ontology, the classic method treats all the nodes in the ontology DAG as
a flat list, applies the GSEA-CSW algorithm on each node simultaneously regardless
of the DAG hierarchical structure. This is identical to the original classic method dis-
cussed previously. The elim method, on the other hand, investigates the nodes in the
DAG level by level from the bottom of the DAG (highest level) to the root. Nodes
in the same level are tested simultaneously because there are no edges between them.
This way, the algorithm assures that for the currently tested node all children have also
been tested. When a node u is found significantly enriched, all of the genes of u are
marked as removed in all nodes of upperInducedGrapgh(u), that is in all ancestors
of node u. The rationale behind the elim method is to try to prevent genes in u repeat-
edly contributing to the enrichment of u’s ancestors. In a count based algorithm like
Fisher’s exact test, all of the genes in S contribute equally to the enrichment of u so
all of them are removed from u’s ancestors. However, in a score based approach like
GSEA-CSW, it is the leading edge subset (see section 1.2) actually contributing to the
enrichment of u while the other genes in u are ‘unused’, thus removing those ‘unused’
genes is inappropriate. In order to preserve the effect of the ‘unused’ genes, options are
available to configure the algorithm to remove only the leading edge subset of genes of
u, allowing those ‘unused’ genes to be tested further in the ancestor nodes. Also, due
to the ‘roll-up’ process discussed earlier, not just the genes but their scores are aggre-
gated bottom-up from the ontology DAG. Instead of removing the genes completely, a
better alternative to prevent the genes re-contributing to the ancestor nodes is to reduce
the gene scores of those genes. These approaches are implemented in topOnto and the
details of the elim GSEA-CSW algorithm is summarized in fig. 3.8.
132 Chapter 3. An R package for generalized ontology term enrichment analysis
Figure 3.8: The GSEA-CSW algorithm with the elimination topology method.
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The GSEA-CSW is particularly suitable for analysis of large lists of genes with
gene annotation generated by automatic methods. It is not intended to increase the
statistical power of GSEA, but to incorporate important gene annotation score infor-
mation into the enrichment test process result. Such score can be a reflection of the
degree of certainty of the gene disease associations, as well as the source of the gene
disease associations. For example, associations from manually curated database are
more reliable than others, thus could have a higher weighting in GSEA-CSW algo-
rithm. However, in the currently implementation, the algorithm is blind to the calcula-
tion of the confidence score. The actual calculation of the the confidence score, such
as those discussed in section 2.3.2, needs to take into account such information.
In terms of validating the method, as pointed out by Huang et al in [16], there
is currently no appropriate standard evaluation procedure to evaluate new enrichment
methods. The method proposed in [16] aims to evaluate different enrichment meth-
ods on a data set generated by randomly shuffling the phenotype labels of an afore-
mentioned experimental data set. The rationale behind this method is that a gene set
deemed significantly enriched by more statistical methods is less likely to be false than
a gene set deemed significant by fewer statistic methods. An MC (mutual coverage)
score is computed for each statistical method against others representing the the de-
gree of mutually identified enriched gene sets between them. This method cannot be
directly applied to evaluate the GSEA-CSW due to the lack of standard weighted an-
notation data. Thus, in the following section, simulated data were used to evaluate the
performance of the algorithm.
3.2.7.1 Validation of GESA-CSW with synthetic data
In order to test the algorithm, gene expression data were simulated in a fashion to rep-
resent typical gene set structures found in real gene expression data. The objective
of the validation is three-fold: 1) to illustrate that GESA-CSW works equal well on
structure-less gene set as the original GSEA methods; and 2) to demonstrate GESA-
CSW’s performance with integrated topology information and 3) to test GESA-CSW’s
performance on detecting different annotation scores. The three tests were done inde-
pendently to reduce the complicity of the interpretation of the test result.
Test GESA-CSW against GESA
Gene sets with different levels of differential expression (∆µ = 0,0.75) were generated
with varying levels of intra-group correlation (ρ = 0,0.6). Mixed gene sets, i.e. gene
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sets that included both differentially expressed and non-differentially expressed genes
were also constructed. A flat list of gene sets were used for the original GSEA method,
but hierarchically structured in an ontology fashion to be used for GESA-CSW.
The simulated gene expression data set consisted of 1000 genes with n = 20 sam-
ples, 10 in each of two groups (C1 and C2), for example, disease and control. The
data were generated using a 1000-dimensional multivariate normal distribution, with
variances set to 1 and means and correlations specified as follows:
• background: 960 genes with µ = 0 = 0 and ρ = 0.
• set 1: (differential expression, correlation): 20 genes with ∆µ = 0.75 (difference
of mean value between two groups, µC1 = 0,µC2 = 0.75 ) and pairwise correla-
tion ρ = 0.6 among the genes.
• set 2: (differential expression, no correlation): same as set 1 but with ρ = 0
between the genes in the set.
• set 3: (no differential expression, no correlation): 20 genes selected randomly
from the background.
• set 4: (differential expression, correlation, mixed with background): 10 genes
with ∆µ = 0.75 and ρ = 0.6 from set 1, the other 10 randomly selected from the
background.
• set 5: (differential expression, no correlation, mixed with background): same as
set 4 but with ρ = 0 between the genes in the set (i.e. 10 genes from set 2 and 10
genes from the background).
Thus, the 1000 simulated genes are constituted by the background set, S1 and S2.
The gene set enrichment analysis should be able to detect at least the pure sets S1
and S2, but ideally also the mixed sets S4 and S5 where only half of the genes are
differentially expressed. S3 serves as a negative control.
Using this data I first conducted gene set enrichment analysis with the original
GSEA algorithm and the GSEA-CSW algorithm with the exponent p set to 1 (ignoring
annotation score). The enrichment result is shown in table 3.3. The two methods
produced exactly the same result, successfully identified gene set 1,2,4,5 (p− value <
0.05) while leaving negative control S3 out. The result indicated that GSEA-CSW is
equivalent to the original GSEA method when analysing a flat list of gene sets without
any assessment of gene annotation confident within each gene set.
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GSEA GSEA-CSW
Gene Set ES NES p Group Gene Set ES NES p GROUP
S1 -0.90918 -1.7937 0 C2 S1 -0.909 -1.794 0.001 C2
S2 -0.85816 -2.0921 0 C2 S2 -0.858 -2.092 0.001 C2
S3 -0.27419 -0.88935 0.8086 - S3 -0.274 -0.889 0.686 -
S4 -0.68183 -1.7685 0.024 C2 S4 -0.682 -1.769 0.024 C2
S5 -0.74842 -2.0934 0 C2 S5 -0.748 -2.093 0.001 C2
Table 3.3: Enrichment result of simulation data between GSEA and GSEA-CSW. The
two methods produce identical result, indicating that GSEA-CSW performed equally
good as GSEA with a flat list of gene sets without any annotation confident within each
gene set.
Test GESA-CSW with integrated topology information
In order to test GESA-CSW’s performance with integrated topology information, four
more gene sets, set 6,7,8,9, were generated using the same 1000 simulated genes. The
four gene sets are hierarchically structured (fig. 3.9), where S8 is the child set of S9
and the parent set of S6 and S7. The set up are specified as follows:
• set 6: 5 genes randomly selected from set 1, 95 genes randomly selected from
the background.
• set 7: 5 genes randomly selected from set 2, the same 95 genes from background
as set 6.
• set 8: empty gene set to test the topology effect.
• set 9: empty gene set to test the topology effect.
Using the above four gene set, I conducted gene set enrichment analysis using
GSEA and GSEA-CSW algorithm with the classic and the elim topology method. The
GSEA algorithm does not account for topology information of the gene set, thus the
sets are considered as a flat list during the analysis. The exponent p was set to 1
(ignoring annotation score). The enrichment result is shown in table 3.4.
The algorithm behaved as expected for the four gene sets. None of the algorithm
pick up set 6 or set 7, which were designed to fail the enrichment test since each of
them contains only 5% of differential expressed genes. GSEA did not use any topology
information from the sets, thus S8 and S9 were empty during the test. As a result,
GSEA does not find any signifiant enriched gene set. In terms of GSEA-CSW, S8 was
detected by both topology methods because the annotation roll-up process, that is, the
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Figure 3.9: The simulated hierarchical structure of the simulated gene set 6,7,8 and 9.
S8 is the child set of S9 and the parent set of S6 and S7.
ancestors of S6 and S7 inherited their annotation. The join effect of S6 and S7 were
strong enough to be detected when each of them alone was too weak to be detected.
S9, however, was assessed as enriched by the classic method, but not the elim method,
due to the elimination process which remove the annotation from S9 giving that S8
was found enriched.
GSEA GSEA-CSW classic GSEA-CSW elim
Gene Set ES NES p Group Gene Set ES NES p Group Gene Set ES NES p Group
S6 -0.284 -1.248 0.095 C2 S6 -0.284 -1.248 0.095 C2 S6 -0.284 -1.248 0.095 C2
S7 -0.266 -1.171 0.17 C2 S7 -0.266 -1.171 0.17 C2 S7 -0.266 -1.171 0.17 C2
S8 - - - - S8 -0.329 -1.439 0.014 C2 S8 -0.329 -1.439 0.014 C2
S9 - - - - S9 -0.329 -1.439 0.014 C2 S9 - - - -
Table 3.4: Enrichment result of simulation data between original GSEA, classic and elim
GSEA-CSW. The original GSEA did not find any significant gene set. The GSEA-CSW
elim method found S8 enriched while the GSEA-CSW classic methods found S8 and
S9 enriched.
Test GESA-CSW with annotation confidence scores
Recall that in GSEA-CSW, an enrichment score (ES) is calculated by walking down
a ranked gene list L, increasing a running-sum statistic (RES) when encountering a
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member gene of set S (Phit) and decreasing it when encountering a non-member gene
of set S (Pmiss) (Equation eq. (1.1) on page 18). The magnitude of the increment during
the running-sum process is controlled by an exponent p which is calculated base on
the annotation confidence score of the gene. Thus, a higher scored gene will result in
a larger increment of the RES compared to a lower scored gene, which will also effect
on the final enrichment score (ES) and the p− value.
In order to illustrate the effect of annotation score in GESA-CSW, a simulated gene
set, S10, was generated from the same 1000 simulated genes from above. S10 was de-
signed to have a weak signal, only one third of its genes were differential expressed
genes. The objective of this test is to exam the effect of the annotation score in detect-
ing S10, and the corresponding leading edge genes of the gene set. The details were
specified as follows:
• set 10: 5 genes randomly selected from differential expressed genes, 10 genes
randomly selected from the background.
S10 was initially assessed without annotation score and was not found significantly
enriched(p = 0.078). The ES score peaked at -0.588 at position 660 in the ranked gene
list L as shown in fig. 3.10a. This result was used as a base line to compare with the
result using annotation score. Annotation score were randomly generated, between 0 to
1, and assigned to the 15 genes in S10. Such process was repeated 100 times, resulting
in 100 different variation of S10, on which GSEA-CSW was performed. The result
idicated that the integration of the annotation score affected the ES value its position,
which in turn affecting the p− value (fig. 3.10b). This effect of the annotation score
can be either positive or negative. i.e, a different annotation score may result in a more
extrema ES value and a smaller p−value, or it may weaken the enrichment, producing
a less extrema ES value and a bigger p− value.
Next, annotation scores of genes in S10 were deliberately assigned so that only one
of the 15 genes in S10 have a high score (0.9) while the rest have a low score (0.1). The
high scored gene was shift among the 15 genes which result in 15 different annotation
score variation. GSEA-CSW was then perform and compared to the baseline(S10
without annotation score). The algorithm behave as expected (fig. 3.11). The high
scored gene result in a larger increasement of the RES. As the high scored gene shifting
from the first gene to the last gene in S10, different maximun ES score appeared in
different positons, as expected.
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(a)
(b)
Figure 3.10: (a)The enrichment result of gene set 10 with GSEA-CSW without anno-
tation score. S10 was not significantly enriched (p− value = 0.0781). (b) Annotation
score were randomly assigned the genes in S10 100 times. The enrichment result
enrichment result indicated that the ES value, the position of the maximum ES in the
ranked gene list, and the p− value vary under different annotation score combination.
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(a) (b)
(c) (d)
Figure 3.11: Enrichment analysis with GSEA-CSW algorithm on the simulated gene
set S10. S10 contains 15 genes(black vertical bar in each graph) located in different
position of the 1000 simulated gene rank list L. Annotation scores are assigned to the
15 gene so that each time, one gene has a high score (0.9) while the result are low
scored (0.1). Each line of the RES represent one test with the indicated gene being
high scored. The BASE (black line) is the result when annotation score was not used.
The vertical dash line idicated the position of the maximun ES value. The RES lines
vary base on different annotation score set up, indicating the effect of the annotation
score in GSEA-CSW algorithm.
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3.3 Application of topOnto
Arc/Arg3.1 (activity-regulated cytoskeleton-associated protein/activity-regulated gene
3.1), for simplicity henceforth refer to as Arc, is a cytoskeletal protein first character-
ized in 1995 [274]. It is mainly localized at postsynaptic sites [275] but has also been
found in NMDA receptor complexes [276, 277] and PSD95/Dlg4 complexes [278].
Despite Arc having been studied for many years, little is known about its protein com-
plexes or role in disease. Mutation in the human ARC gene has not been directly
linked to any mental disorder. However, previous studies show that Arc complexes
play an important role in schizophrenia [278,279] suggesting that Arc complexes may
be involved with multiple diseases of cognition. A recent study5 from Grant et. al.
(Seth.Grant@ed.ac.uk) identified, in mice, 107 high-confidence Arc interactors from
the Arc complexes. Human genetic studies identified mutations and variants in Arc
interacting proteins that are enriched in schizophrenia, intellectual disability, epilepsy
and normal variation in intelligence. To reaffirm and extend the evidence of the Arc
complexes role in disease, enrichment analysis was performed with topOnto using
the Human Disease Ontology (HDO), Human Phenotype Ontology, Gene Ontology
(GOBP, GOCC, GOMF) and Reactome Pathway Ontology (RPO). The 107 protein
encoding genes in mice are projected to 106 human homology genes, which we use
as input for enrichment analysis, with one missing gene B630019K06Rik (NCBI En-
trez id:102941) could not be mapped from mouse to human. Fisher’s exact test was
used with four topology methods classic,elim,weight01 and parentchild. The top 10
enriched terms for each topology method with HDO are shown in table 3.5. The corre-
sponding results for the other ontologies are list as appendix in the table A1-table A5
on page 226.
HDO The enriched HDO terms for genes from the ARC complex make biologi-
cal sense (table 3.5). Schizophrenia is the most significantly enriched disease found by
classic,elim and weight01 methods while its parent terms ‘psychotic disorder, cognitive
disorder’ and ‘disease of mental health’ were also identified by classic and parentchild
methods. Neurodegenerative diseases like ‘Parkinson’s disease’ and ‘Alzheimer’s dis-
ease’, brain diseases including ‘epilepsy, frontotemporal dementia’ and ‘cerebral de-
generation’, and cognitive disorders like ‘vascular dementia’ were also found en-
riched. Other enriched diseases not shown here including ‘autistic disorder’ (elim
5https://www.genes2cognition.org/publications/tap-arc/
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TERM.ID Term Level classic elim weight01 parentchild
DOID:5419 schizophrenia 6 7.8e-21 7.8e-21 9.4e-20 0.77349
DOID:2468 psychotic disorder 5 9.8e-21 1.00000 1.00000 7.8e-06
DOID:936 brain disease 6 1.0e-17 0.10353 1.00000 1.1e-07
DOID:1561 cognitive disorder 4 1.6e-16 0.66238 1.00000 0.00223
DOID:150 disease of mental health 3 1.8e-16 0.09385 1.00000 1.8e-16
DOID:1826 epilepsy syndrome 7 4.1e-15 0.00020 3.6e-05 0.00091
DOID:331 central nervous system disease 5 3.4e-12 0.46574 1.00000 0.00293
DOID:863 nervous system disease 4 9.8e-11 0.11586 1.00000 2.3e-07
DOID:1443 cerebral degeneration 7 5.4e-10 5.4e-10 3.6e-11 0.00242
DOID:9255 frontotemporal dementia 8 1.0e-09 1.0e-09 1.0e-09 0.24237
(a) classic
TERM.ID Term Level classic elim weight01 parentchild
DOID:5419 schizophrenia 6 7.8e-21 7.8e-21 9.4e-20 0.77349
DOID:1443 cerebral degeneration 7 5.4e-10 5.4e-10 3.6e-11 0.00242
DOID:9255 frontotemporal dementia 8 1.0e-09 1.0e-09 1.0e-09 0.24237
DOID:3328 temporal lobe epilepsy 9 7.8e-07 7.8e-07 7.8e-07 0.29681
DOID:84 osteochondritis dissecans 8 5.1e-06 5.1e-06 5.1e-06 0.01030
DOID:8725 vascular dementia 6 1.1e-05 1.1e-05 1.1e-05 0.00552
DOID:14330 Parkinson’s disease 8 1.2e-05 1.2e-05 4.2e-05 0.42649
DOID:0060125 heavy chain disease 7 2.7e-05 2.7e-05 0.03239 0.00079
DOID:10652 Alzheimer’s disease 8 7.5e-05 7.5e-05 7.5e-05 0.91964
DOID:1826 epilepsy syndrome 7 4.1e-15 0.00020 3.6e-05 0.00091
(b) elim
TERM.ID Term Level classic elim weight01 parentchild
DOID:5419 schizophrenia 6 7.8e-21 7.8e-21 9.4e-20 0.77349
DOID:1443 cerebral degeneration 7 5.4e-10 5.4e-10 3.6e-11 0.00242
DOID:9255 frontotemporal dementia 8 1.0e-09 1.0e-09 1.0e-09 0.24237
DOID:3328 temporal lobe epilepsy 9 7.8e-07 7.8e-07 7.8e-07 0.29681
DOID:84 osteochondritis dissecans 8 5.1e-06 5.1e-06 5.1e-06 0.01030
DOID:8725 vascular dementia 6 1.1e-05 1.1e-05 1.1e-05 0.00552
DOID:1826 epilepsy syndrome 7 4.1e-15 0.00020 3.6e-05 0.00091
DOID:14330 Parkinson’s disease 8 1.2e-05 1.2e-05 4.2e-05 0.42649
DOID:10652 Alzheimer’s disease 8 7.5e-05 7.5e-05 7.5e-05 0.91964
DOID:0050709 Ohtahara syndrome 10 0.00035 0.00035 0.00035 0.59558
(c) weight01
TERM.ID Term Level classic elim weight01 parentchild
DOID:150 disease of mental health 3 1.8e-16 0.09385 1.00000 1.8e-16
DOID:936 brain disease 6 1.0e-17 0.10353 1.00000 1.1e-07
DOID:863 nervous system disease 4 9.8e-11 0.11586 1.00000 2.3e-07
DOID:2468 psychotic disorder 5 9.8e-21 1.00000 1.00000 7.8e-06
DOID:7 disease of anatomical entity 3 8.5e-05 0.27073 1.00000 8.5e-05
DOID:0080008 ischemic bone disease 7 0.00014 0.30680 1.00000 0.00034
DOID:0060125 heavy chain disease 7 2.7e-05 2.7e-05 0.03239 0.00079
DOID:1826 epilepsy syndrome 7 4.1e-15 0.00020 3.6e-05 0.00091
DOID:1561 cognitive disorder 4 1.6e-16 0.66238 1.00000 0.00223
DOID:1443 cerebral degeneration 7 5.4e-10 5.4e-10 3.6e-11 0.00242
(d) parentchild
Table 3.5: Disease enrichment analysis of the ARC complex with different topology
methods. The resulting enriched disease terms vary based on the topology method
used.
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p=4.8e− 3), ‘intellectual disability’ (elim p=2.5e− 2) and one of its particular sub-
types ‘autosomal dominant non-syndromic intellectual disability’ (elim p=1.2e− 3).
There is a possible error in the enrichment result - ‘osteochondritis dissecans’ which
is type of bone disease is enriched that could be error in the annotation. This term is
annotated with 21 genes (42 times in total, 35 from GeneRIF, 1 from OMIM, 6 from
Var). By checking the annotation, only 5 genes (10 times) are correctly annotated to
this term. The other 16 genes (32 times) are wrongly annotated to this term because of
the inappropriate usage of the ambiguous synonym, ‘OCD’, in the HDO. The abbrevi-
ation ‘OCD’ can refer to osteochondritis dissecans and obsessive-compulsive disorder
at the same time, but only appears as synonym in the former term definition. As a
result, OntoSuite-Miner wrongly linked genes that are found relevant with obsessive-
compulsive disorder to osteochondritis dissecans. The use of abbreviation is a frequent
source of error which is discuss in section 2.3.4.1 on page 76. These types of error are
induced by the ambiguous abbreviation synonym defined in the ontology, suggesting
that ontologies should be carefully used distinguishing terminology to avoid mapping
problems, especially with abbreviations.
HPO Similar to the result from HDO, Schizophrenia was also the most significantly
enriched term in HPO (table A1). ‘Seizures’, ‘Alzheimer disease’, ‘Dementia’ and
terms from ‘Encephalopathy’ (brain disease, damage, or malfunction) were also found
to be enriched. ‘Autism’ (elim p=5.3e− 3), ‘Intellectual disability’ (elim p=2.4e− 3)
and one of its child terms Intellectual disability, severe (elim p=2e−2) are reported to
be significant but not shown here.
ReactomePathway The most enriched pathway for the ARC complexes is Unblock-
ing of NMDA receptor, glutamate binding and activation (table A2). When a neuron
is not sending a signal, it is “at rest”. The NMDA receptor is blocked by extracellular
Mg2+ ions and is not activated in this state by ligands. This pathway involves remov-
ing the block from the NMDA receptor which activates it. Pathways involved in the
neurotransmitter release cycle, such as the ‘glutamate neurotransmitter release cycle’
and ‘GABA synthesis, release, reuptake and degradation’, receptor binding and recy-
cling including ‘Insulin receptor recycling’, ‘Ion channel transport’ were also found
to be enriched. Downstream signaling pathways including ‘Trafficking of AMPA re-
ceptors’, ‘post NMDA receptor activation events’ and its downstream ‘Ras activation
event’ were reported to be enriched. Besides all the signaling pathways, another in-
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teresting pathway, ‘Prefoldin mediated transfer of substrate to CCT/TriC’, is enriched.
Prefoldins are a family of proteins working as a transfer proteins in conjunction with
the chaperonins, CCT/TriC, to form a chaperone complex and correctly fold other pro-
teins. One of prefoldin’s main uses is the formation of molecules of actin for use in
the cytoskeleton. This enrichment reflects the functional role of ARC complex in the
cytoskeleton by regulating the folding and formation of actins and tubulins.
GO The Gene Ontology Biological Process describes genes and their functions (ta-
ble A3). ‘synaptic transmission’ is the most significantly enriched term while other
functional terms relevant to ion transport, cell-cell signaling and localization such
as ‘sodium ion export from cell’ and ‘ionotropic glutamate receptor signaling path-
way’ were also enriched. Interestingly, the term ‘learning’ (Any process in an or-
ganism in which a relatively long-lasting adaptive behavioral change occurs as the
result of experience) is enriched which agrees with the HDO and HPO results, sug-
gesting that the ARC complexes play an important role in memory and experience-
related behave patterns. Enrichment with the Gene Ontology Cellular Component
reveals the localization of ARC complexes. Postsynaptic structures like ‘postsynap-
tic membrane, postsynaptic density’ and t̀extitdendritic spine’ were enriched indicat-
ing that the ARC complex is mainly localized at postsynaptic sites. The enrichment
of ‘endocytic vesicle membrane, synaptic vesicle’ and ‘extracellular exosome’ sup-
port observations in [280, 281] that the ARC complex interacts with the endocytic
machinery to regulate AMPA receptor trafficking. In addition, ‘NMDA selective glu-
tamate receptor complex’ (not shown, elim p=3.3e− 05) was found to be enriched,
backing up previous findings from [276, 277]. Further evidence from the Gene Ontol-
ogy Molecular Function shows that ‘extracellular-glutamate-gated ion channel activ-
ity, sodium:potassium-exchanging ATPase activity, NMDA glutamate receptor activity’
and ‘AMPA glutamate receptor activity’ (not shown, elim p=2.3e− 4) were enriched
emphasizing again the important role of ARC complexes in the endocytic machinery.
By summarizing enrichment results across different ontologies, a better and more
complete picture of the ARC complex is achieved. The complex is mainly localized
in postsynaptic sites which contain extensive molecular machinery that link the post-
synaptic membranes and presynaptic membranes together and carry out the signaling
process. Different types of receptor such as NMDARs and AMPARs are located at
the postsynaptic membranes which receive neurotransmitter, glutamate for example,
and transfer them into the cell body to trigger downstream signaling cascades. The
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ARC complex also exists in receptor complexes and plays an important role in acti-
vation and regulation of these receptors. Evidence shows that the genes in the ARC
complexes are significantly associated with mental health diseases and nervous system
diseases including schizophrenia, Alzheimer’s disease, Parkinson’s disease, intellec-
tual disability, autism, and epilepsy. Among these diseases, schizophrenia shows the
strongest link to the genes found in the ARC complexes.
Generally speaking, the classic and parentchild approaches tend to identify terms
that are close to the root and provide a top-down view of the gene set in relation to
the ontologies. For example, the HDO terms ‘cognitive disorder’ and ‘nervous system
disease’ are very general terms identified by the classic and parentchild methods, but
not by elim and weight01. On the other hand, elim and weight01 tend to find more
specific terms such as ‘Alzheimer’s disease’, which was not reported to be significant
by the parentchild method. The average depth of the top 10 enriched terms for different
topology methods across different ontologies are shown in fig. 3.12a and different
performance of the topology methods are shown in fig. 3.12b. It is recommended
to look at the result from the classic and parentchild to get an overview of the gene set
in relation to the ontologies first, then move to the result of the elim and weight01 for
more specific information.
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Figure 3.12: Depth of (a)the top 10 enriched terms and (b) all enriched terms for the
ARC complex with different topology methods. The classic and parentchild methods
tend to identify terms that are close to the root and provide a top-down view. While the
elim and weight01 methods usually identify specific terms that are close to the leaves
of the ontology DAG, thus provide a bottom-up view of the ontology DAG. The classic
method generated the largest number of enriched diseases among all the methods.
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3.4 Conclusions and future work
In this chapter I reviewed the usefulness and common limitations of current enrich-
ment tools, and proposed the second part of the OntoSuite framework, the OntoSuite-
Analytics, which consists of a set of R packages including topOnto and the corre-
sponding data packages for the ontologies. I discussed statistical limitations, back-end
annotation database, multiple hypothesis correction and the key design decisions to
ameliorate them. The usage of the package was illustrated by analysing the activity-
regulated cytoskeleton-associated protein (ARC) complex.
The topOnto package was built on top of the existing bioconductor topGO package,
which is specifically designed for GO enrichment analysis. It implements a range of
popular statistical algorithms and topology methods for gene set enrichment analysis
and facilitates easy cross comparison of enrichment results between different statistic/-
topology combinations. topOnto provides all the features of the topGO package with
extra features including 1) An mechanism to run enrichment analysis across any stan-
dard ontology and present the result for easy comparison, 2) addition methods to work
on the ontology DAG and 3) the addition of the GSEA and the GSEA-CSW meth-
ods. One of the key features topOnto provides is unified enrichment analysis across
ontologies. Linux shell scripts are available to convert ontologies stored in standard
OBO format, into the corresponding ontology package that can be used by topOnto.
The package currently supports the HDO (Human Disease Ontology), HPO (Human
Phenotype Ontology), PCO (Panther Protein Class Ontology), CO (Chromosome On-
tology), RPO (Reactome Pathway Ontology) and the three GO ontologies GO-BP (Bi-
ological Process), GO-MF (Molecular Function) and GO-CC (Cellular Component).
Scripts are available to convert ontologies from a standard OBO file into the corre-
sponding ontology package that to be used by topOnto. Currently in September 2016,
106 ontologies are represented natively in OBO in the NCBO bioportal ontology repos-
itory while 351 ontologies are represented natively in OWL. OBO has became a sub
language of OWL, and can be created from OWL. Therefore, potentially there are more
than 450 ontologies that can be used in enrichment analysis by topOnto. Since NCBO
has been the central repository of biomedical ontologies, it would be interesting to
build a pipeline that pragmatically accesses ontologies from the NCBO and converts
them into ontology packages that can be used by topOnto.
A new algorithm, named GSEA-CSW was implemented in topOnto as a modifica-
tion of the original GSEA algorithm, which is particularly suitable for enrichment anal-
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ysis when the back-end annotation data are scored. GSEA-CSW differs from GSEA on
the way it controls the step length when calculate a Kolmogorov-Smirnov like statis-
tic. GSEA-CSW takes into account the gene confidence score, thus amplifying the
contribution of high scored gene associations in the enrichment analysis.
The GSEA-CSW algorithm was described and implemented and tested with simu-
lated data but not with real biological data.. This is because evaluating the performance
of enrichment methods is difficult due the absence of any gold standard, especially for
weighted association which has not been done before. [16], Huang et.al developed a
system to evaluate different enrichment methods by computing an MC (mutual cover-
age) score, representing the degree of mutually identified enriched gene set between
them. Thus enrichment methods with a higher MC score are suggested to perform bet-
ter than others. This system cannot be directly applied to evaluate the GSEA-CSW due
to the lack of standard weighted annotation data. Further evaluation of the algorithm
is needed in the future with the availability of standard evaluation methods and testing
data.
The GSEA method is computationally intensive due to the permutation process,
and so is GSEA-CSW. This problem is amplified when the algorithm is implemented
into topOnto when the elim method is used taking into account the ontology structure.
This results in a long processing time when using GSEA-CSW with the elim topology
method. The elim algorithm considers one level of ontology terms at a time and the
result will affect the next level of terms, thus within one level, the algorithm is paral-
lelalizable. However, the cost of dividing/distributing the task, and merging the result
needs to be calculated and tested further to prove that it is worth implementing.
The topOnto package, together with the gene disease association data set HDGDB
discussed in chapter 2 on page 33, have been used by Mclean et.al. in [282], a co
publication with me as the second author, to validate the performance of a novel scal-
able modularity based clustering algorithm, the Spectral Modularity algorithm, which
can be use to detect community structure in biological networks. topOnto package
was used in the study to assess the disease relevance of the detected communities in
three previously studied biological networks including 1)the MASC complex, repre-
senting a protein complex surrounding the mammalian NMDA receptor [283] consists
of 101 proteins and 246 interactions, 2) the PostSynaptic Density (PSD) [284] con-
sists of 1312 proteins and 8031 protein interactions, and 3) the Human interactome
network BioPlex [285], which contains 7668 proteins and 23744 protein interactions,
found using high-thoughput affinity purification mass spectrometry in human embry-
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onic kidney (HEK) 293T cells. The disease enrichment result was used to evaluate
the performance of different community detection algorithms with some unexpected
implication of the connection between the BioPlex network and Alzheimers disease.
topOnto is implemented as an R package using the R/Bioconductor system and is
freely available on github (https://github.com/statbio/topOnto). The package has been
submitted to Bioconductor and is being reviewed at the time of writing this thesis.
It would be much more useful to implement it as a user-friendly web interface like
DAVID [53] and DisGeNET [192].
Chapter 4
A comprehensive disease profile of
human genes
The search for feature enrichment in gene sets is a widely used characterisation method.
Instead of focusing on individual genes, such analyses try to summarize the informa-
tion for a set of genes grouped together based on shared features. For example, genes
that are involved in the same pathway or genes that located in a certain region of the
chromosome. HDGDB contains high-quality gene annotations for human diseases. It
should be of great utility for the exploration of relationships between and within gene
sets in human disease research using HDGDB.
Ontology annotation provides a natural way to categorize human genes. Genes an-
notated to the same ontology term are implied to be involved in the same biological
concepts. In the following section, I use four ontologies to categorize genes including
1) genes involved in the same pathways based on the Reactome database [172] (Reac-
tome pathway ontology, RPO), 2) gene products belonging to the same protein classes
based on Panther Protein Class [173, 174] (Protein class ontology,PCO), 3) genes that
are located in the same chromosome region (limited to only one sub-band level) of
the human genome (Chromosome ontology,CO) and 4) genes that are associated with
the same human diseases (Human disease ontology, HDO). Note that strictly speaking,
RPO, PCO and CO are not formally defined ontologies. They are however terminolo-
gies that contain all essential ontology features including unique and consistent ids of
terms, names, definitions and most importantly, the relations between terms. These
terminologies are structured hierarchically so that the terms near the root of the struc-
ture are more generic, exactly as for an ontology. Even though these terminologies do
not always provide all the optional information that is commonly found in an ontology,
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for example, cross links to other ontology terms, the existing data provided by the ter-
minologies and has covered all the essential features in an ontology thus, is sufficient
to be used in this way. As a result, the above three terminologies were parsed into
ontologies and subsequently used in the enrichment analysis.
4.1 Profiling gene sets with disease based annotations
HDGDB contains high quality gene annotations for human disease, making it possible
to construct a comprehensive disease profile for gene sets. Three ontologies, including
RPO, PCO and CO and their gene annotations were used to construct the gene sets of
interests, for example, genes that are located in the same chromosome region or their
encoded proteins are involved in the same pathway. A gene set, in terms of the en-
richment test, is conceptually similar to an ontology term, where genes are grouped by
their characteristic. It is interesting to use all the terms in RPO (1921), PCO (245) and
CO (114) to construct the gene sets and all of the terms in the HDO (6819) for disease
enrichment analysis. This results in a large amount of gene sets and generates very de-
tailed results for each of them. However, it is sometimes more interesting to summarize
disease information, for example for all signaling molecules (PC00207), rather a pro-
filing a specific type of signaling molecule, for example, Chemokine (PC00074) which
are a family of small signaling proteins that exert their biological effects by interacting
with G protein-linked transmembrane receptors called chemokine receptors [286].
In order to do this, a set of generalized terms like ‘PC00207 signaling molecules’
needs to be selected from the ontologies to give a broad overview of the ontology
content without the detail of the specific fine grained terms. However, ontologies were
defined independently by different consortium, and have different levels of detail in
each domain. In an ontology DAG, the leaf node represents the most specific concept
in a branch. The number of leaf nodes in a certain level in the ontology varies between
ontologies (fig. 4.1). Some of the leaf nodes are as deep as level 14 (14 nodes away
from the ontology root) while others are much closer to the root. The unbalance of
ontology structures makes it difficult to select general terms from any given ontology.
Note that CO is an exception because it represents chromosome regions detailed to
one sub band level, thus has a maximum of 3 levels and the level 3 terms are those
representing the individual sub bands.
Manually selection of terms can be accurate but requires domain knowledge and
is subjective since it is unclear how to sensibly compare between terms derived from
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different ontologies (for example: ‘PC00207 signaling molecules’ in PCO versus ‘R-
HSA-162582 Signal Transduction’ in RPO) and even within the same ontology (‘PC00194
protein kinase receptor’ versus ‘PC00193 protein kinase’ and ‘PC00197 receptor’).
Another approach to select a set of general terms is by using the ontologies’ struc-
tures themselves, choosing an appropriate level of abstraction based on the ontologies’
hierarchy. This requires minimum domain knowledge and reflects the native parent-
children relationship between ontology terms. However, ontologies were created to
represent different domain knowledge, thus have different structures. A uniform level
cut will result in the terms representing different level of abstraction among ontologies.
To avoid subjective selection of the ontology terms, I used the latter approach and man-
ually inspected the ontologies in order to select a proper level. As a result, I choosed
the level 3 terms of RPO ,PCO and CO to build disease profiles, even though this ap-
proach is still suffered from the ontology unbalanced structure. For the same reason,
136 level 3 HDO terms were used in order to generate a reasonable degree of gran-
ularity to represent all human disease. This resulted in a total of 277 ontology terms
and 73 PCO terms, 128 RPO terms and 76 CO terms being profiled. PCO1, RPO2 and
CO3 annotations were taken from the corresponding websites on 20th July 2016. Gene
annotations were rolled-up before the profiling process using the ‘true path rule’ of
the ontology definition where all attributes (including gene annotation) of the children
must hold for all parents. Thus, for example, the level 2 RPO term ‘Apoptosis’ has 35
children including ‘Intrinsic Pathway for Apoptosis’, ‘Regulation of Apoptosis’ and ‘a
poptotic execution phase’. Genes annotated to these 35 terms, were aggregated into
the term ‘Apoptosis’. Disease enrichment analysis was then perform on each of the
290 constructed gene sets (ontology terms) against the 136 HDO terms using topOnto
and HDGDB with the elim topology methods. During enrichment analysis, the gene
background (the reference gene set used in Fisher type significant test) was defined
as the overlapping genes between a particular ontology and HDO. For example, we
profiling RPO terms, genes that do not exist in RPO annotation but present in HDO
annotation are removed. This is similar to the enrichment analysis performed on mi-
croarray data where the gene background is usually defined as all the genes measured
by the microarray.
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Figure 4.1: The number of leaf nodes in a certain level in the ontology varies between
ontologies. Some of the leaf nodes are as deep as level 14 (14 nodes away from the
ontology root) while other is little closer as 2 nodes away from the root.
the CO, terms representing sub bands including ‘1p1’, ‘1p2’, ‘1p3’, ‘1q2’, ‘1q3’ and
‘1q4’ were grouped with the parent CO term ‘chromosome 1’; while in RPO, a series
of signaling pathways such as ‘Signalling by Activin’ and ‘Signalling by NOTCH’
were grouped into the parent RPO term ‘Signal Transduction’. In order to explore
consistent patterns from the disease profile within each group, it would be interesting
to find out those diseases that were found enriched across multiple terms within the
same group. Let’s define NG as the number of ontology term tested in group G, and
ND,G as the number of times a disease D was found to be enriched within group G,






A high PD,G value indicates that disease D is consistently enriched across group G,
such a pattern may be of interested for further exploration. For example, the pathway
group ‘R-HSA-73894 DNA Repair’ contains 6 pathways, out of which 5 were enriched
for ‘DOID:162 cancer’. PDOID:162,R−HSA−73894 = 83%. In addition to the enrichment
analysis, a PD,G was calculated for each disease-group pair across ontologies. Those
groups that contain only one term are ignored since the PD,G is always 100% in this
case. For example, pathway group ‘R-HSA-1474165 Reproduction’ contains only one
sub pathway ‘R-HSA-1187000 Fertilization’.
The following of this section details the setup of the disease enrichment process
and presents the results from each of the three ontologies including CO, RPO and
PCO, will be discussed. Some interesting observations from the results are discussed
further with supporting evidence from the literature.
4.1.1 Chromosome region
Each human chromosome has a short (denoted ‘p) and long arm (denoted ‘q’), sepa-
rated by a centromere. Each chromosome arm is further divided into regions, or cyto-
genetic bands, that can be seen using a microscope and special stains. The cytogenetic
bands are labeled p1, p2, q1, q2, etc., counting from the centromere out toward the
ends of the chromosome which are called telomeres. At higher resolutions, sub-bands
can be seen within the bands. The sub-bands are also numbered from the centromere
out towards the telomere. For example, the cytogenetic map location of the CFTR
gene is 7q31.2, which indicates it is on chromosome 7, q arm, band 3, sub-band 1, and
sub-sub-band 2.
The non-random distribution of polymorphic loci associated with breast cancer
[287] and schizophrenia [288] was reported and suggested that human chromosomes
are heterogeneous in structure and function. Identifying the correlation between hu-
man diseases and chromosome location can provide useful etiological insights and
help prioritize likely causal relationships. Disease enrichment analysis is an ideal ap-
proach to explore such relationships and the results provide a human disease ‘hot-spot’
profile for each of the 76 chromosome sub-band locations tested and can be used to
answer questions such as ‘what is the most enriched disease in chromosome 22q1?’.
The Chromosome Ontology (CO) was created to represent chromosome location based
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on chromosome structure and is used here in enrichment analysis. Gene annotations
were downloaded from the EntrezGene database and aggregated to sub-band level,
which contains 37638 human genes annotated with 76 CO terms. The summarized
results are shown in fig. A1. Previous studies support many of the results. For ex-
ample, ‘DOID:1561 cognitive disorder’ was found enriched in 13 chromosome sub
bands, among which 22q1 (p=9.7e−7) has the most significant result. This is due to
22q11.2 deletion syndrome, which is a disorder caused by the deletion of a small piece
of chromosome 22q11.2, and which has been linked to developmental delays, includ-
ing delayed growth and speech development, and learning disabilities. People with
22q11.2 deletion syndrome also have an increased risk of developing mental illnesses
such as schizophrenia, depression, anxiety, and bipolar disorder later in life [289,290].
Another example is ‘DOID:2914 immune system disease’, which is defined as a dis-
ease of anatomical entity that is located in the immune system in the Human disease
ontology, that was found to be significantly enriched (top 5 elim p<= 0.05) in 8 chro-
mosome sub-bands including 1q2 (p=1.47e− 2), 1q3 (p=4.9e− 9), 6p1 (p=4.3e− 2),
6p2 (p=7e− 13), 6q2 (p=2.8e− 2), 9p2 (p=9.8e− 3), 12q1 (p=2.6e− 3) and 18q2
(p=1.5e− 2). In particular, the most dense area was found on 1q3, where more than
20% of genes were linked to some type of immune system disease, followed by 6p2
and 18q2 with the corresponding gene percentages being 14% and 12.6% respectively.
The top enriched immune system disease (not shown here) in 1q3 is ‘DOID:12554
hemolytic-uremic syndrome’ (p=6.5e−15), which is a condition caused by the abnor-
mal destruction of red blood cells clogging the filtering system in the kidneys [291].
Other diseases including ‘DOID:10608 celiac disease’ (p=5e− 4) and ‘DOID:626
complement deficiency’ (p=5.7e− 4) were also found enriched [292, 293]. Previous
studies have confirmed the strong relationship between chromosome 6 and immune
system disease. The HLA gene family [294] including more than 220 different genes
are located close together on a 3 Mbp stretch within chromosome 6p2, and provides in-
structions for making a group of related proteins known as the human leukocyte antigen
(HLA) complex. The HLA complex helps the immune system distinguish the body’s
own proteins from proteins made by foreign invaders such as viruses and bacteria; its
function is essential to the immune system. Diseases including ‘DOID:8857 lupus
erythematosus’ (p=2.7e−28) where human immune system becomes hyperactive and
attacks healthy tissues, and ‘DOID:12361 Graves’ disease’ (p=3.9e−18) which is the
leading cause of hyperthyroidism, a condition in which the thyroid gland produces
excessive hormones, are among the top enriched diseases in 6p2 [295].
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On average, 40% of the genes on chromosome sub bands are annotated with at
least one disease according to our HDGDB data (fig. 4.2). The most highly disease
annotated sub band is 16q2 where 57.3% genes were annotated with at least one dis-
ease, while Yq1 is the least annotated sub band, only 3.7% of its genes were found
associated with any disease. Most disease genes are annotated to a small number of
diseases. Others (mostly cancer related genes) are linked to a large number of diseases
such as TNF (427) on 6p2, VEGFA (414) on 6p1 and TP53 (401 disease) on 17p1.
A weak positive linear relationship (Pearson correlation = 0.29) was observed be-
tween the number of genes located on a chromosome sub band region and the number
of enriched diseases found in that region (fig. 4.3). Some of the regions contain a
large number of genes but show little relationship in terms of diseases (1p3, 19q1,
11q1, ect.) while other smaller regions show stronger relationship with diseases (3p2,
9p2, 8p2, ect.). In particular, 1p3 is the largest chromosome sub band containing
1335 genes, but only two types of disease were found to be significantly enriched,
‘DOID:0060239 Van der Woude syndrome’ (p=2.3e−5) and ‘DOID:535 sleep disor-
der’ (p=2.7e−02). 19q1 is the second largest chromosome sub band with 1182 genes,
but only one disease ‘DOID:8545 malignant hyperthermia’ (p=2.4e− 2) was found
enriched. On the other hand, 9p2 is a relatively small sub band with 287 genes while
11 types of diseases were found enriched including ‘DOID:863 nervous system dis-
ease’ (p=1.1e−4),‘DOID:934 viral infectious disease’ (p=6.9e−4) and ‘DOID:1561
cognitive disorder’ (p=6e−3). 6p2, containing 1003 genes, was identified as the most
dense sub band for disease where 19 types of diseases were enriched.
To explore the disease pattern of each chromosome, the PD,G value was calculated
and those with PD,G > 50% are shown in table 4.1. It is observed that three types of
diseases, ‘DOID:863 nervous system disease’ with chromosome 10, ‘DOID:0060037
developmental disorder of mental health’ with chromosome X and ‘DOID:15 repro-
ductive system disease’ with chromosome Y, were found enriched across the whole
chromosome group which suggests a close relationship between these diseases and the
corresponding chromosome region. Some of these relationships had been observed in
previous literature [296–301].
The disease profile of chromosomes could indicate the importance of chromosome
regions in a disease context. It also provides a set of dense areas in chromosomes
for particular type of diseases, which may be used as a guidance to discover novel
gene functions or gene disease associations. It is observed that the chromosome area
where known chromosomal rearrangements (truncation, deletion. etc.) occur are more
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Figure 4.2: The distribution of disease and non disease genes on each chromosome
sub band. On average, 40% of the genes in chromosome sub bands are annotated
with at least one disease according to HDGDB data. The most disease annotated sub
band is 16q2 with 57.3% of genes annotated with at least one disease, while Yq1 is the
least annotated sub band with only 3.7% of genes associated with disease.
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Figure 4.3: Chromosome size and the number of enriched diseases. A weak positive
linear relationship (Pearson correlation = 0.29) was observed between the number of
genes located on a chromosome sub band region and the number of enriched diseases
found in that region
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Group Term.ID Term.DEF ND,G NG PD,G
chromosome 2 DOID:7 disease of anatomical entity 3 5 60.0%
chromosome 5 DOID:1579 respiratory system disease 3 4 75.0%
chromosome 6 DOID:2914 immune system disease 3 4 75.0%
chromosome 6 DOID:1287 cardiovascular system disease 3 4 75.0%
chromosome 9 DOID:0060158 acquired metabolic disease 3 5 60.0%
chromosome 10 DOID:1579 respiratory system disease 2 3 66.7%
chromosome 10 DOID:863 nervous system disease 3 3 100.0%
chromosome 11 DOID:1398 parasitic infectious disease 2 3 66.7%
chromosome 11 DOID:9007 sudden infant death syndrome 2 3 66.7%
chromosome 12 DOID:0060158 acquired metabolic disease 2 3 66.7%
chromosome 12 DOID:17 musculoskeletal system disease 2 3 66.7%
chromosome 12 DOID:0014667 disease of metabolism 2 3 66.7%
chromosome 16 DOID:104 bacterial infectious disease 2 3 66.7%
chromosome 16 DOID:0060340 ciliopathy 2 3 66.7%
chromosome 16 DOID:0050545 visceral heterotaxy 2 3 66.7%
chromosome 17 DOID:16 integumentary system disease 2 3 66.7%
chromosome 18 DOID:1287 cardiovascular system disease 2 3 66.7%
chromosome X DOID:0050177 monogenic disease 3 4 75.0%
chromosome X DOID:0060037 developmental disorder of mental health 4 4 100.0%
chromosome Y DOID:15 reproductive system disease 2 2 100.0%
Table 4.1: Chromosome disease pair with PD,G > 50%.
likely to become disease hot spots, for example 22q1 [302]. However, these result may
be biased by the uneven research focus on genes, i.e, some genes (regions) are more
studied than others, and are therefore better annotated, which increases the likelihood
finding enriched diseases. Further data and tests are needed to distinguish between the
above two possibilities for each particular chromosome region.
4.1.2 Reactome pathway
A biological pathway is a series of actions among molecules (proteins, small molecules,
genes, etc) in a cell that leads to a certain product or a change in the cell. For exam-
ple, a pathway can trigger the assembly of new molecules, turn genes on and off, or
spur a cell to move. There are many types of biological pathways. Among the most
well-known are pathways involved in metabolism, in the regulation of genes and in
the transmission of signals. In the Reactome pathway database, large pathways were
divided into sub-pathways, which may be further divided into smaller sub-pathways
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until reaching the individual steps in a pathway, known as reactions. There are 1921
pathways/reactions in Reactome (20 July 2016) and these are structured hierarchically
(fig. 4.4). From top to bottom of the pathway hierarchy, pathways become smaller,
more specific, and finally divide into reactions.
Figure 4.4: Reactome pathway hierarchical structure. From top to bottom of the path-
way hierarchy, large pathways were divided into sub-pathways, which may be further di-
vided into smaller sub-pathways until reaching the individual steps in a pathway, known
as reactions.
In order to profile Reactome pathway with human diseases, Reactome pathway
and the pathway annotation data were downloaded from the Reactome website on
17/02/2016. An ontology, refer to as RPO (Reactome pathway ontology), was cre-
ated to represent Reactome pathway based on the pathway hierarchy and subsequently
used in the enrichment analysis. Pathway annotations, containing 8446 unique human
genes, were aggregated to 145 level 3 RPO terms. belonging to 24 level 2 Reactome
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pathway, which were subsequently used in disease enrichment analysis with topOnto
and HDGDB. elim topology methods were used to estimate the enrichment p-value. As
a result, 128 Reactome pathways were found with at least one enriched disease. The
summarized results are shown in fig. A2. The PD,G value for each pathway-disease
pair was calculated and those with PD,G > 50% are shown in table 4.2.
The results make biological sense and most of them can be confirmed by review-
ing the literature. ‘R-HSA-109582 Hemostasis’ (fig. A2c) is a physiological response
that culminates in the arrest of bleeding from an injured vessel. The HDO term
‘DOID:1287 cardiovascular system disease’ was found enriched with PDOID:1287,Hemostasis =
85.7%. This disease includes a set of blood, heart, blood vessel and lymphatic sys-
tem disease that are closely related to crucial processes like clot formation, platelet
activation and interactions with the vascular wall. In Reactome pathway group ‘R-
HSA-397014 Muscle contraction’, it is observed that closely related diseases such as
‘DOID:1287 cardiovascular system disease’ (PD,G = 100%) and ‘DOID:17 muscu-
loskeletal system disease’ (PD,G = 67%) were found enriched.
The ‘R-HSA-112316 Neuronal System’ (fig. A2a) represents neurons in the brain
and their communication mechanisms. The communication occurs across synapses,
the functional connection between neurons. Neurotransmitters which are chemical
agents released by presynaptic neurons, are transmitted to postsynaptic neurons and
activate specific receptor molecules. Neurons’ physiological changes in the brain (neu-
ronal loss, changes in the synaptic physiology) results in variable degrees of cognitive
decline which result in a wide ranger of nervous system disease and cognitive disor-
ders [303].
The Reactome pathway group ‘R-HSA-168256 Immune System’ (fig. A2b) rep-
resents the ability of the human body to avoid/defend infection other organisms. Vi-
ral/bacterial/parasitic infectious diseases, as well as ‘DOID:2914 immune system dis-
ease’ were significantly enriched in this group. Interestingly, ‘DOID:162 cancer’
was enriched with 3 out of 4 (PD,G = 75%) Reactome pathways including ‘R-HSA-
1280218 Adaptive Immune System’ (p=6.4e− 10), ‘ R-HSA-168249 Innate Immune
System’ (p=1.8e−16) and ‘R-HSA-1280215 Cytokine Signaling in Immune system’
(p=1.9e− 16). Until recently, investigations into the nature of cancer focused strictly
on the cancer cell and on cancer as a genetic disease. This is perfectly illustrated by the
six consensus characteristics (hallmarks), proposed by Hanahan and Weinberg [304],
to define cancerous cells including the capacity to sustain proliferative signaling, to re-
sist cell death, to induce angiogenesis, to enable replicative immortality, to activate in-
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vasion and metastasis, and to avoid growth suppressors. These hallmarks are reflected
by the enrichment results of cancer in Reactome pathway groups including ‘R-HSA-
162582 Signal Transduction’ (PD,G = 83%), ‘R-HSA-2262752 Cellular responses to
stress’ (PD,G = 80%), ‘ R-HSA-73894 DNA Repair’ (PD,G = 83%), ‘R-HSA-1640170
Cell Cycle’ and ‘R-HSA-5357801 Programmed Cell Death’ (PD,G = 100%). However,
a picture of cancer is emerging with a new understanding of the relationship between
immunology and cancer. Immunology was previously considered not to be a critical
discipline for understanding cancer is now providing important new clues to cancer
biology. Four additional hallmarks were proposed, out of which two of them highlight
the newly recognized dual interaction between cancer and the immune system: the
ability to avoid immune destruction which results in acute inflammation and cancer
elimination, and the potential for chronic inflammation that promotes tumor growth
rather than elimination [305, 306]. Studies of cancer and immune system interactions
have revealed that every known innate and adaptive immune effector mechanism par-
ticipates in tumor recognition and control [307], and immunotherapy, which works on
strengthening the cancer patient’s immune system by improving its ability to recognize
the tumor or providing a missing immune effector function, is one of the recent cancer
treatment approaches that holds promise of a life-long cure [308].
In ‘R-HSA-1852241 Organelle biogenesis and maintenance’ (fig. A2d), a serious
of cilia related diseases, refereed to as Ciliopathies which are human diseases aris-
ing from disruption of cilia structure and/or function, were enriched in the Reactome
pathway ‘R-HSA-5617833 Assembly of the primary cilium’. The primary (nonmotile)
cilia are closely related to sensory and cell signaling functions. Availability of low-cost
next generation sequencing has facilitated the explosion of new knowledge in the ge-
netic etiology of ciliopathies and reviewed that many genes are shared in common
between otherwise clinically distinct ciliopathies [309]. ‘DOID:1148 polydactyly’
(p=5.1e−14) and ‘DOID:2490 congenital nervous system abnormality’ (p=1.9e−5),
which have been recently linked to cilia defect [310,311], as well as the master term for
ciliopathy ‘DOID:0060340 ciliopathy’ (p=1e−30)’ were found significantly enriched.
‘R-HSA-4839726 Chromatin organization’ (fig. A2e) refers to the composition and
conformation of complexes (chromatin) between DNA, protein, and RNA. The com-
plexes decrease the accessibility of DNA but also help to protect it from damage. The
most enriched type of disease in this group is ‘DOID:162 cancer’ (p=4.4e− 06). In
fact, one of the first steps in cancer is the acquisition of genome instability which can
be the result of changes in chromatin structure. Polak et.al. [312] compared the ge-
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nomic distribution of mutations of 173 cancer genomes from eight different cancer
types, to 424 epigenetic features and observed that epigenomics features indicative of
active chromatin and transcription were associated with low mutation density, whereas
repressive chromatin features were associated with regions of high mutation density.
It was concluded that chromatin accessibility and modification, together with replica-
tion timing, explain up to 86% of the variance in mutation rates along cancer genomes
tested in the paper.
‘R-HSA-5205647 Mitophagy’ contains only one sub Reactome pathway ‘R-HSA-
5205685 Pink Parkin Mediated Mitophagy’ (fig. A2g). This Reactome pathway is
the process of selective removal of damaged mitochondria by autophagosomes which
is induced by PINK1 activities [313]. PINK1 causes the parkin protein to bind to
depolarized mitochondria to induce autophagy of those mitochondria. Mutation in
the PINK1 gene leads the aggregation of mitochondria which has been associated with
Parkinson’s disease [314]. Its regulatory roles for mitochondrial function also suggests
that it is possibly involved in the pathogenesis of other nervous system disease such as
‘DOID:10652 Alzhermer’s disease’ [315] and ‘DOID:12217 lewy body disease’ [316],
which reflects the enriched HDO term ‘DOID:863 nervous system disease’ (p=1.2e−
3) in this group.
‘R-HSA-1430728 Metabolism’ (fig. A2h) describes processes in human cells that
generate energy and mediate the synthesis of diverse essential molecules, as well as the
inactivation and elimination of toxic ones generated endogenously or present in the ex-
tracellular environment. ‘DOID:0080074 neural tube defect’, which is mainly caused
by folic acid deficiency [317], was found enriched in ‘R-HSA-196854 Metabolism
of vitamins and cofactors’ (1.5e− 10) and ‘R-HSA-211859 Biological oxidations’
(1.5e−5), while ‘DOID:655 inherited metabolic disorder’, which in the vast majority
of cases is the result of mutations in TCA cycle enzymes, was also enriched in the
group (PD,G = 53.8%).
‘R-HSA-162582 Signal Transduction’ (fig. A2i) represents the process in which
extracellular signals elicit changes in cell state and activity. Transmembrane receptors
sense changes in the cellular environment by binding ligands, such as hormones and
growth factors, or reacting to other types of stimuli, such as light. Such stimulation of
transmembrane receptors leads to their conformational change which propagates the
signal to the intracellular environment by activating downstream signaling cascades.
Depending on the cellular context, this may impact cellular proliferation, differentia-
tion, and survival. At the organism level, signal transduction regulates overall growth
4.1. Profiling gene sets with disease based annotations 163
and behavior. ‘DOID:162 cancer’ was enriched in this group of Reactome pathways
with PD,G = 83.3% indicating its close relationship with cell signaling. Some of the Re-
actome pathways including ‘R-HSA-5683057 MAPK family signaling cascades’ (65
cancer terms), ‘R-HSA-195721 Signaling by Wnt’ (67) and ‘R-HSA-157118 Signal-
ing by NOTCH’ (68), together with growth factor related pathway including ‘R-HSA-
190236 FGFR’ (69), ‘R-HSA-1236394 EGFR’ (70) and ‘R-HSA-194138 VEGF’ (72)
were found linked to a large number of types of cancers, pinpointing potential com-
monalities in tumour signalling mechanisms.. In fact, signal transduction has long
been used to explain cancer mechanisms and as a therapeutic target [318–321]. The
dy-regularization of signaling pathways often leads to changes in the tumor microenvi-
ronment, angiogenesis, inflammation and in gene expression and cellular metabolism,
which result in the inactivation of tumor suppressor genes that normally ensure that
cells do not proliferate inappropriately or survive outside their normal cycle. For exam-
ple, the Receptor tyrosine kinase (RTK) pathways including EGFR [322], FGFR [323],
insulin receptor [324], NGF [325], PDGF [326] and VEGF [327], frequently activate
downstream signaling through RAF/MAP kinases [109, 328], AKT [329] and PLC-
gamma [330], which ultimately results in tumor suppressors being inhibited such as
p16 [331]. The Hippo pathway plays a critical role in regulating contact inhibition
of proliferation [332]. The disruption of this pathway suppresses the transcriptional
coactivator YAP, which is emerging as a key tumor suppressor pathway in many can-
cers [333–335]. The hyperactivated NOTCH pathway can stimulate the cell cycle and
also inhibits apoptosis in T cells which contributes to cancer such as acute lymphocytic
leukemia [336]. The involvement of Notch signaling in many cancers has led to inves-
tigation of notch inhibitors (especially gamma-secretase inhibitors) as potential cancer
treatments [337].
The disease profile of Reactome pathways presents a board overview of pathways
in the context of human disease. On average, each Reactome pathway was annotated
with 151 genes and was found enriched with 12 diseases. A weak positive linear
relationship (Pearson correlation = 0.41) was observed between the number of genes
in a Reactome pathway and the number of enriched diseases found within that pathway
(fig. 4.5). Various signalling transduction pathways were crowded on the bottom right
part of the figure, indicating their close relationship with a variety of diseases. These
pathways were often responsible for controlling cell proliferation and regulating cell
growth, thus tightly related to a variety of cancers. On the other hand, some other
pathways are less versatile in terms of disease and only a few diseases were enriched.
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For example, only one disease ‘DOID:15 reproductive system disease’ (p=3.1e− 3)
was found enriched in the ‘R-HSA-1187000 Fertilization’ pathway.
Figure 4.5: The correlation between the size of the Reactome Pathway and the number
of significantly enriched disease. A weak positive linear relationship (Pearson correla-
tion = 0.41) was observed between the number of genes in a Reactome pathway and
the number of enriched diseases found within that pathway.
A surprisingly high number of genes (average 81% across all pathways) were anno-
tated with Reactome pathways are disease genes that were linked to at least one HDO
term. Almost all genes in the pathway group ‘R-HSA-1474244 Extracellular matrix
organization’ were disease genes (fig. 4.6). This is much higher than the correspond-
ing figure among Chromosome genes because Reactome pathways are well defined
molecular networks which when disturbed, usually result in a cascade of changes of
other downstream pathways often leading to disease.
Group Term.ID Term.DEF N {D,G} N {G} P {D,G}
Hemostasis DOID:77 gastrointestinal system disease 4 7 57.1%
Hemostasis DOID:18 urinary system disease 4 7 57.1%
Hemostasis DOID:934 viral infectious disease 4 7 57.1%
Hemostasis DOID:15 reproductive system disease 4 7 57.1%
Hemostasis DOID:0060043 sexual disorder 4 7 57.1%
Continued on next page
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Table 4.2 – continued from previous page
Group Term.ID Term.DEF N {D,G} N {G} P {D,G}
Hemostasis DOID:1398 parasitic infectious disease 4 7 57.1%
Hemostasis DOID:162 cancer 5 7 71.4%
Hemostasis DOID:17 musculoskeletal system disease 5 7 71.4%
Hemostasis DOID:1579 respiratory system disease 5 7 71.4%
Hemostasis DOID:2914 immune system disease 6 7 85.7%
Hemostasis DOID:1287 cardiovascular system disease 6 7 85.7%
Neuronal System DOID:1561 cognitive disorder 2 2 100.0%
Neuronal System DOID:0060037 developmental disorder of mental health 2 2 100.0%
Neuronal System DOID:863 nervous system disease 2 2 100.0%
Neuronal System DOID:9007 sudden infant death syndrome 2 2 100.0%
Developmental Biology DOID:162 cancer 4 6 66.7%
Developmental Biology DOID:0060072 benign neoplasm 5 6 83.3%
Metabolism DOID:655 inherited metabolic disorder 7 13 53.8%
Extracellular matrix organization DOID:2914 immune system disease 4 7 57.1%
Extracellular matrix organization DOID:934 viral infectious disease 4 7 57.1%
Extracellular matrix organization DOID:0050177 monogenic disease 4 7 57.1%
Extracellular matrix organization DOID:9250 acrocallosal syndrome 4 7 57.1%
Extracellular matrix organization DOID:162 cancer 6 7 85.7%
Extracellular matrix organization DOID:77 gastrointestinal system disease 6 7 85.7%
Extracellular matrix organization DOID:18 urinary system disease 6 7 85.7%
Extracellular matrix organization DOID:1287 cardiovascular system disease 6 7 85.7%
Extracellular matrix organization DOID:15 reproductive system disease 6 7 85.7%
Extracellular matrix organization DOID:1579 respiratory system disease 6 7 85.7%
Extracellular matrix organization DOID:16 integumentary system disease 7 7 100.0%
Extracellular matrix organization DOID:17 musculoskeletal system disease 7 7 100.0%
Extracellular matrix organization DOID:0060072 benign neoplasm 7 7 100.0%
Signal Transduction DOID:0060071 pre-malignant neoplasm 13 24 54.2%
Signal Transduction DOID:0060233 cardiofaciocutaneous syndrome 13 24 54.2%
Signal Transduction DOID:303 substance-related disorder 14 24 58.3%
Signal Transduction DOID:0080014 chromosomal disease 14 24 58.3%
Signal Transduction DOID:2914 immune system disease 15 24 62.5%
Signal Transduction DOID:934 viral infectious disease 15 24 62.5%
Signal Transduction DOID:863 nervous system disease 15 24 62.5%
Signal Transduction DOID:28 endocrine system disease 15 24 62.5%
Signal Transduction DOID:0050567 orofacial cleft 15 24 62.5%
Signal Transduction DOID:1579 respiratory system disease 15 24 62.5%
Signal Transduction DOID:77 gastrointestinal system disease 16 24 66.7%
Signal Transduction DOID:17 musculoskeletal system disease 16 24 66.7%
Signal Transduction DOID:15 reproductive system disease 16 24 66.7%
Signal Transduction DOID:16 integumentary system disease 17 24 70.8%
Signal Transduction DOID:0050177 monogenic disease 17 24 70.8%
Signal Transduction DOID:1287 cardiovascular system disease 18 24 75.0%
Signal Transduction DOID:0060072 benign neoplasm 19 24 79.2%
Signal Transduction DOID:162 cancer 20 24 83.3%
Cell Cycle DOID:162 cancer 3 4 75.0%
Cell Cycle DOID:2490 congenital nervous system abnormality 3 4 75.0%
Cell Cycle DOID:0060071 pre-malignant neoplasm 4 4 100.0%
Immune System DOID:162 cancer 3 4 75.0%
Immune System DOID:934 viral infectious disease 3 4 75.0%
Immune System DOID:0060043 sexual disorder 3 4 75.0%
Continued on next page
166 Chapter 4. A comprehensive disease profile of human genes
Table 4.2 – continued from previous page
Group Term.ID Term.DEF N {D,G} N {G} P {D,G}
Immune System DOID:77 gastrointestinal system disease 4 4 100.0%
Immune System DOID:2914 immune system disease 4 4 100.0%
Immune System DOID:17 musculoskeletal system disease 4 4 100.0%
Immune System DOID:104 bacterial infectious disease 4 4 100.0%
Immune System DOID:1398 parasitic infectious disease 4 4 100.0%
Immune System DOID:1579 respiratory system disease 4 4 100.0%
Cellular responses to stress DOID:77 gastrointestinal system disease 3 5 60.0%
Cellular responses to stress DOID:16 integumentary system disease 3 5 60.0%
Cellular responses to stress DOID:18 urinary system disease 3 5 60.0%
Cellular responses to stress DOID:0060072 benign neoplasm 3 5 60.0%
Cellular responses to stress DOID:1287 cardiovascular system disease 3 5 60.0%
Cellular responses to stress DOID:162 cancer 4 5 80.0%
Muscle contraction DOID:17 musculoskeletal system disease 2 3 66.7%
Muscle contraction DOID:1561 cognitive disorder 2 3 66.7%
Muscle contraction DOID:150 disease of mental health 2 3 66.7%
Muscle contraction DOID:1287 cardiovascular system disease 3 3 100.0%
Circadian Clock DOID:162 cancer 2 2 100.0%
Circadian Clock DOID:934 viral infectious disease 2 2 100.0%
Circadian Clock DOID:1561 cognitive disorder 2 2 100.0%
Circadian Clock DOID:0060158 acquired metabolic disease 2 2 100.0%
Circadian Clock DOID:11612 polycystic ovary syndrome 2 2 100.0%
Circadian Clock DOID:0060043 sexual disorder 2 2 100.0%
Programmed Cell Death DOID:162 cancer 2 2 100.0%
Programmed Cell Death DOID:77 gastrointestinal system disease 2 2 100.0%
Programmed Cell Death DOID:2914 immune system disease 2 2 100.0%
Programmed Cell Death DOID:16 integumentary system disease 2 2 100.0%
Programmed Cell Death DOID:17 musculoskeletal system disease 2 2 100.0%
Programmed Cell Death DOID:18 urinary system disease 2 2 100.0%
Programmed Cell Death DOID:934 viral infectious disease 2 2 100.0%
DNA Repair DOID:0050177 monogenic disease 4 6 66.7%
DNA Repair DOID:162 cancer 5 6 83.3%
Table 4.2: Pathway disease pairs with PD,G > 50%.
4.1.3 Panther protein class
PANTHER (Protein Analysis Through Evolutionary Relationships) protein classifica-
tion system (version 7.0) contains 243 protein classes ranging from general terms in-
cluding ‘PC00095 enzyme modulator’ and ‘PC00218 transcription factor’, to specific
types of receptor such as ‘PC00001 AMPA receptor’ and ‘PC00030 NMDA recep-
tor’. In order to profile protein classes with human diseases, the PANTHER protein
classification system and the corresponding annotation data were downloaded from
the PANTHER database on 17/02/2016. An ontology, refereed as PCO (Protein class
ontology), was created and subsequently used in disease enrichment analysis. The
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annotation data, containing 8852 unique human genes, were aggregated to 97 level 3
PO terms, which were tested with topOnto and HDGDB. The elim topology method
was used to estimate the enrichment p-value. The summarized results are shown in
fig. A3. The PD,G value for each proteinclass-disease pair was calculated and those
with PD,G > 50% are shown in table 4.3.
The enrichment results again make biological sense and are supported be the lit-
erature. ‘PC00197 receptor’ represents receptors which are a molecules within a cell
or on the cell surface characterized by selective binding of a specific substance and
a specific physiologic effect that accompanies the binding. As shown in fig. A3f,
‘DOID:1561 cognitive disorder’ was significantly enriched in ‘G-protein coupled re-
ceptor’ (p=5.6e−07), which has been long considered responsible for major cognitive
disorder such as schizophrenia and moon disorder [338]. ‘PC00084 cytokine receptor’
were closely related to ‘DOID:2914 immune system disease’ (p=1e− 30), together
with ‘DOID:934 viral infectious disease’ (p=1.5e−23) and ‘DOID:104 bacterial infec-
tious disease’ (p=4.4e−22) [339, 340]. Homeostasis of hormone systems is essential
for human health, and aberrant regulation of hormone signaling has been associated
with many diseases, including cancer, diabetes, and diseases of inflammation. Hor-
mone signaling pathways have become a major interest for pharmacological interven-
tion in many health abnormalities [341]. The hormones androgen and estrogen have
long been known to play key roles in development, growth, and homeostasis of repro-
ductive systems and their dysregulation is the major cause of prostate cancer and breast
cancer [342, 343]. Besides the two classical steroid hormone receptors, the androgen
and estrogen receptors, orphan nuclear receptors are also known to play important roles
in tumorigenesis [344] which is consistent with the enrichment of ‘DOID:162 cancer’
in ‘PC00169 nuclear hormone receptor’ (p=e2.4e−07).
‘PC00220 transferase’ (fig. A3g) represents any one of a class of enzymes that
enact the transfer of specific functional groups (e.g. a methyl or glycosyl group)
from one molecule (called the donor) to another (called the acceptor). DNA methy-
lation is an epigenetic modification critical to normal genome regulation and devel-
opment in which the vitamin folate (or its synthetic form folic acid) is a key source
of the one carbon group used to methylate DNA [345]. This explains the result that
‘DOID:0080074 neural tube defect’ (p=e4.3e− 05), which is mainly caused by folic
acid deficiency [317], was enriched in ‘PC00155 methyltransferase’.
‘PC00085 cytoskeletal protein’ (fig. A3b) represents the major constituents of the
cytoskeleton found in the cytoplasm of eukaryotic cells. They form a flexible frame-
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work for the cell, provide attachment points for organelles and formed bodies, mak-
ing communication between parts of the cell possible. ‘PC00157 microtubule family
cytoskeletal protein’ represent proteins that are either microtubules or bind to micro-
tubules to form the cytoskeleton of the cell. It is enriched by ‘DOID:0060340 cil-
iopathy’ (p=4.6e− 08)’ which represent a group of disorders associated with either
abnormal formation or function of cilia [203]. Cilia are microtubule-based, hair-like
cytoplasmic extensions with motile and a range of sensory functions, which are critical
for developmental and physiological functions. The microtubule family cytoskeletal
proteins are essentially involved in ciliogenesis. In addition, ‘DOID:2490 congenital
nervous system abnormality’ (p=3.3e− 07), which has recently been linked to cilia
defects [310, 311] was also enriched. In the same figure, a host of different immune
system diseases were enriched in ‘PC00090 defense immunity protein’. In particular,
‘DOID:2914 immune system disease’ (p=6.4e− 09),‘DOID:104 bacterial infectious
disease’ (p=8.4−09) and ‘DOID:934 viral infectious disease’ (p=1.2e−07) were en-
riched in ‘PC00149 major histocompatibility complex antigen’, a set of cell surface
proteins essential for the acquired immune system to recognize foreign molecules in
vertebrates, which in turn determines histocompatibility. The main function of the
MHC complex is to bind to peptide fragments derived from pathogens and display
them on the cell surface for recognition by the appropriate T-cells [346], thus closely
related to immune/infectious diseases.
In the protein class ‘PC00207 signaling molecule’ (fig. A3f), it is found that a
wide range of diseases including ‘DOID:2914 immune system disease’ (p=1e− 30),
‘DOID:15 reproductive system disease’ (2.3e− 14) and ‘DOID:28 endocrine system
disease’ (p=6e− 12) were enriched in ‘PC00083 cytokine’. Cytokines usually act
through receptors, and are especially important in the immune system [347]. They
are also involved in several developmental processes during embryogenesis [348,349].
‘DOID:162 cancer’ (e4.5e− 11) and ‘DOID:0060072 benign neoplasm’ (p=2.2e−
10) were the top two enriched disease found in ‘PC00112 growth factor’, while for
‘PC00179 peptide hormone’, closely related diseases such as ‘DOID:15 reproductive
system disease’ (p=3.9e−14) and ‘DOID:28 endocrine system disease’ (p=5.3e−14)
were highly significantly enriched.
The disease profile of protein classes presents a broad overview of different pro-
tein classes and their involvement in the context of human disease. All the genes in
the PCO annotation were annotated with at least one human disease from HDGDB.
No correlation was observed between the size of a protein class and the number of
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enriched diseases found within that class (fig. 4.7). Similar to the pathway result, most
of the protein classes involved in cell signaling, were enriched with a large number
of diseases. For example, ‘PC00083 cytokine’ (33 diseases) and ‘PC00169 nuclear
hormone receptor’ (29).
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Figure 4.6: The distribution of disease gene and non disease gene in pathways. The
pathway is indexed by its unique id for visibility. A surprisingly high number of genes
(average 81% across all pathways) annotated with pathways are disease genes that
were linked to at least one HDO term.
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Figure 4.7: Protein class size and the number of enriched diseases. No correlation was
observed between the number of protein in a protein class and the number of enriched
disease found within that class. The most disease dense protein class was ‘cytokine’
where 33 disease were enriched.
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Group Term.ID Term.DEF ND,G NG PD,G
protein class DOID:2914 immune system disease 2 3 66.7%
protein class DOID:934 viral infectious disease 3 3 100.0%
calcium-binding protein DOID:1287 cardiovascular system disease 2 2 100.0%
calcium-binding protein DOID:11612 polycystic ovary syndrome 2 2 100.0%
cell adhesion molecule DOID:16 integumentary system disease 2 2 100.0%
cell junction protein DOID:16 integumentary system disease 2 2 100.0%
defense immunity protein DOID:934 viral infectious disease 2 3 66.7%
defense immunity protein DOID:77 gastrointestinal system disease 2 3 66.7%
defense immunity protein DOID:2914 immune system disease 2 3 66.7%
defense immunity protein DOID:16 integumentary system disease 2 3 66.7%
defense immunity protein DOID:104 bacterial infectious disease 2 3 66.7%
defense immunity protein DOID:18 urinary system disease 3 3 100.0%
defense immunity protein DOID:17 musculoskeletal system disease 3 3 100.0%
defense immunity protein DOID:1579 respiratory system disease 3 3 100.0%
extracellular matrix protein DOID:18 urinary system disease 2 3 66.7%
extracellular matrix protein DOID:17 musculoskeletal system disease 2 3 66.7%
extracellular matrix protein DOID:0060072 benign neoplasm 2 3 66.7%
extracellular matrix protein DOID:0050769 N syndrome 2 3 66.7%
lyase DOID:655 inherited metabolic disorder 3 4 75.0%
oxidoreductase DOID:655 inherited metabolic disorder 4 6 66.7%
receptor DOID:1579 respiratory system disease 3 4 75.0%
receptor DOID:0060072 benign neoplasm 3 4 75.0%
receptor DOID:28 endocrine system disease 3 4 75.0%
receptor DOID:1287 cardiovascular system disease 4 4 100.0%
signaling molecule DOID:1287 cardiovascular system disease 3 4 75.0%
signaling molecule DOID:11612 polycystic ovary syndrome 3 4 75.0%
signaling molecule DOID:934 viral infectious disease 3 4 75.0%
signaling molecule DOID:16 integumentary system disease 3 4 75.0%
signaling molecule DOID:17 musculoskeletal system disease 3 4 75.0%
signaling molecule DOID:1579 respiratory system disease 3 4 75.0%
signaling molecule DOID:0060072 benign neoplasm 3 4 75.0%
signaling molecule DOID:15 reproductive system disease 3 4 75.0%
signaling molecule DOID:28 endocrine system disease 3 4 75.0%
signaling molecule DOID:18 urinary system disease 4 4 100.0%
signaling molecule DOID:2914 immune system disease 4 4 100.0%
signaling molecule DOID:162 cancer 4 4 100.0%
transcription factor DOID:162 cancer 4 6 66.7%
transferase DOID:655 inherited metabolic disorder 4 5 80.0%
transporter DOID:655 inherited metabolic disorder 3 5 60.0%
Table 4.3: Protein class-disease pair with PD,G > 50%.
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4.2 Profiling human disease with gene sets
In the above sections, I explored some of the well-established gene sets (created from
ontologies) from a disease perspective and tried to answer biological questions like
‘what are the most relevant diseases of a particular gene set, for example, for all the
protein kinase genes?’. Similarly, using the same method and data, I explore here
the molecular basis of human diseases, trying to ask questions like ‘what are the
most relevant pathways/protein classes that are known to be involved in a disease,
e.g. schizophrenia?’.
HDGDB contains gene annotations for 3140 human diseases, out of which 1310
have more than 10 gene annotations (the remaining 1830 diseases were removed be-
cause the number of annotations was too small to yield any statistically significant
results). Term enrichment analysis was performed on each of the 1310 human diseases
against 8 ontologies including 1) RPO, 2) PCO, 3) CO, 4) HPO and the three ontolo-
gies from the Gene Ontology namely GOBP (Biological Process), GOMF (Molecular
Function) and GOCC (Cellular Component) and HDO itself. The annotation of the
ontologies was taken from the corresponding websites on 20th July 2016, except for
the HPO annotation, which was generated using OntoSuite-Miner using human phe-
notype ontology, just like HDGDB with HDO. topOnto and HDGDB were used with
the elim topology method for analysis. Furthermore, in order to explore diseases that
share similar underlying molecular mechanisms, the 1310 diseases were then tested
against HDO itself.
By including seven ontologies and HDO itself, a ‘disease environment’ was cre-
ated for each of the 1310 human diseases defined by HDO. Two types of node exist in a
disease environment, ontology nodes representing the ontology terms and gene nodes
represent significant genes. An ontology node is connect to a gene node via edges if
the gene is annotated to that ontology term. Each ontology in the disease environment
inspects the disease with respect to a different biological theme. For example, for a
given disease, the enriched CO terms indicate whether the known disease genes are
densely located in a particular chromosome region, while enriched HPO terms reflect
the phenotypic abnormalities observed in that disease. A comprehensive over view
with possible new insights into each of the 1310 human disease is archived when inte-
grating heterogeneous ontologies into the same environment. In the following section,
I will present the disease environment for two diseases, ‘DOID:1612 breast cancer’
and ‘DOID:5419 schizophrenia’. The results of the other disease are available as sup-
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plementary information (attached disk) but not presented in the thesis itself.
Note that due to the complicity of the disease environment and it’s visibility as
a graph in the thesis, only the top 5 enriched terms in each ontology were included.
The result of the enriched term were ignored, thus may result in the lost of possible
interesting information. More detail analysis could be carried out to use all enriched
terms but has not been done in this thesis.
4.2.1 The Disease environment of breast cancer
Breast cancer is the most common invasive cancer in women, affecting about 12% of
women worldwide [350] and comprising 16% of all female cancers [351]. About 5-
10% of breast cancers are thought to be hereditary, caused by abnormal genes passed
from parent to child, including BRCA1 and BRCA2 among others. Hereditary breast
cancers tend to develop earlier in life than noninherited cases. Some genes such as
TP53, CDH1, PTEN, BRCA1 and BRCA2 are associated with a high risk of developing
breast cancer, thus described as ‘high penetrance’ genes. These genes are usually in-
volved directly in fixing damaged DNA, which helps to maintain the stability of a cell’s
genetic information. They are described as tumor suppressors because they help keep
cells from growing and dividing too fast or in an uncontrolled way. Mutations in these
genes usually impair DNA repair, allowing potentially damaging mutations to persist
in DNA. As these defects accumulate, they can trigger cells to grow and divide without
a control in order to form a tumor. Other genes that have been studied as possible risk
factors for breast cancer, either provide instructions for making proteins that interact
with the ‘high penetrance’ genes [352–355], or play a role through other pathways
that control the growth, division (proliferation) or apoptosis of cells, or involved in the
repair of danged DNA [356]. The combined influence of variations in these genes may
significantly impact the risk of developing breast cancer.
In HDGDB, 3222 unique genes were annotated to the HDO term ‘DOID:1612
breast cancer’ and scored based on 26674 pieces of evidence from the three data
sources, OMIM, GeneRIF and Ensembl Variation. The top 20 scored GDAs are listed
in table 4.4. A series of well known tumor suppressors including TP53, BRCA1-2 and
CHK2 were found amongs the top scoring genes. The ESR1 gene, encodes estrogen re-
ceptor (ER), which is the primary therapeutic target in breast cancer and is expressed in
70% of cases [357]. Mutations in CDH1 often lead to hereditary diffuse gastric cancer,
which is often considered a significant risk factor for breast cancer. CDH1 dysfunction
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may result in a loss of E-cadherin, which may allow breast cells to grow and divide
unchecked, leading to a cancerous tumor. Furthermore, since E-cadherin helps neigh-
boring cells stick to one another (cell adhesion) to form organized tissues, the resulting
loss of E-cadherin may also make it easier for cancer cells to detach from a primary
tumor and spread (metastasize) to other parts of the body [354]. These highly scored
breast cancer genes were well studied genes that are closely involved in breast cancer
disease mechanism. Together with the lower scoring breast cancer genes, ontology
enrichment analysis were performed with 7 ontologies and HDO itself and a breast
cancer disease environment was created and is shown in fig. 4.8.
It has been suggested that loci associated with the risk of breast cancer may be
distributed non-randomly on chromosomes [287]. However, many previous studies
which investigated the association between single nucleotide polymorphisms (SNP)
of candidate genes and breast cancer risk yielded inconsistent results, which could be
partly due to insufficient power (sample size). It is observed that 17q1 (p=9.2− e4),
20q1 (p=9.5e− 3), 1q3 (p=1.2− e2) and 8q2 (p=1.3− e2) chromosome sub bands
were enriched in the breast cancer environment, out of which only 8q2 was supported
by previous evidence [287]. There are 39, 62 and 43 breast cancer genes located on
17q1, 20q1 and 1q3 respectively, almost one-third of the genes located on 17q1 were
annotated to breast cancer. These regions were not identified as breast cancer suscep-
tibility region previously probably due to the different methodology and data used to
determine the region’s significance. I am using all of the breast cancer genes found
in HDGDB which also includes those ‘low-penetrance’ genes and possibly genes that
were only associated with breast cancer recently. Thus, the above three chromosome
sub bands could be potentially interesting in breast cancer susceptibility and worth
further investigation.
‘R-HSA-114604 GPVI-mediated activation cascade’ (p=2.9e− 12), which leads
to downstream platelet activation with its downstream pathway ‘R-HSA-76005 Re-
sponse to elevated platelet cytosolic Ca2+’ (p=4.4e− 10), has been identified as the
most enriched pathway for breast cancer. Previous studies have shown that an in-
creased circulating platelet count (thrombocytosis) is associated with a poor breast
cancer prognosis, suggesting a potential direct role for platelets in the pathogenesis
of breast cancer [358, 359]. In fact, direct evidence exists, supporting the close in-
volvement of platelet in 6 out of the 10 hallmarks [305] that defines cancer pathogene-
sis [360–363], which is also consistent with the RPO disease profile of ‘R-HSA-76002
Platelet activation, signaling and aggregation’ (fig. A2c) enriched with ‘DOID:162
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cancer’ (p=1.80e−07). Thus together with its preponderance in the breast cancer dis-
ease environment, the current under-explored anti-platelet therapy could be promis-
ing adjunct to existing breast cancer treatments. The presence of ‘R-HSA-2219530
Constitutive Signaling by Aberrant PI3K in Cancer’ and ‘R-HSA-1257604 PIP3 ac-
tivates AKT signaling’ were interesting. The PI3K/AKT signaling is frequently con-
stitutively activated in cancer via gain-of-function mutations in one of the two PI3K
subunits, PI3KCA or PIK3R1. Mutations in PIK3CA enable the kinase to achieve an
active conformation, producing PIP3 and activating downstream AKT in the absence
of growth factors. Aberrant gain of Akt activation underlies the pathophysiological
properties of a variety of complex diseases, not only breast cancer but also cancers in
general [329, 364].
Different types of cancer are presented in the breast cancer environment because
cancer often share similar pathogenesis such as uncontrolled cell growth and division.
Thus they are likely to share a large amount of genes. Interestingly, even though breast
cancer is rare in males, ‘DOID:10283 prostate cancer’ (p=1e−30) was present in the
breast cancer environment. This, beside the general cancer mechanism, is probably be-
cause in a small number of men, prostate cancer is linked to alterations in the BRCA1
or, more often, the BRCA2 gene [365, 366]. In fact, a recent study found that a family
history of prostate cancer was associated with a modest increase in breast cancer risk,
which suggests that prostate cancer diagnosed among first-degree family members in-
creases a woman’s risk of developing breast cancer [367]
4.2.2 The Disease environment of schizophrenia
Schizophrenia is a disease characterized by a disintegration of the processes of think-
ing and of emotional responsiveness. It ranks among the top 20 causes of disability
worldwide and caused more loss of life than several cancers and other physical ill-
nesses [368]. A number of theories have been developed, attempting to explain how
changes in brain function can contribute to symptoms of the disease [369–372] but the
underlying mechanisms of schizophrenia are complex and is not entirely clear yet. In
an attempt to gain a better understanding of schizophrenia, ontology enrichment analy-
sis was performed using schizophrenia genes against 7 ontologies and HDO itself and
a schizophrenia disease environment was created, representing the current knowledge
of the disease and possible insights. The schizophrenia disease environment is shown
in fig. 4.8.
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DOID Disease Gene Score Score.o Score.g Score.v #Evidence (o/g/v)
1 DOID:1612 breast cancer BRCA2 0.84 0.217 0.319 0.259 2/273/2466
2 DOID:1612 breast cancer ESR1 0.72 0.167 0.318 0.196 1/373/11
3 DOID:1612 breast cancer TP53 0.72 0.167 0.317 0.167 1/221/1
4 DOID:1612 breast cancer CDH1 0.71 0.167 0.314 0.188 1/57/3
5 DOID:1612 breast cancer PALB2 0.71 0.167 0.314 0.196 1/43/11
6 DOID:1612 breast cancer ATM 0.71 0.167 0.311 0.192 1/46/5
7 DOID:1612 breast cancer AKT1 0.71 0.167 0.308 0.182 1/86/2
8 DOID:1612 breast cancer AR 0.71 0.167 0.307 0.188 1/48/3
9 DOID:1612 breast cancer BARD1 0.70 0.167 0.303 0.182 1/15/2
10 DOID:1612 breast cancer PPM1D 0.69 0.167 0.299 0.182 1/10/2
11 DOID:1612 breast cancer PIK3CA 0.66 0.167 0.258 0.188 1/71/3
12 DOID:1612 breast cancer CHEK2 0.66 0.167 0.258 0.182 1/61/2
13 DOID:1612 breast cancer RAD51 0.65 0.167 0.249 0.182 1/33/2
14 DOID:1612 breast cancer BRIP1 0.65 0.167 0.25 0.192 1/11/5
15 DOID:1612 breast cancer BRCA1 0.64 0.05 0.319 0.259 1/484/1914
16 DOID:1612 breast cancer PHB 0.64 0.167 0.242 0.188 1/5/3
17 DOID:1612 breast cancer CASP8 0.59 0.167 0.198 0.182 1/19/2
18 DOID:1612 breast cancer FGFR2 0.57 0 0.304 0.252 0/44/16
19 DOID:1612 breast cancer TGFB1 0.51 0 0.312 0.167 0/74/1
20 DOID:1612 breast cancer CCND1 0.51 0 0.308 0.19 0/68/4
Table 4.4: Top scored gene-disease associations for breast cancer in the Human Dis-
ease Gene Database.
In HDGDB, 1844 unique genes were annotated to the HDO term ‘DOID:5419
schizophrenia’ and scored base on 3920 pieces of evidence from the three data sources,
OMIM (29), GeneRIF (2441) and Ensembl Variation (1450). The top 20 scored GDAs
are listed in table 4.4. COMT (Catechol-O-methyltransferase) is a gene that produces
an enzyme that helps maintain appropriate levels of certain neurotransmitters such as
dopamine and norepinephrine at the prefrontal cortex. Most studies have focused on
the effects of a particular common variation in COMT, which alters a single protein
building block in the enzyme, replacing the amino acid Valine with the amino acid
Methionine subsequently affecting the enzyme’s ability to break down neurotransmit-
ters in the prefrontal cortex. Since dopamine has long been considered as central to
the pathophysiology of schizophrenia [373], COMT is a clear functional candidate
gene for Schizophrenia and has received a lot of research attention because its in-
volvement in the regulation of dopamine. For the same reason, the DRD2 and DRD3
gene are scored highly in the list because they encode the D3 and D2 subtypes out
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of the five (D1-D5) subtypes in dopamine receptors. Other top scored genes includ-
ing DISC1,MTHFR and PRODH are all thought to be associated with susceptibility
schizophrenia [374–376].
Interestingly, the two genes HTR3A and HTR3B were found in the schizophre-
nia disease environment, contributing to the enrichment of terms across all of the 8
ontologies with relatively low scores. HTR3A and HTR3B, both scored 0.188, were
associated to schizophrenia by OntoSuite-Miner based on 4 (2 each) GeneRIFs from
the GeneRIF database from 3 recent PubMed entries [377–379]. In humans, the two
genes encode two of the five subunits (HTR3A-E) of the 5-hydroxytryptamine recep-
tor 3 (HTR3), a group of G protein-coupled receptors (GPCRs) and ligand-gated ion
channels found in the central and peripheral nervous system that have been suggested
to play a role in the pathophysiology and treatment of schizophrenia [380, 381]. Vari-
ants of HTR3 genes have been associated with treatment outcomes of antipsychotics
in schizophrenia [381]. Genetic association studies have shown that the chromosome
11q22-24 region, which is enriched (p=2e−04) in the schizophrenia environment, is a
susceptibility locus for schizophrenia [382]. HTR3A and HTR3B are the two out of the
five HTR3 genes that located within the region of chromosome 11q23.1, which makes
them most interesting for schizophrenia studies. A case study with 140 schizophre-
nia patients taking clozapine (a medication that treats schizophrenia) for 6 months
revealed significant allelic association of clozapine response with three variants in the
HTR3A receptor and suggested that variants in the HTR3A receptor gene can play a
role in the treatment outcome of clozapine in schizophrenia patients that are refractory
or intolerant of atypical antipsychotic therapy [378]. Another study with 222 Korean
schizophrenia patients [377] found an association of the HTR3B with poor concen-
tration in schizophrenia patients, suggested that the HTR3B may be involved in the
attention problem of schizophrenia in the Korean population. These recent studies
consider a small number of subjects, thus the findings are preliminary and need to be
further validated. The high involvement of the HTR3A and HTR3B in the schizophre-
nia environment not only supports the importance of these two genes in schizophrenia,
but also suggests that low score genes might be important in the disease especially
when the low score is due to the fact that they come from very recent findings. Such
property of low scored genes in HDGDB is likely to be true for all diseases explored
in this way.
The top enriched pathway in the schizophrenia disease environment was ‘R-HSA-
438066 Unblocking of NMDA receptor, glutamate binding and activation’ (p=8.7e−
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DOID Disease Gene Score Score.o Score.g Score.v #Evidence (o/g/v)
1 DOID:5419 schizophrenia COMT 0.65 0.167 0.25 0.182 1/98/2
2 DOID:5419 schizophrenia DRD3 0.65 0.167 0.248 0.182 1/24/2
3 DOID:5419 schizophrenia DISC1 0.60 0.167 0.199 0.182 1/68/2
4 DOID:5419 schizophrenia MTHFR 0.60 0.167 0.199 0.167 1/29/1
5 DOID:5419 schizophrenia PRODH 0.59 0.167 0.194 0.197 1/7/15
6 DOID:5419 schizophrenia RTN4R 0.59 0.167 0.194 0.19 1/6/4
7 DOID:5419 schizophrenia DRD2 0.45 0 0.249 0.182 0/57/2
8 DOID:5419 schizophrenia ZNF804A 0.45 0 0.249 0.19 0/35/4
9 DOID:5419 schizophrenia AKT1 0.45 0.167 0.247 0 1/16/0
10 DOID:5419 schizophrenia TCF4 0.45 0 0.246 0.195 0/10/8
11 DOID:5419 schizophrenia NRG1 0.40 0.167 0.199 0 1/75/0
12 DOID:5419 schizophrenia DTNBP1 0.40 0.167 0.199 0 1/48/0
13 DOID:5419 schizophrenia DAOA 0.40 0.167 0.199 0 1/36/0
14 DOID:5419 schizophrenia HTR2A 0.40 0.167 0.199 0 1/28/0
15 DOID:5419 schizophrenia CACNA1C 0.40 0 0.197 0.194 0/12/6
16 DOID:5419 schizophrenia GRM3 0.40 0 0.198 0.167 0/18/1
17 DOID:5419 schizophrenia RELN 0.40 0 0.198 0.167 0/18/1
18 DOID:5419 schizophrenia DAO 0.40 0.167 0.197 0 1/14/0
19 DOID:5419 schizophrenia DGCR6 0.40 0 0.182 0.197 0/2/15
20 DOID:5419 schizophrenia ANK3 0.39 0 0.195 0.192 0/8/5
Table 4.5: Top scored gene-disease associations for schizophrenia in the Human Gene
Disease Database.
09). The neurotransmitter glutamate and the reduced function of the NMDA gluta-
mate receptor has been hypothesized in the pathophysiology of schizophrenia, which
was largely suggested by abnormally low levels of glutamate receptors found in post-
mortem brains of people previously diagnosed with schizophrenia [371] and the dis-
covery that glutamate blocking drugs can mimic the symptoms and cognitive problems
associated with schizophrenia [383]. The enriched pathway ‘R-HSA-977441 GABA
A receptor activation’ (p=4.7e−07) supports an alternative schizophrenia pathophys-
iology hypothesis which was recently proposed, that of dysfunction of interneurons
(GABAergic) in the brain. The GABAergic system is principally involved in the bal-
ance of excitation and inhibition in the brain. GABA is synthesized in 20-30% of
all central nervous system (CNS) neurons and is the primary transmitter at 25-50%
of synapses in mammalian brain. Its ubiquity means that almost all neurons express
GABA receptors, thus it is expected that most brain functions involve GABAergic
transmission [384]. GABA has three known classes of receptors: GABA-A, GABA-
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B and GABA-C receptors. GABA-A and GABAC receptors are ligand gated ion
channels (ionotropic), while the GABAB receptors are G-protein coupled receptors
(metabotropic). In particular, GABA-A receptors are the most complex of the three,
and play a critical role in brain development, facilitating neuronal migration and regu-
lating differentiation and synaptogenesis, and mediating both fast and tonic GABAer-
gic inhibition. Changes in the function and expression of these receptors have been
strongly implicated in schizophrenia [385–387] and their therapeutic potential has
been explored [388]. This was also captured by the schizophrenia environment by
the co-enrichment of terms from multiple ontologies including ‘GO:0004890 GABA-
A receptor activity’ (p=9.1e− 09), ‘GO:0045211 postsynaptic membrane’ (p=1e−
30), ‘GO:0030054 cell junction’ (p=1.0e− 25), ‘GO:0007268 synaptic transmission’
(p=1.5e−19), ‘GO:0042493 response to drug’ (p=1.5e−17), ‘R-HSA-975298 Ligand-
gated ion channel transport’ (p=2.1e−07) and ‘PC00023 GABA receptor’ (p=4.6e−
11). The precise role GABA plays in the pathogenesis of schizophrenia is not en-
tirely clear. However, GABA appears to have an effect on regulation of dopamine
levels in the brain, which is an inhibitory neurotransmitter involved in the pathology
of schizophrenia that is also enriched with 15 terms including ‘R-HSA-379397 Enzy-
matic degradation of dopamine by COMT’ (p=1.9e−2) and ‘GO:0042053 regulation
of dopamine metabolic process’ (p=7.0e− 07) (not shown in the Figure). There is a
growing body of research suggesting that GABA-dopamine interaction is responsible
for some symptoms of schizophrenia [389].
In terms of enriched chromosome sub bands, the non-random distribution of poly-
morphic loci associated with breast cancer [287] suggested that human chromosomes
are heterogeneous in structure and function. Schizophrenia is a common and seri-
ous psychiatric illness with strong evidence for genetic causation, thus chromosomal
abnormalities associated with schizophrenia may help to understand the genetic com-
plexity of the illness. It is observed in the schizophrenia disease environment that 22q1
chromosome sub band was the top enriched chromosome sub band for schizophrenia.
This is probably due to 22q11.2 deletion syndrome (22qDS), which is the only genetic
form of schizophrenia that is recurrent, clinically recognizable, and has confirmatory
genetic testing available [290]. Even though no single 22q11.2 deletion region is nec-
essary and sufficient for expressing the major features of 22qDS [390], a typical 3-Mb
hemizygous 22q11.2 deletion is most commonly associated with schizophrenia [391].
6p2 chromosome sub band was identified as the second enriched chromosome sub band
in the schizophrenia disease environment. Similar results have been found in [288]
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where 39 loci associated with schizophrenia risk were tested and the result revealed
that chromosome segments 6p21.1-p22.3 bear a significantly higher number of suscep-
tible loci. Furthermore, in 2011, a meta-analysis of genome-wide association studies
discovered that 129 out of 136 single-nucleotide polymorphisms (SNP) significantly
associated with schizophrenia were located in the major histocompatibility complex
(MHC) region which occurs on chromosome 6 from 6p22.1 to 6p21.3 [392]. Such as-
sociation of schizophrenia and the MHC complex suggests a connection of the disease
to the human immune system, which has been proposed recently as a novel hypoth-
esis of schizophrenia pathophysiology [393, 394]. Chromosome sub band 5q2, 11q2
and 9p2 were enriched, where 22, 46 and 19 genes were associated with schizophre-
nia but there is no evidence found in the literature that statistically tests these regions
for schizophrenia susceptibility. Such results suggest possible novel chromosome sub
bands for schizophrenia susceptibility but further investigations is needed , for exam-
ple, using genetic screening methods to find and compare mutations in the genes found
in these sub bands between people with and without schizophrenia.
The enrichment of HDO terms highlighted a similar genetic signature between
these diseases and schizophrenia. ‘DOID:3312 bipolar disorder’, ‘DOID:1094 atten-
tion deficit hyperactivity disorder’, ‘DOID:12849 autistic disorder’ and ‘DOID:1470
major depressive disorder’ are all mental disorders with symptoms similar to those
seen in schizophrenia. Roughly 50% of the genes annotated to these diseases were also
associated with schizophrenia, indicating a large shared underlying molecular mecha-
nisms for these diseases. Such overlapping also result in the overlap of shared/similar
clinical features/symptoms that make diagnostically differentiating between these dis-
eases difficult. For example, childhood-onset schizophrenia (COS), considered a rare
and severe form of schizophrenia, frequently presents with premorbid developmental
abnormalities that exhibit clinical features includes deficits in communication, social
relatedness, and motor development, similar to those seen in autism spectrum disor-
ders. ‘Schizoaffective disorder’, which is an intermediate diagnosis for patient has
features of both schizophrenia and a mood disorder, either bipolar disorder or depres-
sion, but does not strictly meet diagnostic criteria for either alone.
4.2.3 Exploration of connection between human disease
In order to explore the inter connection between diseases, I defined NA,B to be the
number of times disease A and disease B found enriched at the same time among the
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top 5 diseases in a gene class. I calculated N for each enriched disease pair in the
277 gene classes tested, a summary of results (N > 5) where is shown in fig. 4.10.
Interestingly, it is observed that some disease groups were enriched together more often
than others. ‘immune system disease’ was found to coexist with a range of diseases
including ‘gastrointestinal system disease’(N = 19) and ‘viral infectious disease’(N =
18), reflecting the importance of the immune system. ‘cancer’ was enriched together
with ‘benign neoplasm’(18), ‘disease of cellular proliferation’(8) and ‘pre-malignant
neoplasm’(8). These observations identify a group of closely related diseases, some
of which are well known to be connected while others are clinically distinct diseases.
Coexistence suggests that diseases may have a similar or share common underlying
molecular mechanisms.
Even through the annotation of the 277 gene classes was created separately by the
corresponding ontology consortium, the disease profile shows a consistent result for
similar gene classes across different ontologies. This overlap is mostly between PCO
and RPO. For instance, in the gene class group level (level 2 ontology terms), recall that
I defined PD,G which is an indication of a disease D being consistently enriched across
group G, there are Pcancer,signalingmolecule = 100% in PCO vs Pcancer,SignalTransduction =
83% in RPO. In the gene class level(level 3 ontology term), ‘neural tube defect’ was
enriched in PCO ‘methyltransferase’ and in RPO including ‘Metabolism of vitamins
and cofactors’ and ‘Biological oxidations’. Such consistency increases confidence in
disease mechanisms, as well as the utility of the HDGDB disease annotation database.
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Figure 4.10: The number of co-existing disease pairs among the top enriched diseases
between the 277 gene classes.
4.3 Conclusions
In the above section, I used disease enrichment analysis with the created gene disease
annotation, HDGDB, to profile 277 gene classes, constructed from level 3 ontology
terms from the three ontologies including CO, PCO and RPO. The results, firstly, pro-
vided an overview of the importance/involvement of each gene class in the context
of human disease, in which most of them make biological sense and were supported
in the literature; and secondly, demonstrated that the integration of disease data and
other divergent information can recover well known disease knowledge as well as give
potentially new insight into some of the less well known diseases.
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Similarly, I explored the molecular basis of human diseases, created a ‘disease
environment’, with the top 5 enriched terms in each ontology, for each of the 1310
human disease with 8 ontologies including 1) RPO, 2) PCO, 3) CO, 4) HPO, 5) HDO
and the three ontologies from the Gene Ontology namely GOBP (Biological Process),
GOMF (Molecular Function) and GOCC (Cellular Component). In particular, I pre-
sented the disease environment for two diseases, ‘breast cancer’ and ‘schizophrenia’.
A lot of important aspects of the two disease were inspected, discussed and supported
by literature. The result suggests that the integration of multiple biological ontolo-
gies is potentially more powerful than using single one and the ‘disease environment’
is an interesting analytical approach to systematically gather knowledge for disease
with the potential of gaining new insight into the disease mechanisms by transferring
knowledge from other close related diseases.
Individual gene level statistics were not discussed in this section because the level
3 ontology terms are aggregated from their child terms. For example, for disease an-
notation, the term ‘cancer’ contains all the genes that were annotated to different types
of cancer, including those genes that only affect specific types of cancer. Thus, ‘can-
cer’ is a representation of all known cancer related genes in the HDGDB data; while
for the protein class ‘cytokine’, it contains annotation from sub protein classes includ-
ing ‘TGF-beta superfamily member’, ‘chemokine’ and ‘tumor necrosis factor family
member’. The disease profiling is intended to generate an overview of the tested gene
class. For the same reason, there is a lot of confirmatory (expected), but not novel,
observations in the disease profiles. However, it is expected that more insightful re-




Ontologies are semantic frameworks upon which biological data can be structured and
have grown to be one of the great enabling technologies of modern bioinformatics.
The transformation of unstructured to structured data using data mapped to ontologies
has largely been achieved in a time-consuming manner which relies on human experts.
Such manual data curation is accurate but hard to scale and unable to keep pace with
the rapid expansion and refinement of both ontologies and the data that we would like
to annotate to them. Many bioinformatic tools only support analysis using the Gene
Ontology because it is the best annotated and is the most widely used and cited. The
delay annotating new ontologies and the lack of support for them in existing analyti-
cal tools to aid biological interpretation of data has become a major limitation to their
utility and uptake. The work presented in this thesis aimed to develop automatic ap-
proaches to facilitate the transformation of unstructured data to unlock the potential
of all ontologies, with corresponding bioinformatics tools to support their interpre-
tation. The proposed OntoSuite framework, provided not only the transformation of
unstructured data to ontology base data using scalable text mining approaches, but also
the corresponding bioinformatics tools to support the usage of the resulting ontology
based annotation. Human disease ontology was used to defenestrate the functionali-
ties of the framework but the usage of the framework is not limited to any particular
ontology. In this concluding chapter, I will discuss briefly the value and limitations of
the work presented, together with a speculative discussion on possible improvements.
More in depth discussion of limitations can be found in the conclusion section of each
chapter.
In chapter 1 on page 1, I introduced the importance and the challenges of trans-
forming unstructured biological data into ontology based annotation and reviewed re-
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lated work in the field that contributed to the challenge. The motivation of the work
presented in the thesis was summarized.
In chapter 2 on page 33, I proposed the first part of the OntoSuite framework
named OntoSuite-Miner, which uses natural language processing approaches for the
integration of biological text corpora onto unifying ontologies that structurally repre-
sent biological information across a whole host of domains. Two of the most com-
monly used nature language processing toolkits in the bio-text mining domain, namely
Metamap(MeM) and NCBO Annotator(NcA) were integrated into OntoSuite-Miner,
with the possibility of adding extra annotators such as the Concept Mapper. The
performance of OntoSuite-Miner was evaluated using manually curated GWAS data
which result in a better F score than using MeM and NcA alone, indicating the benefit
of the integration. Three publicly available biomedical databases, OMIM, GeneRIF
and Ensembl Variation, and created a human gene disease annotation dataset, named
HDGDB, with the Human disease ontology (HDO). Scores were assigned to each gene
disease annotation based on the evidences from the three data sources. All of the sup-
porting evidence is linked to the corresponding gene disease association, allowing the
user to trace back to the original source of information and to explore the association in
its original context. These aspects are of crucial importance in evaluating the evidence
supporting a scientific assertion, in order to determine its relevance in the user con-
text. Due to the fact that the annotation was automatically generated based on natural
language processing algorithms, errors are inevitable. Thus, I assessed and evaluated
HDGDB, and discussed limitations of the approach and the possible future improve-
ments. Since biomedical databases are regularly updated, OntoSuite-Miner can be
configured to update automatically so that the annotation database can be kept up to
date. OntoSuite-Miner has been implemented and applied to generated Human Disease
Ontology(HDO) annotation via publicly available bio-medical text corpus. However,
the usage of OntoSuite-Miner is not limited to HDO. The advantage of the framework
is that it allows the creation of any ontology based annotation given a proper text cor-
pus. This functionality, to a certain degree, facilitates the usage of some of the less
used ontologies and enables the usage of customized ontologies in gene annotation.
In chapter 3 on page 113, I reviewed the different statistical methods used in
the enrichment analysis and proposed the second half of the OntoSuite framework,
OntoSuite-Analytics, which integrates a collection of enrichment analysis methods into
a unified R package named topOnto. The package supports enrichment analysis across
multiple ontologies with a set of implemented statistical/topological algorithms, allow-
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ing comparison of enrichment result across multiple ontologies. Besides the standard
over-represent enrichment analysis methods and GSEA, I also proposed the GSEA-
CSW algorithm which takes into account a annotation confident score when calculating
the enrichment p-value. The algorithm was particularly designed for gene set enrich-
ment analysis when the back-end annotation data are scored, such as those generated
in HDGDB. Validation of the algorithm was performed on simulated gene expression
data. The result indicated that the GSEA-CSW performs as good as the original GSEA
algorithm, and it is able to capture the different of annotation confidence score when
they are available. Limitations of OntoSuite-Analytics and possible future work was
also discussed at the end of chapter 3 on page 113.
In chapter 4 on page 149, I systemically profiled human genes with human diseases
using HDGDB and OntoSuite-Miner. I demonstrated the value of integrating multiple
ontologies into enrichment analysis, showing how orthogonal ontologies can improve
the interpretation of biological data which would have been missed by using a single
ontology.
5.1 Limitations and future work
A few points about the implementation and methodology need further discussion and
improvement. The current version of OntoSuite-Miner only returns a binary connec-
tion between entities in the text corpus. Thus it can not provide information about
the level of certainty between the entities. In other words, the same link between
gene A and disease B will be constructed for the following three texts: 1) ‘Gene A
is associated with disease B’, 2) ‘Gene A might be associated with disease B’ and 3)
‘Gene A is over expressed in disease B’. Several approaches have been proposed to
overcome the problem in the field of relation extraction (RE) including rule-based ap-
proaches [133,234], co-occurrence based statistic approaches [154,235,236], machine
learning [45, 237–240], NLP-based systems [241, 242]. Integrating one or a few of
these approaches to OntoSuite-Miner would allow the capture of an extra layer of data
and could potentially increase the usefulness of the resulting gene annotation data.
In addition, OntoSuite-Miner implements two of the most commonly used nature
language processing toolkits in the bio-text mining domain, namely Metamap and
NCBO Annotator. A bio-text/ontology mapping is considered more reliable if it is
agreed upon by both concept recognizers simultaneously. Under this rationale, it is
possible to add more concept recognizer modules into the framework. One possible
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alternative is the Concept Mapper [147], which is a tool that was not specifically de-
veloped for biomedical term recognition but performs very well in biomedical text
mining tasks base on the review by Funk et.al. [144]. With extra concept recognizer
modules, OntoSuite-Miner could potentially generate more accurate results, which in
turn benefits downstream analysis. What’s more, since NCBO is the central reposi-
tory for bioontologies, it would be useful to synchronize ontologies with NCBO and
automatically add them into the OntoSuite framework. This would greatly increase
the number of supported ontologies and ease the burden for users for parsing/loading
ontologies into the framework.
A confidence score has been implemented, indicating the level of certainty of each
gene disease association(GDA) generated from OntoSuite-Mner. The score takes into
account the number of sources, the amount of evidence that supports the association
and the number of annotators that identified the association. It provides a way to
rank/weight the associations based on the evidence and assists in the prioritization
and navigation of the GDAs. In the current implementation, the sources are equally
weighted, which is not a true reflection of the quality of the source. For example, gene
disease associations identified in GeneRIF are likely to be less precise than a human cu-
rated sources such as OMIM. However, it is not obvious how to weight theses sources
when no training data is available to estimate the weight. Thus, a better estimation of
the GDA score can be achieved when such data become available.
What’s more, In section 2.2.2, genes were linked to diseases by SNP based on their
location on the chromosome. Currently, the closest up/down stream and the overlap-
ping genes of a SNP were linked to the disease/phenotype via the SNP. The reason
of including the closest up/down stream blindly is due to the lack of understanding of
non-coding genome. As the improvement of screening technology, the functions of
non-coding region are being revealed. The gene-SNP mapping could be improved as
such data become available. For example, gene can be weighted by different factors
regarding the relation of the gene to the SNP. A higher weighted could be assign to the
gene-SNP mapping If the SNP is located in the regulatory region of the gene.
There are other aspects of the implementation that could be improved regarding
OntoSuite-Analytics. First of all, topOnto is currently implemented in R, which re-
quires users to have some experience of programming or using the command line. It
would be more convenient to provide a user friendly web interface for the user to sim-
ply upload their gene list, choose the algorithm and get the results without needing to
consider the code.
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Secondly, the newly implemented GSEA-CSW method was implemented, and
tested only with syntactic data.. This is because evaluating the performance of the
algorithm is difficult due the absence of gold standards. In [16], Huang et.al devel-
oped a method to evaluate different enrichment methods on a data set generated by
randomly shuffling the phenotype labels of an experimental data set. The rationale
behind the method is that a gene set deemed significantly enriched by more statistical
methods is less likely to be false than a gene set deemed significant by fewer statis-
tic methods. An MC (mutual coverage) score is computed for each statistical method
against others representing the degree of mutually identified enriched gene set between
them. This methods cannot be directly applied to evaluate GSEA-CSW due to the lack
of standard weighted annotation data. GSEA-CSW is a modified version of the orig-
inal GSEA algorithm, which itself has been carefully tested. The difference between
the GSEA and GSEA-CSW is that GSEA-CSW changes the step length based on the
annotation score, thus increasing the contribution of highly weighted genes in the en-
richment analysis. A scaling factor λ was introduced in the algorithm to control the
magnitude of the effect of the annotation score, but the optimized value of λ was not
determined. It is still unclear how this value can be estimated due to the complicity of
real biological data, thus further work is needed to estimate the λ.
Thirdly, the well recognized multiple hypothesis testing problem [55,90,94–97] is
not solved in OntoSuite-Analytics. This is because the multiple hypothesis correction
itself is still an open research question and it has a relatively small impact compared to
other factors that affect enrichment analysis, such as the topology algorithm or back-
ground annotation data used. The independent test assumption does not fit into the
enrichment test where terms are interconnected in an ontology. As a result, the current
implementation of topOnto returns the raw p-values as a result but provides options for
the user to choose predefined multiple hypothesis correction methods based on their
needs. If the user aims to find out a set of enriched processes for further experimental
validation, then a simple Bonferroni correction could be applied to produce the most
conservative result to prevent false positive results being tested further in expensive
biological experiments. If the analysis is more of exploratory and the genes under test
have a complicated correlation, then it is more appropriate to use, for example, the
Benjamini-Yekutieli(2001) [119] FDR correction.
It has been shown (see section 2.3.4.5) in this thesis that background annotation
data greatly affects the enrichment results, and proper pre-processing of the back-
ground can lead to a reduction of false positives in the result. This is the case for
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‘clip’ ontologies where an even more domain specific subset of the ontology is created
and used instead of the full ontology. However, the clipping process proposed in [37]
requires human experts to manually inspect the ontology and choose appropriate terms,
which is difficult and time-consuming. Thus it would be interested to develop auto-
matic methods to achieve the clipping process, which in turns improves the enrichment
analysis.
Last but not least, topOnto uses topology awareness algorithms to estimate the
enrichment p-value, thus it can be computational intensive for certain types of statistic-
topology method combinations. For standard over-representation hypergeometric tests,
topOnto usually returns the result within about a minute depending on the size of the
ontology. However, the process can be very slow for the GSEA and GSEA-CSW al-
gorithm when using the elim topology method, ranging from hours to days depending
on the number of samples and the number of permutations required. This limits the
usage of the algorithm despite its advantages at the statistical level, for example, it
can not be used on the fly as a web tool. Further optimization is need to speed up the
algorithm. One possible approach would be to parallelize part of the processing. The
elim algorithm considers one level of ontology terms at a time and the result affects the
next level of terms, thus within one level, the algorithm is parallelisable. However, the
cost of dividing/distributing the task, and merging the results needs to be calculated
and tested further to prove that it is possible and efficacious.
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A.4 Enrichment analysis results of the ARC complex
TERM.ID Term Level classic elim weight01 parentchild
HP:0100753 Schizophrenia 7 7.7e-20 7.7e-20 7.7e-20 2.9e-07
HP:0012638 Abnormality of nervous system physiology 5 7.0e-16 0.42183 1.00000 9.4e-07
HP:0000708 Behavioral abnormality 6 7.1e-15 0.67728 1.00000 0.00426
HP:0001250 Seizures 6 7.1e-12 4.4e-09 2.5e-08 5.2e-06
HP:0000707 Abnormality of the nervous system 4 1.8e-10 0.80585 1.00000 1.9e-10
HP:0012639 Abnormality of nervous system morphology 5 2.4e-07 0.17432 1.00000 0.09045
HP:0002011 Morphological abnormality of the central... 6 5.4e-07 0.15205 1.00000 0.53314
HP:0001298 Encephalopathy 6 6.0e-07 0.00327 0.01815 0.00028
HP:0002529 Neuronal loss in central nervous system 8 6.3e-06 6.3e-06 6.3e-06 0.00019
HP:0012823 Clinical modifier 3 2.0e-05 0.01382 1.00000 2.0e-05
(a) classic
TERM.ID Term Level classic elim weight01 parentchild
HP:0100753 Schizophrenia 7 7.7e-20 7.7e-20 7.7e-20 2.9e-07
HP:0001250 Seizures 6 7.1e-12 4.4e-09 2.5e-08 5.2e-06
HP:0002529 Neuronal loss in central nervous system 8 6.3e-06 6.3e-06 6.3e-06 0.00019
HP:0200134 Epileptic encephalopathy 7 3.7e-05 3.7e-05 3.7e-05 0.34006
HP:0003745 Sporadic 4 7.0e-05 7.0e-05 7.0e-05 0.01010
HP:0000726 Dementia 9 0.00015 0.00015 0.00058 0.01383
HP:0002511 Alzheimer disease 7 0.00021 0.00021 0.00021 0.09168
HP:0007105 Infantile encephalopathy 7 0.00045 0.00045 0.00045 0.29452
HP:0002539 Cortical dysplasia 11 0.00057 0.00057 0.00057 0.32578
HP:0000733 Stereotypic behavior 7 0.00070 0.00070 0.00070 0.00442
(b) elim
TERM.ID Term Level classic elim weight01 parentchild
HP:0100753 Schizophrenia 7 7.7e-20 7.7e-20 7.7e-20 2.9e-07
HP:0001250 Seizures 6 7.1e-12 4.4e-09 2.5e-08 5.2e-06
HP:0002529 Neuronal loss in central nervous system 8 6.3e-06 6.3e-06 6.3e-06 0.00019
HP:0200134 Epileptic encephalopathy 7 3.7e-05 3.7e-05 3.7e-05 0.34006
HP:0003745 Sporadic 4 7.0e-05 7.0e-05 7.0e-05 0.01010
HP:0002511 Alzheimer disease 7 0.00021 0.00021 0.00021 0.09168
HP:0007105 Infantile encephalopathy 7 0.00045 0.00045 0.00045 0.29452
HP:0002539 Cortical dysplasia 11 0.00057 0.00057 0.00057 0.32578
HP:0000726 Dementia 9 0.00015 0.00015 0.00058 0.01383
HP:0000733 Stereotypic behavior 7 0.00070 0.00070 0.00070 0.00442
(c) weight01
TERM.ID Term Level classic elim weight01 parentchild
HP:0000707 Abnormality of the nervous system 4 1.8e-10 0.80585 1.00000 1.9e-10
HP:0100753 Schizophrenia 7 7.7e-20 7.7e-20 7.7e-20 2.9e-07
HP:0012638 Abnormality of nervous system physiology 5 7.0e-16 0.42183 1.00000 9.4e-07
HP:0001250 Seizures 6 7.1e-12 4.4e-09 2.5e-08 5.2e-06
HP:0012823 Clinical modifier 3 2.0e-05 0.01382 1.00000 2.0e-05
HP:0000005 Mode of inheritance 3 7.5e-05 0.01812 0.32023 7.5e-05
HP:0002529 Neuronal loss in central nervous system 8 6.3e-06 6.3e-06 6.3e-06 0.00019
HP:0001298 Encephalopathy 6 6.0e-07 0.00327 0.01815 0.00028
HP:0100547 Abnormality of forebrain morphology 8 5.4e-05 1.00000 1.00000 0.00339
HP:0011355 Localized skin lesion 6 0.00592 0.28545 1.00000 0.00373
(d) parentchild
Table A1: ARC complexes HPO enrichment result
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TERM.ID Term Level classic elim weight01 parentchild
R-HSA-112315 Transmission across Chemical Synapses 3 4.2e-18 0.05137 1.00000 0.00458
R-HSA-112316 Neuronal System 2 3.2e-16 0.04956 1.00000 3.2e-16
R-HSA-438066 Unblocking of NMDA receptor, glutamate... 6 7.5e-13 7.5e-13 7.5e-13 0.00264
R-HSA-442755 Activation of NMDA receptor upon glutama... 5 4.6e-11 0.13060 1.00000 0.00137
R-HSA-112314 Neurotransmitter Receptor Binding And Do... 4 3.0e-10 0.03488 1.00000 0.86560
R-HSA-442729 CREB phosphorylation through the activat... 7 2.2e-09 2.2e-09 2.2e-09 0.01584
R-HSA-442742 CREB phosphorylation through the activat... 7 3.0e-09 0.08115 1.00000 0.13206
R-HSA-442982 Ras activation uopn Ca2+ infux through N... 8 5.4e-09 5.4e-09 5.4e-09 0.16126
R-HSA-399719 Trafficking of AMPA receptors 6 6.8e-09 5.1e-06 5.1e-06 1.00000
R-HSA-399721 Glutamate Binding, Activation of AMPA Re... 5 6.8e-09 1.00000 1.00000 0.00720
(a) classic
TERM.ID Term Level classic elim weight01 parentchild
R-HSA-438066 Unblocking of NMDA receptor, glutamate... 6 7.5e-13 7.5e-13 7.5e-13 0.00264
R-HSA-442729 CREB phosphorylation through the activat... 7 2.2e-09 2.2e-09 2.2e-09 0.01584
R-HSA-442982 Ras activation uopn Ca2+ infux through N... 8 5.4e-09 5.4e-09 5.4e-09 0.16126
R-HSA-5578775 Ion homeostasis 4 1.5e-08 1.5e-08 1.5e-08 0.00181
R-HSA-936837 Ion transport by P-type ATPases 4 2.8e-08 2.8e-08 2.8e-08 0.00753
R-HSA-5682910 LGI-ADAM interactions 3 1.0e-07 1.0e-07 1.0e-07 1.8e-05
R-HSA-399719 Trafficking of AMPA receptors 6 6.8e-09 5.1e-06 5.1e-06 1.00000
R-HSA-888590 GABA synthesis, release, reuptake and de... 5 1.2e-08 7.3e-06 0.00017 0.02655
R-HSA-210500 Glutamate Neurotransmitter Release Cycle 5 5.9e-05 5.9e-05 5.9e-05 0.60134
R-HSA-389957 Prefoldin mediated transfer of substrate... 6 8.2e-05 8.2e-05 8.2e-05 0.47513
(b) elim
TERM.ID Term Level classic elim weight01 parentchild
R-HSA-438066 Unblocking of NMDA receptor, glutamate b... 6 7.5e-13 7.5e-13 7.5e-13 0.00264
R-HSA-442729 CREB phosphorylation through the activat... 7 2.2e-09 2.2e-09 2.2e-09 0.01584
R-HSA-442982 Ras activation uopn Ca2+ infux through N... 8 5.4e-09 5.4e-09 5.4e-09 0.16126
R-HSA-5578775 Ion homeostasis 4 1.5e-08 1.5e-08 1.5e-08 0.00181
R-HSA-936837 Ion transport by P-type ATPases 4 2.8e-08 2.8e-08 2.8e-08 0.00753
R-HSA-5682910 LGI-ADAM interactions 3 1.0e-07 1.0e-07 1.0e-07 1.8e-05
R-HSA-399719 Trafficking of AMPA receptors 6 6.8e-09 5.1e-06 5.1e-06 1.00000
R-HSA-210500 Glutamate Neurotransmitter Release Cycle 5 5.9e-05 5.9e-05 5.9e-05 0.60134
R-HSA-389957 Prefoldin mediated transfer of substrate... 6 8.2e-05 8.2e-05 8.2e-05 0.47513
R-HSA-77387 Insulin receptor recycling 4 8.2e-05 8.2e-05 8.2e-05 0.01819
(c) weight01
TERM.ID Term Level classic elim weight01 parentchild
R-HSA-112316 Neuronal System 2 3.2e-16 0.04956 1.00000 3.2e-16
R-HSA-382551 TM transport of small molecul... 2 2.0e-07 0.02895 1.0000 2.0e-07
R-HSA-1266738 Developmental Biology 2 1.1e-06 0.44056 1.00000 1.1e-06
R-HSA-74752 Signaling by Insulin receptor 3 2.8e-06 1.00000 1.00000 1.2e-06
R-HSA-5682910 LGI-ADAM interactions 3 1.0e-07 1.0e-07 1.0e-07 1.8e-05
R-HSA-397014 Muscle contraction 2 6.7e-05 0.70095 1.00000 6.7e-05
R-HSA-2586552 Signaling by Leptin 3 0.00026 1.00000 1.00000 0.00026
R-HSA-5673001 RAF/MAP kinase cascade 8 0.00020 0.00020 0.00028 0.00043
R-HSA-194138 Signaling by VEGF 3 0.00059 0.54018 1.00000 0.00056
R-HSA-177929 Signaling by EGFR 3 0.00091 0.60478 1.00000 0.00087
(d) parentchild
Table A2: ARC complexes RECTOMEPATHWAY enrichment result
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TERM.ID Term Level classic elim weight01 parentchild
GO:0007268 synaptic transmission 9 1.4e-28 3.0e-10 7.9e-09 1.00000
GO:0099536 synaptic signaling 7 1.4e-28 1.00000 1.00000 5.0e-07
GO:0099537 trans-synaptic signaling 8 1.4e-28 1.00000 1.00000 1.00000
GO:0007267 cell-cell signaling 6 5.2e-23 0.38090 0.25777 7.1e-16
GO:0006811 ion transport 7 8.5e-21 0.38187 1.00000 9.4e-09
GO:0050804 modulation of synaptic transmission 10 8.6e-16 0.00010 0.06192 2.6e-09
GO:0030001 metal ion transport 9 6.2e-15 0.14213 1.00000 0.04726
GO:0034220 ion transmembrane transport 8 7.8e-15 0.00465 0.00014 0.04620
GO:0006812 cation transport 8 1.3e-14 0.08283 1.00000 0.46859
GO:0055085 transmembrane transport 7 2.2e-14 0.04115 0.03305 3.3e-11
(a) classic
TERM.ID Term Level classic elim weight01 parentchild
GO:0007268 synaptic transmission 9 1.4e-28 3.0e-10 7.9e-09 1.00000
GO:0035235 ionotropic glutamate receptor signaling ... 9 7.0e-09 7.0e-09 7.0e-09 0.02103
GO:0035249 synaptic transmission, glutamatergic 11 2.4e-08 2.4e-08 3.3e-08 0.39242
GO:0015991 ATP hydrolysis coupled proton transport 13 2.4e-08 2.4e-08 2.4e-08 1.00000
GO:0036376 sodium ion export from cell 13 5.3e-08 5.3e-08 2.4e-07 0.27778
GO:0030007 cellular potassium ion homeostasis 11 1.1e-07 1.1e-07 1.1e-07 2.1e-05
GO:0006883 cellular sodium ion homeostasis 11 7.3e-07 7.3e-07 7.3e-07 0.00013
GO:0010107 potassium ion import 13 1.1e-06 1.1e-06 2.8e-05 0.00052
GO:0033572 transferrin transport 13 1.9e-06 1.9e-06 1.9e-06 2.1e-05
GO:0007612 learning 8 1.3e-10 4.1e-06 4.8e-07 0.01308
(b) elim
TERM.ID Term Level classic elim weight01 parentchild
GO:0035235 ionotropic glutamate receptor signaling ... 9 7.0e-09 7.0e-09 7.0e-09 0.02103
GO:0007268 synaptic transmission 9 1.4e-28 3.0e-10 7.9e-09 1.00000
GO:0015991 ATP hydrolysis coupled proton transport 13 2.4e-08 2.4e-08 2.4e-08 1.00000
GO:0035249 synaptic transmission, glutamatergic 11 2.4e-08 2.4e-08 3.3e-08 0.39242
GO:0030007 cellular potassium ion homeostasis 11 1.1e-07 1.1e-07 1.1e-07 2.1e-05
GO:0036376 sodium ion export from cell 13 5.3e-08 5.3e-08 2.4e-07 0.27778
GO:0007612 learning 8 1.3e-10 4.1e-06 4.8e-07 0.01308
GO:0006883 cellular sodium ion homeostasis 11 7.3e-07 7.3e-07 7.3e-07 0.00013
GO:0033572 transferrin transport 13 1.9e-06 1.9e-06 1.9e-06 2.1e-05
GO:0086064 cell communication by electrical couplin... 11 4.4e-06 4.4e-06 4.4e-06 0.04663
(c) weight01
TERM.ID Term Level classic elim weight01 parentchild
GO:0007267 cell-cell signaling 6 5.2e-23 0.38090 0.25777 7.1e-16
GO:0055085 transmembrane transport 7 2.2e-14 0.04115 0.03305 3.3e-11
GO:1902578 single-organism localization 4 5.1e-14 0.95988 1.00000 5.1e-11
GO:0051179 localization 3 7.3e-10 0.93114 1.00000 7.3e-10
GO:0050804 modulation of synaptic transmission 10 8.6e-16 0.00010 0.06192 2.6e-09
GO:0023052 signaling 3 3.1e-09 0.90943 1.00000 3.1e-09
GO:0006811 ion transport 7 8.5e-21 0.38187 1.00000 9.4e-09
GO:0044763 single-organism cellular process 4 7.2e-10 0.23259 1.00000 1.7e-08
GO:0007399 nervous system development 7 1.1e-09 0.00447 0.08974 2.3e-08
GO:0044708 single-organism behavior 4 1.1e-08 0.53844 1.00000 1.2e-07
(d) parentchild
Table A3: ARC complexes GOBP enrichment result
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TERM.ID Term Level classic elim weight01 parentchild
GO:0097458 neuron part 5 5.8e-18 0.01328 1.00000 9.2e-17
GO:0043005 neuron projection 6 1.3e-17 0.01162 0.00290 4.1e-05
GO:0071944 cell periphery 5 1.8e-16 0.19275 1.00000 1.6e-14
GO:0098805 whole membrane 4 2.7e-16 0.45342 1.00000 3.0e-10
GO:0042995 cell projection 5 8.6e-16 0.06371 0.37528 1.6e-14
GO:0098590 plasma membrane region 8 2.1e-15 1.00000 1.00000 2.9e-07
GO:0045202 synapse 3 3.8e-15 0.04574 0.01386 3.8e-15
GO:0098589 membrane region 5 4.4e-15 0.18066 1.00000 2.8e-10
GO:0005886 plasma membrane 6 7.3e-15 5.8e-06 1.1e-05 1.4e-13
GO:0031982 vesicle 4 8.1e-15 0.13391 0.00601 7.3e-14
(a) classic
TERM.ID Term Level classic elim weight01 parentchild
GO:0045211 postsynaptic membrane 10 8.4e-12 8.4e-12 8.4e-12 0.16211
GO:0030054 cell junction 3 3.2e-13 4.3e-11 1.0e-14 3.2e-13
GO:0070062 extracellular exosome 7 4.9e-10 4.9e-10 4.9e-10 0.71396
GO:0030666 endocytic vesicle membrane 12 4.6e-09 4.6e-09 7.4e-08 2.1e-05
GO:0097481 neuronal postsynaptic density 7 5.5e-08 5.5e-08 5.5e-08 0.00011
GO:0008021 synaptic vesicle 11 3.2e-07 3.2e-07 2.4e-06 0.00651
GO:0005890 sodium:potassium-exchanging ATPase... 10 3.8e-07 3.8e-07 3.8e-07 2.1e-05
GO:0014069 postsynaptic density 6 8.7e-12 2.2e-06 2.2e-06 2.6e-11
GO:0005886 plasma membrane 6 7.3e-15 5.8e-06 1.1e-05 1.4e-13
GO:0043197 dendritic spine 8 8.6e-07 1.2e-05 1.0e-05 0.01363
(b) elim
TERM.ID Term Level classic elim weight01 parentchild
GO:0030054 cell junction 3 3.2e-13 4.3e-11 1.0e-14 3.2e-13
GO:0045211 postsynaptic membrane 10 8.4e-12 8.4e-12 8.4e-12 0.16211
GO:0070062 extracellular exosome 7 4.9e-10 4.9e-10 4.9e-10 0.71396
GO:0097481 neuronal postsynaptic density 7 5.5e-08 5.5e-08 5.5e-08 0.00011
GO:0030666 endocytic vesicle membrane 12 4.6e-09 4.6e-09 7.4e-08 2.1e-05
GO:0005890 sodium:potassium-exchanging ATPase... 10 3.8e-07 3.8e-07 3.8e-07 2.1e-05
GO:0014069 postsynaptic density 6 8.7e-12 2.2e-06 2.2e-06 2.6e-11
GO:0008021 synaptic vesicle 11 3.2e-07 3.2e-07 2.4e-06 0.00651
GO:0043197 dendritic spine 8 8.6e-07 1.2e-05 1.0e-05 0.01363
GO:0005886 plasma membrane 6 7.3e-15 5.8e-06 1.1e-05 1.4e-13
(c) weight01
TERM.ID Term Level classic elim weight01 parentchild
GO:0097458 neuron part 5 5.8e-18 0.01328 1.00000 9.2e-17
GO:0045202 synapse 3 3.8e-15 0.04574 0.01386 3.8e-15
GO:0044456 synapse part 4 1.5e-14 1.00000 1.00000 1.5e-14
GO:0042995 cell projection 5 8.6e-16 0.06371 0.37528 1.6e-14
GO:0071944 cell periphery 5 1.8e-16 0.19275 1.00000 1.6e-14
GO:0031982 vesicle 4 8.1e-15 0.13391 0.00601 7.3e-14
GO:0005886 plasma membrane 6 7.3e-15 5.8e-06 1.1e-05 1.4e-13
GO:0030054 cell junction 3 3.2e-13 4.3e-11 1.0e-14 3.2e-13
GO:0098794 postsynapse 5 6.6e-14 1.00000 1.00000 4.6e-13
GO:0031988 membrane-bounded vesicle 5 5.9e-14 0.49712 1.00000 6.4e-13
(d) parentchild
Table A4: ARC complexes GOCC enrichment result
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TERM.ID Term Level classic elim weight01 parentchild
GO:0022891 substrate-specific transmembrane transpo... 5 1.7e-15 0.49631 1.00000 0.00111
GO:0015075 ion transmembrane transporter activity 6 1.9e-15 0.75058 1.00000 0.33200
GO:0022890 inorganic cation transmembrane transport... 8 2.4e-15 1.00000 1.00000 0.00936
GO:0022857 transmembrane transporter activity 4 2.1e-14 0.60800 1.00000 0.00038
GO:0022892 substrate-specific transporter activity 4 8.3e-14 0.66654 1.00000 0.00192
GO:0008324 cation transmembrane transporter activit... 7 1.6e-13 1.00000 1.00000 0.29821
GO:0015077 monovalent inorganic cation transmembran... 9 3.2e-12 0.00026 1.00000 0.36195
GO:0022804 active transmembrane transporter activit... 5 5.2e-12 0.04140 1.00000 0.00571
GO:0019829 cation-transporting ATPase activity 14 6.5e-12 0.02009 1.00000 6.1e-05
GO:0042625 ATPase activity, coupled to transmembran... 13 9.0e-12 1.00000 1.00000 4.1e-05
(a) classic
TERM.ID Term Level classic elim weight01 parentchild
GO:0005234 extracellular-glutamate-gated ion channe... 12 1.3e-09 1.3e-09 1.3e-09 0.00194
GO:0005391 sodium:potassium-exchanging ATPase activ... 16 9.8e-08 9.8e-08 9.8e-08 0.00118
GO:0023026 MHC class II protein complex binding 7 2.5e-06 2.5e-06 2.5e-06 1.00000
GO:0004972 NMDA glutamate receptor activity 12 1.3e-05 1.3e-05 1.3e-05 0.33591
GO:0019901 protein kinase binding 7 2.8e-05 2.8e-05 0.00055 0.29117
GO:0005200 structural constituent of cytoskeleton 4 3.2e-05 3.2e-05 3.2e-05 0.00891
GO:0042288 MHC class I protein binding 7 6.5e-05 6.5e-05 6.5e-05 0.18571
GO:0005516 calmodulin binding 5 8.7e-05 8.7e-05 8.7e-05 0.00091
GO:0046961 proton-transporting ATPase activity, rot... 16 0.00015 0.00015 0.00015 0.07025
GO:0032403 protein complex binding 5 1.6e-06 0.00019 0.00115 0.00021
(b) elim
TERM.ID Term Level classic elim weight01 parentchild
GO:0005234 extracellular-glutamate-gated ion channe... 12 1.3e-09 1.3e-09 1.3e-09 0.00194
GO:0005391 sodium:potassium-exchanging ATPase activ... 16 9.8e-08 9.8e-08 9.8e-08 0.00118
GO:0023026 MHC class II protein complex binding 7 2.5e-06 2.5e-06 2.5e-06 1.00000
GO:0004972 NMDA glutamate receptor activity 12 1.3e-05 1.3e-05 1.3e-05 0.33591
GO:0005200 structural constituent of cytoskeleton 4 3.2e-05 3.2e-05 3.2e-05 0.00891
GO:0042288 MHC class I protein binding 7 6.5e-05 6.5e-05 6.5e-05 0.18571
GO:0005516 calmodulin binding 5 8.7e-05 8.7e-05 8.7e-05 0.00091
GO:0046961 proton-transporting ATPase activity, rot... 16 0.00015 0.00015 0.00015 0.07025
GO:0005524 ATP binding 10 0.00020 0.00020 0.00020 0.70522
GO:0004971 AMPA glutamate receptor activity 12 0.00023 0.00023 0.00023 0.27219
(c) weight01
TERM.ID Term Level classic elim weight01 parentchild
GO:0005215 transporter activity 3 1.6e-11 0.84654 1.00000 1.6e-11
GO:0008066 glutamate receptor activity 7 1.4e-08 0.08546 1.00000 4.3e-10
GO:0005515 protein binding 4 6.2e-08 0.01142 0.00102 4.6e-08
GO:0001882 nucleoside binding 5 3.4e-06 0.11574 0.03526 2.6e-07
GO:1901265 nucleoside phosphate binding 5 0.00010 0.73511 1.00000 4.4e-06
GO:0043168 anion binding 5 0.00026 0.97678 1.00000 1.4e-05
GO:0042625 ATPase activity, coupled to transmembran... 13 9.0e-12 1.00000 1.00000 4.1e-05
GO:0019829 cation-transporting ATPase activity 14 6.5e-12 0.02009 1.00000 6.1e-05
GO:0005198 structural molecule activity 3 0.00011 0.17612 0.48464 0.00011
GO:0097367 carbohydrate derivative binding 4 3.7e-05 0.58353 1.00000 0.00012
(d) parentchild
Table A5: ARC complexes GOMF enrichment result
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Jane a. Hurst, Johanna Jähn, Laird G. Jackson, Anne M. Kelly, David H.
Ledbetter, Sahar Mansour, Christa L. Martin, Celia Moss, Andrew Mumford,
Willem H. Ouwehand, Soo Mi Park, Erin Rooney Riggs, Richard H. Scott,
Sanjay Sisodiya, Steven Van Vooren, Ronald J. Wapner, Andrew O M Wilkie,
Caroline F. Wright, Anneke T. Vulto-Van Silfhout, Nicole De Leeuw, Bert B a
De Vries, Nicole L. Washingthon, Cynthia L. Smith, Monte Westerfield, Paul
Schofield, Barbara J. Ruef, Georgios V. Gkoutos, Melissa Haendel, Damian
Smedley, Suzanna E. Lewis, and Peter N. Robinson. The Human Phenotype
Ontology project: Linking molecular biology and disease through phenotype
data. Nucleic Acids Research, 42:966–974, 2014.
[41] Ashutosh Malhotra, Erfan Younesi, Michaela Gündel, Bernd Müller, Michael T
Heneka, and Martin Hofmann-Apitius. ADO: a disease ontology representing
the domain knowledge specific to Alzheimer’s disease. Alzheimer’s & dementia
: the journal of the Alzheimer’s Association, 10:238–46, 2014.
[42] Purvesh Khatri and Sorin Drghici. Ontological analysis of gene expression data:
Current tools, limitations, and open problems. Bioinformatics, 21:3587–3595,
2005.
[43] William K. McCoubrey, James F. Ewing, and Mahin D. Maines. Human
heme oxygenase-2: Characterization and expression of a full-length cDNA
and evidence suggesting that the two HO-2 transcripts may differ by choice of
polyadenylation signal. Archives of Biochemistry and Biophysics, 295(1):13–
20, 1992.
[44] William A Baumgartner, K Bretonnel Cohen, Lynne M Fox, George Acquaah-
Mensah, and Lawrence Hunter. Manual curation is not sufficient for annotation
Bibliography 231
of genomic databases. Bioinformatics (Oxford, England), 23(13):i41–i48, jul
2007.
[45] a. Bravo, J. Pinero, N. Queralt, M. Rautschka, and L. I. Furlong. Extraction
of relations between genes and diseases from text and large-scale data analysis:
implications for translational research. bioRxiv, page 007443, 2014.
[46] Noa Rappaport, Noam Nativ, Gil Stelzer, Michal Twik, Yaron Guan-Golan,
Tsippi Iny Stein, Iris Bahir, Frida Belinky, C. Paul Morrey, Marilyn Safran,
and Doron Lancet. MalaCards: An integrated compendium for diseases and
their annotation. Database, 2013, 2013.
[47] Allan Peter Davis, Cynthia Grondin Murphy, Robin Johnson, Jean M. Lay, Kel-
ley Lennon-Hopkins, Cynthia Saraceni-Richards, Daniela Sciaky, Benjamin L.
King, Michael C. Rosenstein, Thomas C. Wiegers, and Carolyn J. Mattingly.
The comparative toxicogenomics database: Update 2013. Nucleic Acids Re-
search, 41(D1), 2013.
[48] Kevin G Becker, Kathleen C Barnes, Tiffani J Bright, and S Alex Wang. The
genetic association database. Nature genetics, 36(5):431–432, 2004.
[49] Y Hakak, J R Walker, C Li, W H Wong, K L Davis, J D Buxbaum, V Haroutu-
nian, and a a Fienberg. Genome-wide expression analysis reveals dysregulation
of myelination-related genes in chronic schizophrenia. Proceedings of the Na-
tional Academy of Sciences of the United States of America, 98:4746–4751,
2001.
[50] Alan R Aronson and François-Michel Lang. An overview of MetaMap: histor-
ical perspective and recent advances. Journal of the American Medical Infor-
matics Association : JAMIA, 17(3):229–36, 2010.
[51] Ramin Homayouni, Kevin Heinrich, Lai Wei, and Michael W. Berry. Gene
clustering by Latent Semantic Indexing of MEDLINE abstracts. Bioinformatics,
21(1):104–115, 2005.
[52] National Center for Biomedical Ontology. NCBO Annotator web interface,
2016. https://bioportal.bioontology.org/annotator.
[53] Da Wei Huang, Brad T. Sherman, Qina Tan, Joseph Kir, David Liu, David
Bryant, Yongjian Guo, Robert Stephens, Michael W. Baseler, H. Clifford Lane,
and Richard a. Lempicki. DAVID Bioinformatics Resources: Expanded anno-
tation database and novel algorithms to better extract biology from large gene
lists. Nucleic Acids Research, 35:169–175, 2007.
[54] Sorin Draghici, Purvesh Khatri, Pratik Bhavsar, Abhik Shah, Stephen a.
Krawetz, and Michael a. Tainsky. Onto-Tools, the toolkit of the modern biolo-
gist: Onto-Express, Onto-Compare, Onto-Design and Onto-Translate. Nucleic
Acids Research, 31:3775–3781, 2003.
232 Bibliography
[55] Barry R Zeeberg, Weimin Feng, Geoffrey Wang, May D Wang, Anthony T Fojo,
Margot Sunshine, Sudarshan Narasimhan, David W Kane, William C Reinhold,
Samir Lababidi, Kimberly J Bussey, Joseph Riss, J Carl Barrett, and John N
Weinstein. GoMiner: a resource for biological interpretation of genomic and
proteomic data. Genome biology, 4:R28, 2003.
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[122] Nils Blüthgen, Karsten Brand, Branka Cajavec, Maciej Swat, Hanspeter Herzel,
and Dieter Beule. Biological profiling of gene groups utilizing Gene Ontol-
ogy. Genome informatics. International Conference on Genome Informatics,
16:106–15, 2005.
[123] Donna Maglott, Jim Ostell, Kim D. Pruitt, and Tatiana Tatusova. Entrez gene:
Gene-centered information at NCBI. Nucleic Acids Research, 39, 2011.
[124] Amos Bairoch, Rolf Apweiler, Cathy H. Wu, Winona C. Barker, Brigitte Boeck-
mann, Serenella Ferro, Elisabeth Gasteiger, Hongzhan Huang, Rodrigo Lopez,
Michele Magrane, Maria J. Martin, Darren A. Natale, Claire O’Donovan, Nicole
Redaschi, and Lai Su L Yeh. The Universal Protein Resource (UniProt). Nucleic
Acids Research, 33, 2005.
[125] J. X. Li, H. R. Zheng, C. N. Ji, X. W. Fei, M. Zheng, Y. J. Gao, Y. Ren, S. H. Gu,
Y. Xie, and Y. M. Mao. A novel splice variant of human XRN2 gene is mainly
expressed in blood leukocyte. DNA Sequence, 16:143–146, 2005.
[126] Brad T Sherman, Da Wei Huang, Qina Tan, Yongjian Guo, Stephan Bour, David
Liu, Robert Stephens, Michael W Baseler, H Clifford Lane, and Richard a Lem-
picki. DAVID Knowledgebase: a gene-centered database integrating heteroge-
neous gene annotation resources to facilitate high-throughput gene functional
analysis. BMC bioinformatics, 8:426, 2007.
[127] KJ Bussey, David Kane, and Margot Sunshine. MatchMiner: a tool for batch
navigation among gene and gene product identifiers. Genome . . . , 4:R27, 2003.
[128] Andreu Alibés, Patricio Yankilevich, Andrés Cañada, and Ramón Dı́az-Uriarte.
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Kaunisto, Eija Hämäläinen, Elisabeth Widén, Joseph Terwilliger, Kathleen
Merikangas, Grant W. Montgomery, Nicholas G. Martin, Mark Daly, Jaakko
Kaprio, Leena Peltonen, Markus Färkkilä, Maija Wessman, and Aarno Palotie.
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